US20200399252A1 - 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives - Google Patents

3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives Download PDF

Info

Publication number
US20200399252A1
US20200399252A1 US17/007,258 US202017007258A US2020399252A1 US 20200399252 A1 US20200399252 A1 US 20200399252A1 US 202017007258 A US202017007258 A US 202017007258A US 2020399252 A1 US2020399252 A1 US 2020399252A1
Authority
US
United States
Prior art keywords
methyl
phenyl
diazaspiro
cis
decan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/007,258
Inventor
Sven Kuehnert
Rene Michael KOENIGS
Achim Kless
Anita WEGERT
Paul Ratcliffe
Ruth Jostock
Thomas Koch
Klaus Linz
Wolfgang Schroeder
Klaus Schiene
lngo KONETZKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Priority to US17/007,258 priority Critical patent/US20200399252A1/en
Assigned to Grünenthal GmbH reassignment Grünenthal GmbH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RATCLIFFE, PAUL, JOSTOCK, RUTH, SCHIENE, KLAUS, KLESS, ACHIM, KOENIGS, RENE MICHAEL, LINZ, KLAUS, KOCH, THOMAS, KONETZKI, INGO, KUEHNERT, SVEN, SCHROEDER, WOLFGANG, Wegert, Anita
Publication of US20200399252A1 publication Critical patent/US20200399252A1/en
Priority to US17/188,743 priority patent/US20210179592A1/en
Priority to US18/103,180 priority patent/US20230174520A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • Opioid receptors are a group of Gi/o protein-coupled receptors which are widely distributed in the human body.
  • the opioid receptors are currently subdivided into four major classes, i.e. the three classical opioid receptors mu-opioid (MOP) receptor, kappa-opioid (KOP) receptor, and delta-opioid (DOP) receptor as well as the opioid receptor-like (ORL-1) receptor, which was more recently discovered based on its high homology with said classical opioid receptors.
  • MOP mu-opioid
  • KOP kappa-opioid
  • DOP delta-opioid
  • ORL-1 opioid receptor-like receptor
  • ORL-1 receptor After identification of the endogenous ligand of the ORL-1 receptor, known as nociceptin/orphanin FQ, a highly basic 17 amino acid peptide isolated from tissue extracts in 1995, the ORL-1 receptor was renamed “nociceptin opioid peptide receptor” and abbreviated as “NOP-receptor”.
  • the classical opioid receptors (MOP, KOP and DOP) as well as the NOP receptor are widely distributed/expressed in the human body, including in the brain, the spinal cord, on peripheral sensory neurons and the intestinal tract, wherein the distribution pattern differs between the different receptor classes.
  • Nociceptin acts at the molecular and cellular level in very much the same way as opioids. However, its pharmacological effects sometimes differ from, and even oppose those of opioids. NOP-receptor activation translates into a complex pharmacology of pain modulation, which, depending on route of administration, pain model and species involved, leads to either pronociceptive or antinociceptive activity. Furthermore, the NOP receptor system is upregulated under conditions of chronic pain. Systemic administration of selective NOP receptor agonists was found to exert a potent and efficacious analgesia in non-human primate models of acute and inflammatory pain in the absence of side effects.
  • NOP receptor agonists might be useful inter alia in the treatment of neuropsychiatric disorders (Witkin et al, Pharmacology & Therapeutics, 141 (2014) 283-299; Jenck et al., Proc. Natl. Acad. Sci. USA 94, 1997, 14854-14858).
  • the DOP receptor is also implicated to modulate not only pain but also neuropsychiatric disorders (Mabrouk et al, 2014; Pradhan et al., 2011).
  • peripherally restricted opioid receptor ligands that do not easily cross the blood-brain barrier and therefore distribute poorly to the central nervous system (see for instance WO 2015/192039).
  • peripherally acting compounds might combine effective analgesia with limited side-effects.
  • a further approach has been to provide multi-opioid receptor analgesics that modulate more than one of the opioid receptor subtypes to provide additive or synergistic analgesia and/or reduced side effects like abuse liability or tolerance.
  • medicaments which are effective in the treatment of pain and which have advantages compared to the compounds of the prior art.
  • medicaments should contain such a small dose of active ingredient that satisfactory pain therapy can be ensured without the occurrence of intolerable treatment-emergent adverse events.
  • n 1, 2 or 3; R 1 and R 2 independently of one another mean
  • aryl includes but is not limited to phenyl and naphthyl.
  • heteroaryl includes but is not limited to -1,2-benzodioxole, -pyrazinyl, -pyridazinyl, -pyridinyl, -pyrimidinyl, -thienyl, -imidazolyl, -benzimidazolyl, -thiazolyl, -1,3,4-thiadiazolyl, -benzothiazolyl, -oxazolyl, -benzoxazolyl, -pyrazolyl, -quinolinyl, -isoquinolinyl, -quinazolinyl, -indolyl, -indolinyl, -benzo[c][1,2,5]oxadiazolyl, -imidazo[1,2-a]pyrazinyl, or -1H-pyrrolo[2,3-b]pyri
  • cycloalkyl includes but is not limited to -cyclopropyl, -cyclobutyl, -cyclopentyl and -cyclohexyl.
  • heterocycloalkyl includes but is not limited to -aziridinyl, -azetidinyl, -pyrrolidinyl, -piperidinyl, -piperazinyl, -morpholinyl, -sulfamorpholinyl, -oxiridinyl, -oxetanyl, -tetrahydropyranyl, and -pyranyl.
  • asymmetric group such as —C( ⁇ O)O— or —C( ⁇ O)O—CH 2 —
  • said asymmetric group may be arranged in either direction.
  • R 4 when R 4 is connected to the core structure through —C( ⁇ O)O—, the arrangement may be either R 4 —C( ⁇ O)O-core or core —C( ⁇ O)O—R 4 .
  • R 7 and R 8 together with the carbon atom to which they are attached form a ring and mean —(CH 2 ) 2 — (i.e. form a cyclopropyl ring) or —(CH 2 ) 3 — (i.e. form a cyclobutyl ring).
  • R 1 means —H; and R 2 means —C 1 -C 6 -alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
  • R 1 means —H and R 2 means —CH 3 .
  • R 1 and R 2 together with the nitrogen atom to which they are attached form a ring and mean —(CH 2 ) 3-6 —.
  • R 1 and R 2 together with the nitrogen atom to which they are attached form a ring and mean —(CH 2 ) 3 —.
  • R 3 means —C 1 -C 6 -alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
  • R 3 means —C 1 -C 6 -alkyl, linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with —OCH 3 .
  • R 3 means a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted, optionally connected through —C 1 -C 6 -alkylene-, linear or branched, saturated or unsaturated, unsubstituted.
  • R 3 means -phenyl unsubstituted, mono- or polysubstituted.
  • R 3 means -benzyl unsubstituted, mono- or disubstituted with —F, —Cl, —CH 3 , —CF 3 , —OH, —OCH 3 , —OCF 3 or —OCH 2 OCH 3 , preferably —F.
  • R 3 means a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted.
  • R 3 means -thienyl or -pyridinyl, in each case unsubstituted, mono- or polysubstituted. More preferably, R 3 means -thienyl, -pyridinyl, -imidazolyl or benzimidazolyl, in each case unsubstituted or monosubstituted with —F, —Cl or —CH 3 .
  • R 4 means —H.
  • R 4 means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein the 3-12-membered cycloalkyl moiety is connected through —C 1 -C 6 -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
  • R 4 means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is connected through —CH 2 — or —CH 2 CH 2 —.
  • R 4 means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —C 1 -C 4 -alkyl, —O—C 1 -C 4 -alkyl, —C( ⁇ O)OH, —C( ⁇ O)OC 1 -C 4 -alkyl, —C( ⁇ O)NH 2 , —C( ⁇ O)NHC 1 -C 4 -alkyl, —C( ⁇ O)N(C 1 -C 4 -alkyl) 2 , —S( ⁇ O)C 1 -C 4 -alkyl and —S( ⁇ O) 2 C 1 -C 4 -alkyl; wherein said 3-12-membered cycloalkyl mo
  • R 4 means a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is connected through —C 1 -C 6 -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
  • R 4 means a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is connected through —CH 2 — or —CH 2 CH 2 —.
  • R 4 means -oxetanyl, -tetrahydrofuranyl or -tetrahydropyranyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —C 1 -C 4 -alkyl, —O—C 1 -C 4 -alkyl, —C( ⁇ O)OH, —C( ⁇ O)OC 1 -C 4 -alkyl, —C( ⁇ O)NH 2 , —C( ⁇ O)NHC 1 -C 4 -alkyl, —C( ⁇ O)N(C 1 -C 4 -alkyl) 2 , —S( ⁇ O)C 1 -C 4 -alkyl and —S( ⁇ O) 2 C 1 -C 4 -alkyl; wherein said -
  • R 4 means -phenyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —C 1 -C 4 -alkyl, —O—C 1 -C 4 -alkyl, —C( ⁇ O)OH, —C( ⁇ O)OC 1 -C 4 -alkyl, —C( ⁇ O)NH 2 , —C( ⁇ O)NHC 1 -C 4 -alkyl, —C( ⁇ O)N(C 1 -C 4 -alkyl) 2 , —S( ⁇ O)C 1 -C 4 -alkyl and —S( ⁇ O) 2 C 1 -C 4 -alkyl; wherein said -phenyl is connected through —CH 2 — or —CH 2 CH 2 —.
  • R 4 means a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is connected through —C 1 -C 6 -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
  • R 4 means a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said -phenyl is connected through —CH 2 — or —CH 2 CH 2 —.
  • R 4 means -pyridinyl, -pyrimidinyl, -pyrazinyl, or -pyrazolinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —C 1 -C 4 -alkyl, —O—C 1 -C 4 -alkyl, —C( ⁇ O)OH, —C( ⁇ O)OC 1 -C 4 -alkyl, —C( ⁇ O)NH 2 , —C( ⁇ O)NHC 1 -C 4 -alkyl, —C( ⁇ O)N(C 1 -C 4 -alkyl) 2 , —S( ⁇ O)C 1 -C 4 -alkyl and —S( ⁇ O) 2 C 1 -C 4 -alkyl; wherein
  • n means 1 or 2.
  • n means 1.
  • R means -phenyl, unsubstituted, mono- or polysubstituted.
  • R 5 means -phenyl unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F; —Cl; —Br; —I; —CN; —OH; —C 1 -C 4 -alkyl; —CF 3 ; -3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; preferably -cyclopropyl, saturated, unsubstituted; -3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; preferably -pyrrolidinyl, -piperidinyl, -morpholinyl, -piperazinyl,
  • R 5 means -pyrazinyl, -pyridazinyl, -pyridinyl, -pyrimidinyl, -thienyl, -imidazolyl, triazolyl, or -1,3-benzodioxolyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F; —Cl; —Br; —I; —CN; —OH; —C 1 -C 4 -alkyl; —CF 3 ; —C 1 -C 4 -alkyl-OH; —C 1 -C 4 -alkyl-C( ⁇ O)NH 2 ; -3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; preferably -cyclopropyl, saturated, unsubstituted; -3-12
  • the compound according to the invention has a structure according to any of general formulas (II-A) to (VIII-C):
  • R C means —H, —OH, —F, —CN or —C 1 -C 4 -alkyl; preferably —H or —OH;
  • R D means —H or —F; or a physiologically acceptable salt thereof.
  • n means 1 or 2;
  • R 1 means —H or —CH 3 ;
  • R 2 means —H or —C 1 -C 6 -alkyl, linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with —OH, —OCH 3 , —C( ⁇ O)OCH 3 , or —CN;
  • R 3 means —C 1 -C 4 -alkyl, optionally monosubstituted with —OCH 3 ;
  • -phenyl, -thienyl or -pyridinyl in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —CN, —CH 3 , —CH 2 CH 3 , —CH 2 F, —CHF 2 , —CF 3 , —OCF3, —OH, —OCH 3 , —
  • —C 1 -C 6 -alkyl linear or branched, saturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, ⁇ O, —OH, —O—C 1 -C 4 -alkyl, —CO 2 H, —C( ⁇ O)O—C 1 -C 4 -alkyl, —C( ⁇ O)NH 2 , —C( ⁇ O)NH—C 1 -C 4 -alkyl, —C( ⁇ O)N(C 1 -C 4 -alkyl) 2 , —C( ⁇ O)NH—C 1 -C 4 -alkyl-CN, —C( ⁇ O)NCH 3 —C 1 -C 4 -alkyl-CN, —C( ⁇ O)NH-cyclopropyl-CN, —C( ⁇ O)
  • n means 1 or 2; and/or R 1 means —H or —CH 3 ; and/or R 2 means —C 1 -C 6 -alkyl, linear or branched, saturated, unsubstituted; preferably, R 2 means —CH 3 or —CH 2 CH 3 ; more preferably, R 1 and R 2 both mean —CH 3 ; and/or R 3 means -phenyl, -thienyl or -pyridinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —CN, —CH 3 , —CH 2 CH 3 , —CH 2 F, —CHF 2 , —CF 3 , —OCF3, —OH, —OCH 3 , —C( ⁇ O)NH 2 , C( ⁇ O)NHCH 3 , —C( ⁇ O)N(CH 3 ) 2 ,
  • —C 1 -C 6 -alkyl linear or branched, saturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, and —O—C 1 -C 4 -alkyl; or 3-6-membered cycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, and —O—C 1 -C 4 -alkyl, wherein said 3-6-membered cycloalkyl is connected through —C 1 -C 6 -alkylene; preferably R 4 means 3-6-membered cycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently
  • the compound according to the invention is selected from the group consisting of
  • SC_2001 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(4-methylsulfonyl-phenyl)-methyl]-8-phenyl-1,3- diazaspiro[4.5]decan-2-one
  • SC_2002 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(3-methoxyphenyl)-methyl]-8-phenyl-1,3- diazaspiro[4.5]decan-2-one
  • SC_2003 CIS-8-Dimethylamino-1-isopropyl-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3- diazaspiro[4.5]decan-2-one
  • SC_2004 CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3- diazaspiro[4.5]de
  • —C 1 -C 4 -alkyl can be unsubstituted, mono- or polysubstituted.
  • substituted alkyl examples include but are not limited to —CH 2 CH 2 OH, —CH 2 CH 2 CH 3 , —CH 2 CH 2 CH 2 OCH 3 , —CH 2 CH 2 S( ⁇ O) 2 CH 3 , —CH 2 C( ⁇ O)NH 2 , —C(CH 3 ) 2 C( ⁇ O)NH 2 , —CH 2 C(CH 3 ) 2 C( ⁇ O)NH 2 , and —CH 2 CH 2 C( ⁇ O)N(CH 3 ) 2 .
  • unsaturated alkylene examples include but are not limited to —CH ⁇ CH—, —C ⁇ C—, —C(CH 3 ) ⁇ CH—, —CH ⁇ C(CH 3 )—, —C(CH 3 ) ⁇ C(CH 3 )—, —CH 2 CH ⁇ CH—, —CH ⁇ CHCH 2 —, —CH ⁇ CH—CH ⁇ CH—, and —CH ⁇ CH—C ⁇ C—.
  • —C 1 -C 6 -alkylene- can be unsubstituted, mono- or polysubstituted.
  • substituted —C 1 -C 6 -alkylene- include but are not limited to —CHF—, —CF 2 —, —CHOH— and —C( ⁇ O)—.
  • moieties may be connected through —C 1 -C 6 -alkylene-, i.e. the moieties may not be directly bound to the core structure of compound according to general formula (I), but may be connected to the core structure of compound according to general formula (I) or its periphery through a —C 1 -C 6 -alkylene- linker.
  • Examples of preferred unsaturated 3-12-membered cycloalkyl moiety moieties according to the invention include but are not limited to cyclopropene, cyclobutene, cyclopentene, cyclopentadiene, cyclohexene, 1,3-cyclohexadiene, and 1,4-cyclohexadiene.
  • the 3-12-membered cycloalkyl moiety which is bonded to the compound according to the invention, in its periphery may optionally be condensed with a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; and/or with a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted.
  • the 3-12-membered cycloalkyl moiety may optionally be connected through —C 1 -C 6 -alkylene-, i.e. the 3-12-membered cycloalkyl moiety may not be directly bound to the compound according to general formula (I) but may be connected thereto through a —C 1 -C 6 -alkylene- linker.
  • Examples include but are not limited to —CH 2 -cyclopropyl, —CH 2 -cyclobutyl, —CH 2 -cyclopentyl, —CH 2 -cyclohexyl, —CH 2 CH 2 -cyclopropyl, —CH 2 CH 2 -cyclobutyl, —CH 2 CH 2 -cyclopentyl, and —CH 2 CH 2 -cyclohexyl.
  • the 3-12-membered cycloalkyl moiety can be unsubstituted, mono- or polysubstituted.
  • substituted 3-12-membered cycloalkyl moieties include but are not limited to —CH 2 -1-hydroxy-cyclobutyl.
  • “3-12-membered heterocycloalkyl moiety” means a non-aromatic, monocyclic, bicyclic or tricyclic moiety comprising 3 to 12 ring atoms, wherein each cycle comprises independently of one another 1, 2, 3, 4 or more heteroatoms independently of one another selected from the group consisting of nitrogen, oxygen and sulfur, whereas sulfur may be oxidized (S( ⁇ O) or (S( ⁇ O) 2 ), whereas the remaining ring atoms are carbon atoms, and whereas bicyclic or tricyclic systems may share common heteroatom(s).
  • Examples of preferred saturated 3-12-membered heterocycloalkyl moieties according to the invention include but are not limited to aziridin, azetidine, pyrrolidine, imidazolidine, pyrazolidine, piperidine, piperazine, triazolidine, tetrazolidine, oxiran, oxetane, tetrahydrofurane, tetrahydropyrane, thiirane, thietane, tetra-hydrothiophene, diazepane, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazoli-dine, morpholine, thiomorpholine.
  • Examples of preferred unsaturated 3-12-membered heterocycloalkyl moiety moieties according to the invention include but are not limited to oxazoline, pyrazoline, imidazoline, isoxazoline, thiazoline, isothiazoline, and dihydropyran.
  • the 3-12-membered heterocycloalkyl moiety which is bonded to the compound according to the invention, in its periphery may optionally be condensed with a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; and/or with a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted.
  • An examples of a 3-12-membered heterocycloalkyl moiety condensed with a 6-14-membered aryl moiety includes but is not limited to 1,2,3,4-tetrahydroquinoline, which is connected through the 3-12-membered heterocycloalkyl moiety.
  • An example of a 3-12-membered heterocycloalkyl moiety condensed with a 5-14-membered heteroaryl moieties includes but is not limited to 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine, which is connected through the 3-12-membered heterocycloalkyl moiety.
  • Examples include but are not limited to —CH 2 -oxetane, —CH 2 -pyrrolidine, —CH 2 -piperidine, —CH 2 -morpholine, —CH 2 CH 2 -oxetane, —CH 2 CH 2 -pyrrolidine, —CH 2 CH 2 -piperidine, and —CH 2 CH 2 -morpholine.
  • the 3-12-membered heterocycloalkyl moiety can be unsubstituted, mono- or polysubstituted.
  • substituted 3-12-membered heterocycloalkyl moieties include but are not limited to 2-carboxamido-N-pyrrolidinyl-, 3,4-dihydroxy-N-pyrrolidinyl, 3-hydroxy-N-pyrimidinyl, 3,4-dihydroxy-N-pyrimidinyl, 3-oxo-N-piperazinyl, -tetrahydro-2H-thiopyranyl dioxide and thiomorpholinyl dioxide.
  • 6-14-membered aryl moiety means an aromatic, monocyclic, bicyclic or tricyclic moiety comprising 6 to 14 ring carbon atoms but no heteroatoms in the ring.
  • 6-14-membered aryl moieties according to the invention include but are not limited to benzene, naphthalene, anthracen, and phenanthren.
  • the ring atoms of the condensed moieties are not included in the 6 to 14 ring carbon atoms of the 6-14-membered heterocycloalkyl moieties.
  • 6-14-membered aryl moieties condensed with 3-12-membered cycloalkyl moieties include but are not limited to 2,3-dihydro-1H-indene and tetraline, which in each case are connected through the 6-14-membered aryl moiety.
  • 6-14-membered aryl moiety condensed with a 3-12-membered heterocycloalkyl moiety includes but is not limited to 1,2,3,4-tetrahydroquinoline, which is connected through the 6-14-membered aryl moiety.
  • 6-14-membered aryl moieties condensed with 5-14-membered heteroaryl moieties include but are not limited to quinoline, isoquinoline, phenazine and phenoxacine, which in each case are connected through the 6-14-membered aryl moiety.
  • the 6-14-membered aryl moiety may optionally be connected through —C 1 -C 6 -alkylene-, i.e. the 6-14-membered aryl moiety may not be directly bound to the compound according to general formula (I) but may be connected thereto through a —C 1 -C 6 -alkylene- linker.
  • Said linker may be connected to a carbon ring atom or to a hetero ring atom of the 6-14-membered aryl moiety. Examples include but are not limited to —CH 2 —C 6 H 5 , —CH 2 CH 2 —C 6 H 5 and —CH ⁇ CH—C 6 H 5 .
  • the 6-14-membered aryl moiety can be unsubstituted, mono- or polysubstituted.
  • substituted 6-14-membered aryl moieties include but are not limited to 2-fluorophenyl, 3-fluorophenyl, 2-methoxyphenyl and 3-methoxyphenyl.
  • Examples of preferred 5-14-membered heteroaryl moieties according to the invention include but are not limited to pyrrole, pyrazole, imidazole, triazole, tetrazole, furane, thiophene, oxazole, isoxazole, thiazole, isothiazole, pyridine, pyridazine, pyrimidine, pyrazine, indolicine, 9H-chinolicine, 1,8-naphthyridine, purine, imidazo[1,2-a]pyrazine, and pteridine.
  • the 5-14-membered heteroaryl moiety which is bonded to the compound according to the invention, in its periphery may optionally be condensed with a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted.
  • the ring atoms of the condensed moieties are not included in the 6 to 14 ring carbon atoms of the 6-14-membered heterocycloalkyl moieties.
  • 5-14-membered heteroaryl moieties condensed with 3-12-membered cycloalkyl moieties include but are not limited to 5,6,7,8-tetrahydroquinoline and 5,6,7,8-tetrahydroquinazoline, which in each case are connected through the 5-14-membered heteroaryl moiety.
  • 5-14-membered heteroaryl moiety condensed with a 3-12-membered heterocycloalkyl moiety includes but is not limited to 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine, which is connected through the 5-14-membered heteroaryl moiety.
  • 5-14-membered heteroaryl moieties condensed with 6-14-membered aryl moieties include but are not limited to quinoline, isoquinoline, phenazine and phenoxacine, which in each case are connected through the 5-14-membered heteroaryl moiety.
  • the 5-14-membered heteroaryl moiety may optionally be connected through —C 1 -C 6 -alkylene-, i.e. the 5-14-membered heteroaryl moiety may not be directly bound to the compound according to general formula (I) but may be connected thereto through a —C 1 -C 6 -alkylene- linker.
  • Said linker may be connected to a carbon ring atom or to a hetero ring atom of the 5-14-membered heteroaryl moiety.
  • Examples include but are not limited to —CH 2 -oxazole, —CH 2 -isoxazole, —CH 2 -imidazole, —CH 2 -pyridine, —CH 2 -pyrimidine, —CH 2 -pyridazine, —CH 2 CH 2 -oxazole, —CH 2 CH 2 -isoxazole, —CH 2 CH 2 -imidazole, —CH 2 CH 2 -pyridine, —CH 2 CH 2 -pyrimidine, and —CH 2 CH 2 -pyridazine.
  • the 5-14-membered heteroaryl moiety can be unsubstituted, mono- or polysubstituted.
  • 5-14-membered heteroaryl moieties include but are not limited to 2-methoxy-4-pyridinyl, 2-methoxy-5-pyridinyl, 3-methoxy-4-pyridinyl, 3-methoxy-6-pyridinyl, 4-methoxy-2-pyridinyl, 2-methylsulfonyl-5-pyridinyl, 3-methylsulfonyl-6-pyridinyl, 3-methoxy-6-pyridazinyl, 2-nitrilo-5-pyrimidinyl, 4-hydroxy-2-pyrimidinyl, 4-methoxy-pyrimidinyl, and 2-methoxy-6-pyrazinyl.
  • the compounds according to the invention have a structure according to general formula (I′)
  • R 1 to R 5 , R 7 , R 8 , R 10 to R 20 and n are defined as above, or a physiologically acceptable salt thereof.
  • the excess of the cis-isomer so designated is at least 50% de, more preferably at least 75% de, yet more preferably at least 90% de, most preferably at least 95% de and in particular at least 99% de.
  • the compound according to the invention has a structure according to general formula (IX)
  • R C means —H or —OH
  • R 3 means -phenyl or -3-fluorophenyl
  • R 5 means 6-14-membered aryl, unsubstituted, mono- or polysubstituted; or 5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted; or a physiologically acceptable salt thereof.
  • R 5 is selected from -phenyl, -pyridyl, pyrimidinyl, or -triazolyl, in each case unsubstituted, mono- or polysubstituted.
  • the compounds according to the invention are in the form of the free bases.
  • the compounds according to the invention are in the form of the physiologically acceptable salts.
  • salt is to be understood as being any form of the compound in which it assumes an ionic form or is charged and is coupled with a counter-ion (a cation or anion) or is in solution.
  • the term is also to be understood as meaning complexes of the compound with other molecules and ions, in particular complexes which are associated via ionic interactions.
  • Preferred salts are physiologically acceptable, in particular physiologically acceptable salts with anions or acids or also a salt formed with a physiologically acceptable acid.
  • Physiologically acceptable salts with anions or acids are salts of the particular compound in question with inorganic or organic acids which are physiologically acceptable, in particular when used in humans and/or mammals.
  • physiologically acceptable salts of particular acids include but are not limited to salts of hydrochloric acid, sulfuric acid, and acetic acid.
  • the invention also includes isotopic isomers of a compound according to the invention, wherein at least one atom of the compound is replaced by an isotope of the respective atom which is different from the naturally predominantly occurring isotope, as well as any mixtures of isotopic isomers of such a compound.
  • Preferred isotopes are 2 H (deuterium), 3 H (tritium), 3 C and 14 C.
  • Certain compounds according to the invention are useful for modulating a pharmacodynamic response from one or more opioid receptors (mu, delta, kappa, NOP/ORL-1) either centrally or peripherally, or both.
  • the pharmacodynamic response may be attributed to the compound either stimulating (agonizing) or inhibiting (antagonizing) the one or more receptors.
  • Certain compounds according to the invention may antagonize one opioid receptor, while also agonizing one or more other receptors.
  • Compounds according to the invention having agonist activity may be either full agonists or partial agonists.
  • agonists compounds that bind to receptors and mimic the regulatory effects of endogenous ligands are defined as “agonists”.
  • antagonists Compounds that bind to a receptor but produce no regulatory effect, but rather block the binding of ligands to the receptor, are defined as “antagonists”.
  • the compounds according to the invention are agonists at the mu opioid (MOP) and/or kappa opioid (KOP) and/or delta opioid (DOP) and/or nociceptin opioid (NOP/ORL-1) receptors.
  • MOP mu opioid
  • KOP kappa opioid
  • DOP delta opioid
  • NOP/ORL-1 nociceptin opioid
  • the compounds according to the invention potently bind to the MOP and/or KOP and/or DOP and/or NOP receptors.
  • the compounds according to the invention can be modulators at the MOP and/or KOP and/or DOP and/or NOP receptors, and therefore the compounds according to the invention can be used/administered to treat, ameliorate, or prevent pain.
  • the compounds according to the invention are antagonists of one or more opioid receptors. In some embodiments, the compounds according to the invention are antagonists of the MOP and/or KOP and/or DOP and/or NOP receptors.
  • the compounds according to the invention have both, (i) agonist activity at the NOP receptor; and (ii) agonist activity at one or more of the MOP, KOP, and DOP receptors.
  • the compounds according to the invention have both, (i) agonist activity at the NOP receptor; and (ii) antagonist activity at one or more of the MOP, KOP, and DOP receptors.
  • the compounds according to the invention have both, (i) antagonist activity at the NOP receptor; and (ii) agonist activity at one or more of the MOP, KOP, and DOP receptors.
  • the compounds according to the invention have both, (i) antagonist activity at the NOP receptor; and (ii) antagonist activity at one or more of the MOP, KOP, and DOP receptors.
  • the compounds according to the invention have selective agonist activity at the NOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention
  • the compounds according to the invention have balanced agonist activity at the NOP receptor as well as at the MOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention
  • the compounds according to the invention have balanced agonist activity at the NOP receptor as well as at the KOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention
  • the compounds according to the invention have balanced agonist activity at the NOP receptor as well as at the DOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention
  • the compounds according to the invention have selective agonist activity at the KOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention
  • the compounds according to the invention have agonist activity at the MOP receptor, agonist activity at the KOP receptor, and antagonist activity at the DOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention
  • the compounds according to the invention have selective agonist activity at the NOP receptor. In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention
  • the compounds according to the invention have selective antagonist activity at the NOP receptor. In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention
  • the compounds according to the invention have antagonist activity at the NOP receptor as well as agonist activity at the DOP receptor. In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention
  • no significant activity means that the activity (agonist/antagonist) of the given compound at this receptor is lower by a factor of 1000 or more compared to its activity (agonist/antagonist) at one or more of the other opioid receptors.
  • a further aspect of the invention relates to the compounds according to the invention as medicaments.
  • a further aspect of the invention relates to the compounds according to the invention for use in the treatment of pain.
  • a further aspect of the invention relates to a method of treating pain comprising the administration of a pain alleviating amount of a compound according to the invention to a subject in need thereof, preferably to a human.
  • the pain is preferably acute or chronic.
  • the pain is preferably nociceptive or neuropathic.
  • a further aspect of the invention relates to the compounds according to the invention for use in the treatment of neurodegenerative disorders, neuroinflammatory disorders, neuropsychiatric disorders, and substance abuse/dependence.
  • a further aspect of the invention relates to a method of treating any one of the aforementioned disorders, diseases or conditions comprising the administration of a therapeutically effective amount of a compound according to the invention to a subject in need thereof, preferably to a human.
  • Another aspect of the invention relates to a pharmaceutical composition which contains a physiologically acceptable carrier and at least one compound according to the invention.
  • composition according to the invention can optionally contain suitable additives and/or auxiliary substances and/or optionally further active ingredients.
  • physiologically acceptable carriers examples include fillers, solvents, diluents, colorings and/or binders. These substances are known to the person skilled in the art (see H. P. Fiedler, Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik and angrenzende füre, Editio Cantor Aulendoff).
  • the pharmaceutical composition according to the invention contains the compound according to the invention in an amount of preferably from 0.001 to 99 wt. %, more preferably from 0.1 to 90 wt. %, yet more preferably from 0.5 to 80 wt. %, most preferably from 1.0 to 70 wt. % and in particular from 2.5 to 60 wt. %, based on the total weight of the pharmaceutical composition.
  • the pharmaceutical composition according to the invention is preferably for systemic, topical or local administration, preferably for oral administration.
  • Another aspect of the invention relates to a pharmaceutical dosage form which contains the pharmaceutical composition according to the invention.
  • the pharmaceutical dosage form according to the invention is produced for administration twice daily, for administration once daily or for administration less frequently than once daily.
  • Administration is preferably systemic, in particular oral.
  • the pharmaceutical dosage form according to the invention can be administered, for example, as a liquid dosage form in the form of injection solutions, drops or juices, or as a semi-solid dosage form in the form of granules, tablets, pellets, patches, capsules, plasters/spray-on plasters or aerosols.
  • auxiliary substances etc. and the amounts thereof to be used depend on whether the form of administration is to be administered orally, perorally, parenterally, intravenously, intraperitoneally, intradermally, intramuscularly, intranasally, buccally, rectally or locally, for example to the skin, the mucosa or into the eyes.
  • compositions in the form of tablets, dragees, capsules, granules, drops, juices and syrups are suitable for oral administration, and solutions, suspensions, readily reconstitutable dry preparations and also sprays are suitable for parenteral, topical and inhalatory administration.
  • the amount of the compounds according to the invention to be administered to the patient varies in dependence on the weight of the patient, on the type of administration, on the indication and on the severity of the disease. Usually, from 0.00005 mg/kg to 50 mg/kg, preferably from 0.001 mg/kg to 10 mg/kg, of at least one compound according to the invention is administered.
  • Another aspect of the invention relates to a process for the preparation of the compounds according to the invention. Suitable processes for the synthesis of the compounds according to the invention are known in principle to the person skilled in the art.
  • the compounds according to the invention can be obtained via different synthesis routes. Depending on the synthesis route, different intermediates are prepared and subsequently further reacted.
  • the synthesis of the compounds according to the invention proceeds via a synthesis route which comprises the preparation of an intermediate according to general formula (IIIa):
  • R 1 , R 2 and R 3 are defined as above.
  • the synthesis of the compounds according to the invention proceeds via a synthesis route which comprises the preparation of an intermediate according to general formula (IIIb):
  • R 1 , R 2 and R 3 are defined as above and PG is a protecting group.
  • the protecting group is -p-methoxybenzyl. Therefore, in another preferred embodiment, the synthesis of the compounds according to the invention proceeds via a synthesis route which comprises the preparation of an intermediate according to general formula (IIIc):
  • R 1 , R 2 and R 3 are defined as above.
  • the -p-methoxybenzyl moiety represents a protecting group which can be cleaved in the course of the synthesis route.
  • the synthesis of the compounds according to the invention proceeds via a synthesis route which comprises the preparation of
  • RT room temperature (23 ⁇ 7° C.)
  • M are indications of concentration in mol/l
  • aq.” means aqueous
  • sat.” means saturated
  • sol.” means solution
  • conc.” means concentrated.
  • the mixing ratios of solvents or eluents for chromatography are specified in v/v.
  • CIS refers to the relative configuration of compounds described herein, in which both nitrogen atoms are drawn on the same face of the cyclohexane ring as described in the following exemplary structure. Two depictions are possible:
  • TRANS refers to compounds, in which both nitrogen atoms are on opposite faces of the cyclohexane ring as described in the following exemplary structure. Two depictions are possible:
  • Step 1 CIS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4,5]decane-2,4-dione
  • Step 2 CIS-8-Dimethylamino-8-phenyl-3-(2-phenyl-ethyl)-1,3-diazaspiro[4.5]decane-2,4-dione
  • Step 3 CIS-8-Dimethylamino-8-phenyl-3-(2-phenyl-ethyl)-1,3-diazaspiro[4.5]decan-2-one
  • Step 1 CIS-1-((1-(benzyloxy)cyclobutyl)methyl)-3-(3,4-dimethoxybenzyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Step 2 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Step 1 1-((CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl)cyclobutanecarbonitrile
  • Step 2 1-((CIS-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl) cyclobutanecarboxamide
  • Step 3 1-((cis-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl)cyclobutane Carbonitrile
  • Step 1 1-Cyclobutylmethyl-3-(4-methoxy-benzyl)-9,12-dioxa-1,3-diazadispiro[4.2.4.2]tetradecan-2-one
  • Step 2 1-Cyclobutylmethyl-3-(4-methoxy-benzyl)-1,3-diaza-spiro[4.5]decane-2,8-dione
  • Step 3 1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile
  • Step 4 CIS-1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Step 5 CIS-1-(cyclobutyl-methyl)-8-(methyl-(2-methyl-propyl)-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • KOtBu (57.0 g, 508.4 mmol) was added to the solution of 2-(pyridin-2-yl)acetonitrile (50.0 g, 423.7 mmol) and ethyl acrylate (89.0 g, 889.8 mmol) in THF (500 mL) at 0° C. and stirred for 16 h at RT. The reaction mixture was quenched with sat. aq. NH 4 Cl and extracted with EtOAc (2 ⁇ 500 mL).
  • Step 1 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carbonitrile
  • Step 3 methyl 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-ylcarbamate
  • Step 1 8-(Dimethylamino)-1,4-dioxaspiro 4.5] decane-8-carbonitrile
  • Dimethylamine hydrochloride 52 g, 0.645 mol was added to the solution of 1,4-dioxaspiro-[4.5]-decan-8-one (35 g, 0.224 mmol) in MeOH (35 mL) at RT under argon atmosphere. The solution was stirred for 10 min and 40 wt % aq. dimethylamine (280 mL, 2.5 mol) and KCN (32 g, 0.492 mol) were sequentially added. The reaction mixture was stirred for 48 h at RT, then diluted with water (100 mL) and extracted with EtOAc (2 ⁇ 200 mL).
  • Step 1 9,12-Dioxa-2,4-diazadispiro[4.2.4 ⁇ circumflex over ( ) ⁇ 8 ⁇ .2 ⁇ circumflex over ( ) ⁇ 5 ⁇ ]tetradecane-1,3-dione
  • Step 2 2-[(4-Methoxyphenyl)-methyl]-9,12-dioxa-2,4-diazadispiro[4.2.4 ⁇ circumflex over ( ) ⁇ 8 ⁇ .2 ⁇ circumflex over ( ) ⁇ 5 ⁇ ]tetradecane-1,3-dione
  • Step 3 2-[(4-Methoxyphenyl)-methyl]-9,12-dioxa-2,4-diazadispiro[4.2.4 ⁇ circumflex over ( ) ⁇ 8 ⁇ .2 ⁇ circumflex over ( ) ⁇ 5 ⁇ ]tetradecan-3-one
  • Step 4 3-[(4-Methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decane-2,8-dione
  • KOtBu (M in THF) (29.30 mL, 29.30 mmol) was added to the solution of CIS-8-Dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one INT-976 (8.0 g, 29.30 mmol) in THF (160 mL) under argon atmosphere and the reaction mixture was stirred for 30 min. 4-Methoxybenzyl bromide (4.23 mL, 29.30 mmol) was added and stirring was continued at RT for 4 h. The reaction completion was monitored by TLC. The reaction mixture was diluted with sat. aq.
  • Step 1 8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4,5]decane-2,4-dione
  • Step 2 8-(dimethylamino)-8-phenyl-1, 3-diazaspiro [4, 5] decan-2-one
  • Step 3 CIS-8-Dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Step 1 CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5] decan-1-yl]-acetic Acid Tert-Butyl Ester
  • Step 2 cis-2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-acetic Acid Trifluoroacetic Acid Salt
  • CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5] decan-1-yl]-acetic acid tert-butyl ester 200 mg, 0.4 mmol was dissolved in TFA (5 mL) and heated to reflux overnight. After cooling to RT all volatiles are removed in vacuo. The residue was taken up in THF (1 mL) and added dropwise to diethyl ether (20 mL).
  • CIS-2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-acetic acid (INT-977) trifluoroacetic acid salt (119 mg, 0.35 mmol) was dissolved in DCM (5 mL). Triethylamine (0.21 mL, 1.6 mmol), dimethylamine (0.54 mL, 1.1 mmol) and T3P (0.63 mL, 1.1 mmol) were sequentially added. The reaction mixture was stirred at RT overnight, then diluted with 1 M aq. Na 2 CO 3 (5 mL).
  • Step 1 CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-1-((1-methylcyclobutyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Step 2 CIS-8-Dimethylamino-1-[(1-methyl-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Step 1 CIS-8-(dimethylamino)-1-isobutyl-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-975) was converted into CIS-8-(dimethylamino)-1-isobutyl-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro [4.5]decan-2-one.
  • Step 2 CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • step 2 CIS-8-(dimethylamino)-1-isobutyl-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one was converted into CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-984).
  • Step 1 CIS-3-benzyl-1-(cyclobutylmethyl)-8-(methylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • N-Iodosuccinimide (3.11 g, 13.92 mmol) was added to the solution of CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[phenyl-methyl]-1,3-diazaspiro[4.5]decan-2-one (INT-950) (4 g, 9.28 mmol) in a mixture of acetonitrile and THF (1:1 v/v, 80 mL) and the resulting mixture was stirred at RT for 16 h. The reaction mixture was basified with 2N aq. NaOH to pH ⁇ 10 and the organic product was extracted with DCM (3 ⁇ 10 mL).
  • Step 2 CIS-3-benzyl-1-(cyclobutylmethyl)-8-(ethyl(methyl)amino)-8-phenyl-1,3-diazaspiro [4.5]decan-2-one
  • Step 3 CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-986)
  • step 2 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (INT-952) was converted into CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-987).
  • Step 1 CIS-8-(dimethylamino)-1-[2-(1-methoxycyclobutyl)ethyl]-3-[(4-methoxyphenyl)methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Step 2 CIS-8-(dimethylamino)-1-(2-(1-methoxycyclobutyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5] decan-2-one (INT-988)
  • Step 1 and step 2 ethyl-(8-phenyl-1,4-dioxa-spiro[4.5]dec-8-yl)-amine Hydrochloride (INT-1004)
  • Step 4 Cis and Trans Mixture of 8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (INT-1006 and INT-1007)
  • Step 5 CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (INT-1006)
  • Step 6 CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (INT-1008)
  • CIS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-976) (5.0 g, 18.31 mmol, 1.0 eq.) in dry THF (500 ml) was added t-BuOK (3.07 g, 27.46 mmol, 1.5 eq.) and the reaction mixture was stirred at RT for 15 min.
  • 3-Bromo-propyne (3.24 g, 13.18 mmol, 1.2 eq., 80% in toluene) was added and stirring was continued at RT for 18 h.
  • the reaction mixture was poured into ice-water and extracted with DCM (800 ml).
  • CIS-2-(4-((8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)methyl)-1H-1,2,3-triazol-1-yl)acetate (INT-1011) (2.0 g, 4.54 mmol, 1.0 eq.) in DMSO (30 ml) was added NaOH (727 mg, 18.18 mmol, 4.0 eq.) at RT and the reaction mixture was heated to 70° C. for 30 min.
  • Step 2 CIS-8-(dimethylamino)-1-(2-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1021)
  • step 1 CIS-8-(dimethylamino)-1-(2-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one was reacted with N-iodosuccinimide to be converted into CIS-1-(2-methoxybenzyl)-8-(methylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1022).
  • Step 2 Synthesis of CIS-1-(tert-butoxycarbonylamino)-4-(dimethylamino)-4-phenylcyclohexanecarboxylic Acid (INT-1023)
  • CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one (SC-2147) was treated with TFA to be converted into CIS-8-(dimethylamino)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one (INT-1028).
  • Titanium ethoxide (58.45 g, 256.4 mmol) was added to a solution of 1,4-dioxaspiro[4.5]decan-8-one (20 g, 128.20 mmol) and 2-methylpropane-2-sulfinamide (15.51 g, 128.20 mmol) in THF (200 mL) at RT and the reaction mixture was stirred at RT for 18 h. The reaction mixture was cooled to 0° C. and quenched by dropwise addition of sat aq. NaHCO 3 (500 mL) over a period of 30 min. The organic product was extracted with EtOAc (3 ⁇ 100 mL).
  • Step 2 2-methyl-N-(8-phenyl-1,4-dioxaspiro[4.5]decan-8-yl)propane-2-sulfinamide
  • Phenylmagnesium bromide (M in THF, 116 mL, 116 mmol) was added dropwise to a solution of 2-methyl-N-(1,4-dioxaspiro[4.5]decan-8-ylidene)propane-2-sulfamide (10 g, 38.61 mmol) in THF (500 mL) at ⁇ 10° C. under argon atmosphere. The reaction mixture was stirred for 2 h at ⁇ 10° C. to 0° C. The reaction completion was monitored by TLC. The reaction mixture was quenched with sat. aq. NH 4 Cl (50 mL) at 0° C. and the organic product was extracted with EtOAc (3 ⁇ 100 mL).
  • Step 4 8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine
  • Step 5 N-methyl-8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine)
  • Step 7 8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione
  • Step 8 CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione
  • Reverse phase preparative HPLC conditions mobile phase: 10 mM ammonium bicarbonate in H 2 O/acetonitrile, column: X-BRIDGE-C18 (150*30), 5 ⁇ m, gradient (T/B %): 0/35, 8/55, 8.1/98, 10/98, 10.1/35, 13/35, flow rate: 25 ml/min, diluent: mobile phase+THF.
  • Step 9 CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1026)
  • Step 2 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one
  • Step 1 9,12-dioxa-2,4-diazadispiro[4.2.4 ⁇ circumflex over ( ) ⁇ 8 ⁇ .2 ⁇ circumflex over ( ) ⁇ 5 ⁇ ]tetradecan-3-one
  • Lithiumaluminiumhydride (2.2 equiv., 292 mmol) was suspended in THF (400 mL) and the suspension was cooled to 0° C.
  • 8-(Dimethylamino)-8-(m-tolyl)-1,3-diazaspiro[4.5]decan-2-one (B, 75 mg, 0,261 mmol) (step 1 of INT-965) was added portionwise at 0° C.
  • the reaction mixture was stirred 1.5 h at 0° C., then overnight at RT and then 2 h at 40° C.
  • the reaction mixture was cooled down to 0° C., quenched carefully with sat. aq.
  • Step 3 8-(dimethylamino)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (INT-1037)
  • Step 1 CIS-1-acetyl-8-(dimethylamino)-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Step 1 TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione
  • Step 2 TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1059)
  • TRANS-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione was treated with LiAlH 4 to be converted into TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1059). Mass: m/z 274.2 (M+H) + .
  • Step 1 CIS-1-acetyl-3-((2-chloropyridin-4-yl)methyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • CIS-1-acetyl-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1064) (1 g, 3.17 mmol) in DMF (37 mL) was added sodium hydride (60 wt % in mineral oil, 1.25 equiv., 3.96 mmol, 159 mg) portionwise at 0° C.
  • the reaction mixture was stirred for 15 min at 0° C. and 2-chloro-4-(chloromethyl)pyridine (1.25 equiv., 3.96 mmol, 0.485 mL) was added.
  • reaction mixture was stirred at RT for 2 h, then cooled down to 0° C., quenched with sat. aq. NaHCO 3 (10 mL), water (10 mL) and extracted with EtOAc (2 ⁇ 50 mL). Combined organic phase was washed with brine, dried over anhydr. Na 2 SO 4 and concentrated under reduced pressure.
  • Step 2 CIS-3-((2-chloropyridin-4-yl)methyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1065)
  • Step 3 1-aminomethyl-N′,N′-dimethyl-4-phenyl-N-(2,2,2-trifluoroethyl)cyclohexane-1,4-diamine
  • Step 4 CIS- and TRANS-8-dimethylamino-8-phenyl-1-(2,2,2-trifluoro-ethyl)-1,3-diaza-spiro[4.5]decan-2-one (INT-1068 and INT-1069)
  • HPLC: 98.53%, Column: Xbridge C-18 (100 ⁇ 4.6), 5p, Diluent: MeOH, Mobile phase: A) 0.05% TFA in water; B) ACN flow rate: 1 ml/min, R 5.17 min.
  • reaction completion was monitored by TLC.
  • the reaction mixture was quenched with sat. aq. NH 4 Cl and the organic product was extracted with EtOAc (2 ⁇ 10 mL). The combined organic extracts were dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure.
  • Step 1 8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile
  • Dimethylamine hydrochloride (76.36 g, 936.39 mmol) was added to a solution of 3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decane-2,8-dione INT-966 (90 g, 312.13 mmol) in MeOH (180 mL) at RT under argon atmosphere. The solution was stirred for 15 min and 40% aq. dimethylamine (780 mL) and KCN (48.76 g, 749.11 mmol) were sequentially added. The reaction mixture was stirred for 48 h while being monitored by NMR. The reaction mixture was diluted with water (1.0 L) and the organic product was extracted with EtOAc (2 ⁇ 2.0 L).
  • Step 2 CIS-8-Dimethylamino-8-(3-fluorophenyl)-3-[(4-methoyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one
  • Step 1 CIS-8-(dimethylamino)-1-isobutyl-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • CIS-8-dimethylamino-8-[3-(methoxymethyloxy)-phenyl]-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (INT-968) was converted into CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(4-methoxybenzyl)-8-(3-(methoxymethoxy)phenyl)-1,3-diazaspiro[4.5]decan-2-one.
  • Step 2 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-hydroxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one
  • KOtBu (411 mg, 3.66 mmol) was added to a solution of CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-987) (250 mg, 0.73 mmol) in THF (6 mL) under nitrogen atmosphere and the reaction mixture was stirred at RT for 30 min. After cooling to 0° C. 3-(chloromethyl)pyridine hydrochloride (180 mg, 1.10 mmol) was added and the reaction mixture was stirred at 0° C. for 30 min and then at RT for 3 days.
  • N-Iodosuccinimide (437 mg, 1.95 mmol) was added to a suspension of CIS-1-(cyclobutyl-methyl)-8-dimethylamino-3-[(3-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_2002) (600 mg, 1.30 mmol) in a mixture of acetonitrile and THF (1:1 v/v, 20 mL) at RT and the resulting mixture was stirred at RT for 16 h. The reaction mixture was basified with 2N aq. NaOH to pH ⁇ 10 and the organic product was extracted with DCM (3 ⁇ 10 mL).
  • the reaction mixture was allowed to stir at RT for 16 h and then diluted with water (15 mL).
  • the organic product was extracted with ethyl acetate (3 ⁇ 25 mL).
  • the combined organic extracts were dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure.
  • the residue was dissolved in THF (8 mL) and cooled to 0° C.
  • a 1M TBAF solution in THF (1.8 mL, 1.81 mmol) was added at 0° C.
  • the reaction mixture was allowed to stir at RT for 2 h.
  • the reaction mixture was diluted with water (10 mL), the organic product was extracted with DCM (3 ⁇ 25 mL).
  • the combined organic extracts were washed with sat. aq.
  • Powdered sodium hydroxide (21 mg, 0.5 mmol) was dissolved in 0.2 mL of dry DMSO. After stirring at RT for 30 min CIS-1-(cyclobutyl-methyl)-8-dimethylamino-3-[(4-hydroxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_2089)(60 mg, 0.13 mmol) was added and the resulting mixture was stirred for another 30 min.
  • N-Iodosuccinimide (233 mg, 1.035 mmol) was added to a solution of CIS-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[(4-methoxyphenyl)-methyl]-8-methylamino-8-phenyl-1,3-diazaspiro [4.5]decan-2-one (SC_2026) (320 mg, 0.690 mmol) in a mixture of acetonitrile and THF (1:1 v/v, 30 mL) at 0° C. and the resulting mixture was stirred for 5 h at RT. The reaction mixture was cooled to 0° C.
  • N-Iodosuccinimide 233 mg, 1.035 mmol
  • the reaction mixture was allowed to warm up to RT and was stirred for further 11 h.
  • the reaction mixture was basified with 2N aq. NaOH to pH ⁇ 10 and the organic product was extracted with ethyl acetate (3 ⁇ 30 mL). The combined organic extracts were dried over anhydrous sodium sulfate and concentrated under reduced pressure.
  • the reaction mixture was diluted with sat. aq. NaHCO 3 (20 mL) and the organic product was extracted with EtOAc (4 ⁇ 50 mL). The combined organic layer was dried over anhydr. Na 2 SO 4 and concentrated in vacuo.
  • the crude product was purified by column chromatography (using 230-400 mesh silica gel and 2-5% MeOH in DCM as eluent) to afford 250 mg of product which was further purified by prep.
  • CIS-8-dimethylamino-8-phenyl-3-prop-2-ynyl-1,3-diaza-spiro[4.5]decan-2-one (INT-1010) (1.0 g, 3.21 mmol, 1.0 eq.) in dioxane/MeOH (50 ml, 9:1) were added sodium azide (418 mg, 6.42 mmol, 2.0 eq.) and cuprous chloride (32 mg, 0.32 mmol, 0.1 eq.) at RT.
  • the reaction mixture was stirred at 80° C. for 18 h, then quenched with water and concentrated under reduced pressure.
  • the resulting residue was purified by column chromatography (silica gel neutralized with aq.
  • Step 1 Synthesis of Tert-Butyl CIS-4-(dimethylamino)-4-phenyl-1-(2-phenylpropan-2-ylcarbamoyl)cyclohexylcarbamate
  • Step 2 Synthesis of CIS-1-amino-4-(dimethylamino)-4-phenyl-N-(2-phenylpropan-2-yl)cyclohexanecarboxamide Hydrochloride
  • Step 3 Synthesis of CIS-N,N-dimethyl-1-phenyl-4-((2-phenylpropan-2-ylamino)methyl)cyclohexane-1,4-diamine
  • Step 3 Synthesis of CIS-8-(dimethylamino)-8-phenyl-3-(2-phenylpropan-2-yl)-1,3-diazaspiro[4.5]decan-2-one SC_2170
  • 1,1′-Carbonyldiimidazole (0.90 g, 5.58 mmol) was added to a solution of CIS-N,N-dimethyl-1-phenyl-4-((2-phenylpropan-2-ylamino)methyl)cyclohexane-1,4-diamine (1.7 g, 4.65 mmol) in DMF (20 mL) at RT. The reaction mixture was stirred at RT for 16 h.
  • Step 1 synthesis of CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one
  • CIS-8-(dimethylamino)-8-phenyl-1-(p-tolylsulfonyl)-1,3-diazaspiro[4.5]decan-2-one (INT-1028) (200 mg, 0.47 mmol, 1 equiv.) was dissolved in DMF (3.6 mL) under argon atmosphere and the solution was cooled down to 0° C.
  • Sodium hydride 60 wt % in mineral oil, 2.1 equiv., 0.98 mmol, 39 mg
  • 4-(Bromomethyl)pyridine hydrobromide (1.05 equiv., 0.49 mmol, 124 mg) was added at 0° C.
  • Step 2 synthesis of CIS-8-(dimethylamino)-8-phenyl-3-(pyridin-4-ylmethyl)-1,3-diazaspiro[4.5]decan-2-one (SC 2180)
  • CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one (110 mg, 0.212 mmol, 1 equiv.) was dissolved in THF (2 mL) and MeOH (4.4 mL) under argon atmosphere. Magnesium turnings (103 mg, 4.24 mmol, 20 equiv.) were added and the resulting mixture was stirred at RT for 18 h. The reaction mixture was diluted with DCM (30 mL) and water (10 mL), stirred at RT for 1.5 h, filtered through celite and the solid residue was washed with DCM (3 ⁇ ).
  • SC_2152 CIS-8-Dimethylamino-8- SC_2151 step 3 of 1H NMR (DMSO-d6): ⁇ 8.45- 379.3 phenyl-3-(2-pyridin-2-yl)- INT-795 8.44 (d, 1H), 7.69-7.65 (m, ethyl)-1,3-diazaspiro[4.5] 1H), 7.37-7.30 (m, 4H), 7.26- decan-2-one 7.16 (m, 3H), 6.65 (br s, 1H), 3.37-3.32 (m, 2H), 2.99 (s, 2H), 2.86-2.82 (t, 2H), 2.28 (m, 2H), 1.91 (m, 6H), 1.72- 1.71 (m, 4H), 1.28-1.26 (m, 2H).
  • SC_2159 CIS-2-[4-[[1-(Cyclobutyl- INT-1030 ammonia SC_2145 1HNMR (DMSO-d6, 400 480.1 methyl)-8-dimethylamino-2- MHz), ⁇ (ppm) 7.86 (s, 1H), oxo-8-phenyl-1,3-diazaspiro- 7.66 (s, 1H), 7.23-7.33 (m, [4.5]decan-3-yl]-methyl]-1H- 6H), 5.00 (s, 2H), 4.30 (s, [1,2,3]triazol-1-yl]-acetamide 2H), 3.09 (s, 2H), 3.04 (s, 2H), 2.61-2.64 (m, 2H), 1.95- 2.02 (m, 11H), 1.69-1.78 (m, 4H), 1.28-1.33 (m, 4H).
  • SC_2172 CIS-8-Dimethylamino-1,3- INT-976 1-(bromomethyl)- SC_2097 1H NMR (DMSO-d6): ⁇ 7.32- 514.2 bis[(2-methoxyphenyl)-methyl]- 2-methoxybenzene 7.14 (m, 9H), 6.99-6.90 (m, 8-phenyl-1,3-diazaspiro[4.5]- 4H), 4.32-4.27 (m, 4H), 3.84- decan-2-one 3.77 (m, 6H), 3.14 (s, 2H), 2.58-2.54 (m, 2H), 2.03-1.97 (m, 2H), 1.89 (s, 6H), 1.29- 1.22 (m, 4H).
  • SC_2174 CIS-8-Dimethylamino-1-[(1- SC_2170 (1-tertbutyl- INT-799 1H NMR (DMSO-d6): ⁇ 7.36- 476.3 hydroxy-cyclobutyl)-methyl]- dimethylsilyloxy)- (step 1) 7.14 (m, 10H), 5.88 (m, 1H), 3-(1-methyl-1-phenyl-ethyl)- cyclobutyl)methyl- 3.33 (s, 2H), 3.03 (s, 2H), 8-phenyl-1,3-diazaspiro[4.5]- 4-methylbenzene- 2.68-2.64 (m, 2H), 2.09-1.95 decan-2-one sulfonate (m, 10H), 1.89-1.81 (m, 2H), 1.61-1.56 (m, 7H), 1.48-1.28 (m, 5H).
  • SC_2176 CIS-3-(1,3-Benzodioxol-4-yl- INT-976 4-(bromomethyl)- SC_2097 1H NMR (600 MHz, DMSO) 408.2 methyl)-8-dimethylamino-8- 1,3-benzodioxole ⁇ 7.37-7.27 (m, 4H), 7.27- phenyl-1,3-diazaspiro[4.5]- 7.20 (m, 1H), 6.88 (s, 1H), decan-2-one 6.83-6.76 (m, 2H), 6.67 (dd, 1H), 5.96 (s, 2H), 4.18 (s, 2H), 2.95 (s, 2H), 2.30-2.26 (m, 2H), 1.93 (s, 6H), 1.84-1.63 (m, 4H), 1.33 (t, 2H).
  • SC_2182 CIS-8-Dimethylamino-8- INT-1028 3-(bromomethyl)- SC_2180 1H NMR (600 MHz, DMSO) 365.2 phenyl-3-(pyridin-3-yl-methyl)- pyridine hydro- ⁇ 8.46 (dd, 1H), 8.42 (dd, 1H), 1,3-diazaspiro[4.5]decan-2-one bromide (step 1) 7.60 (dt, 1H), 7.38-7.30 (m, 3H), 7.31-7.26 (m, 2H), 7.26- 7.20 (m, 1H), 6.97-6.93 (m, 1H), 4.24 (s, 2H), 2.95 (s, 2H), 2.33-2.20 (m, 2H), 1.92 (s, 6H), 1.84-1.60 (m, 4H), 1.35- 1.29 (m, 2H).
  • SC_2184 CIS-8-Dimethylamino-8- INT-1065 piperidine SC_2183 1H NMR (600 MHz, CDCl3) 448.3 phenyl-3-[(2-piperidin-1-yl- ⁇ 8.09 (d, 1H), 7.38 (dd, 2H), pyridin-4-yl-methyl]-1,3- 7.30 (d, 3H), 6.48 (s, 1H), 6.42 diazaspiro[4.5]decan-2-one (dd, 1H), 5.47 (s, 1H), 4.23 (s, 2H), 3.54-3.46 (m, 4H), 2.96 (s, 2H), 2.20-2.15 (m, 4H), 2.07 (s, 6H), 1.92-1.84 (m, 2H), 1.66-1.60 (m, 6H), 1.47- 1.39 (m, 2H).
  • SC_2185 CIS-8-Dimethylamino-3-[(2- INT-1065 morpholine SC_2183 1H NMR (600 MHz, DMSO) 450.3 morpholin-4-yl-pyridin-4-yl)- ⁇ 8.05 (d, 1H), 7.37-7.27 (m, methyl]-8-phenyl-1,3- 4H), 7.26-7.20 (m, 1H), 6.94 diazaspiro[4.5]decan-2-one (s, 1H), 6.59 (s, 1H), 6.50 (dd, 1H), 4.13 (s, 2H), 3.68 (t, 4H), 3.41-3.36 (m, 4H), 2.96 (s, 2H), 2.37-2.22 (m, 2H), 1.93 (s, 6H), 1.86-1.62 (m, 4H), 1.42-1.29 (m, 2H).
  • hMOP human mu-opioid receptor
  • kKOP human kappa-opioid receptor
  • hDOP human delta-opioid receptor
  • hNOP human nociceptin/orphanin FQ peptide receptor
  • the hMOP receptor binding assay was performed as homogeneous SPA-assay (scintillation proximity assay) using the assay buffer 50 mM TRIS-HCl (pH 7.4) supplemented with 0.052 mg/ml bovine serum albumin (Sigma-Aldrich Co. St. Louis. Mo.).
  • the final assay volume 250 ⁇ l/well included 1 nM of [N-allyl-2.3 3 H]naloxone as ligand (PerkinElmer Life Sciences. Inc. Boston. Mass. USA). and either test compound in dilution series or 25 ⁇ M unlabelled naloxone for determination of unspecific binding.
  • the test compound was diluted with 25% DMSO in H 2 O to yield a final 0.5% DMSO concentration. which also served as a respective vehicle control.
  • the assay was started by adding wheat germ agglutinin coated SPA beads (GE Healthcare UK Ltd. Buckinghamshire. UK) which had been preloaded with hMOP receptor membranes (PerkinElmer Life Sciences. Inc. Boston. Mass. USA). After incubation for 90 minutes at RT and centrifugation for 20 minutes at 500 rpm the signal rate was measured by means of a 1450 Microbeta Trilux ⁇ -counter (PerkinElmer Life Sciences/Wallac. Turku. Finland).
  • IC50 Half-maximal inhibitory concentration
  • the hKOP receptor binding assay is run as homogeneous SPA-assay (scintillation proximity assay) using the assay buffer 50 mM TRIS-HCl (pH 7.4) supplemented with 0.076 mg BSA/ml.
  • the final assay volume of 250 ⁇ l per well includes 2 nM of [ 3 H]U69,593 as ligand, and either test compound in dilution series or 100 ⁇ M unlabelled naloxone for determination of unspecific binding.
  • the test compound is diluted with 25% DMSO in H 2 O to yield a final 0.5% DMSO concentration which serves as respective vehicle control, as well.
  • the assays are started by the addition of wheat germ agglutinin coated SPA beads (1 mg SPA beads/250 ⁇ l final assay volume per well) which has been preloaded for 15 minutes at room temperature with hKOP receptor membranes (14.8 ⁇ g/250 ⁇ l final assay volume per well). After short mixing on a mini-shaker, the microtiter plates are covered with a lid and the assay plates are incubated for 90 minutes at room temperature. After this incubation, the microtiter plates are sealed with a topseal and centrifuged for 20 minutes at 500 rpm.
  • the signal rate is measured after a short delay of 5 minutes by means of a 1450 Microbeta Trilux ⁇ -counter (PerkinElmer Life Sciences/Wallac, Turku, Finland).
  • Half-maximal inhibitory concentration (IC50) values reflecting 50% displacement of [ 3 H]U69.593-specific receptor binding are calculated by nonlinear regression analysis and K i values are calculated by using the Cheng-Prusoff equation, (Cheng and Prusoff, 1973).
  • the hDOP receptor binding assay is performed as homogeneous SPA-assay using the assay buffer 50 mM TRIS-HCl, 5 mM MgCl 2 (pH 7.4).
  • the final assay volume (250 ⁇ l/well) includes 1 nM of [Tyrosyl-3,5- 3 H]2-D-Ala-deltorphin II as ligand, and either test compound in dilution series or 10 ⁇ M unlabelled naloxone for determination of unspecific binding.
  • the test compound is diluted with 25% DMSO in H 2 O to yield a final 0.5% DMSO concentration which serves as respective vehicle control, as well.
  • the assays are started by the addition of wheat germ agglutinin coated SPA beads (1 mg SPA beads/250 ⁇ l final assay volume per well) which has been preloaded for 15 minutes at room temperature with hDOP receptor membranes (15.2 ⁇ g/250 ⁇ l final assay volume per well). After short mixing on a mini-shaker, the microtiter plates are covered with a lid and the assay plates are incubated for 120 minutes at room temperature and centrifuged for 20 minutes at 500 rpm. The signal rate is measured by means of a 1450 Microbeta Trilux ⁇ -counter (PerkinElmer Life Sciences/Wallac, Turku, Finland).
  • IC50 Half-maximal inhibitory concentration
  • the hNOP receptor binding assay was performed as homogeneous SPA-assay (scintillation proximity assay) using the assay buffer 50 mM TRIS-HCl. 10 mM MgCl 2 . 1 mM EDTA (pH 7.4).
  • the final assay volume (250 ⁇ l/well) included 0.5 nM of [leucyl- 3 H]nociceptin as ligand (PerkinElmer Life Sciences. Inc. Boston. Mass. USA). and either test compound in dilution series or 1 ⁇ M unlabelled nociceptin for determination of unspecific binding.
  • the test compound was diluted with 25% DMSO in H 2 O to yield a final 0.5% DMSO concentration. which also served as a respective vehicle control.
  • the assay was started by adding wheat germ agglutinin coated SPA beads (GE Healthcare UK Ltd. Buckinghamshire. UK) which had been preloaded with hMOP receptor membranes (PerkinElmer Life Sciences. Inc. Boston. Mass. USA). After incubation for 60 minutes at RT and centrifugation for 20 minutes at 500 rpm the signal rate was measured by means of a 1450 Microbeta Trilux ⁇ -counter (PerkinElmer Life Sciences/Wallac. Turku. Finland). Half-maximal inhibitory concentration (IC50) values reflecting 50% displacement of [ 3 H]nociceptin-specific receptor binding were calculated by nonlinear regression analysis and Ki values were calculated by using the Cheng-Prusoff equation. (Cheng and Prusoff. 1973).
  • the [ 35 S]GTP ⁇ S assays are carried out essentially as described by Gillen et al (2000). They are run as homogeneous scintillation proximity (SPA) assays in microtiter luminescence plates, where each well contains 1.5 mg of WGA-coated SPA-beads.
  • SPA scintillation proximity
  • hNOP hMOP
  • hDOP hKOP receptor expressing cell membranes from CHO-K1 or HEK293 cells
  • 10 or 5 ⁇ g membrane protein per assay are incubated with 0.4 nM [ 35 S]GTP ⁇ S and serial concentrations of receptor-specific agonists in buffer containing 20 mM HEPES pH 7.4, 100 mM NaCl, 10 mM MgCl 2 , 1 mM EDTA, 1 mM dithiothreitol, 1.28 mM NaN 3 , and 10 ⁇ M GDP for 45 min at room temperature.
  • microtiter plates are then centrifuged for 10 min at 830 to sediment the SPA beads.
  • the microtiter plates are sealed and the bound radioactivity [cpm] is determined after a delay of 15 min by means of a 1450 Microbeta Trilux (PerkinElmer, Waltham, Mass.).
  • the unstimulated basal binding activity (UBS obs [cpm]) is determined from 12 unstimulated incubates and is set as 100% basal binding.
  • the arithmetic mean of the observed total [ 3 S]GTP ⁇ S binding (TB obs [cpm]) of all incubates (duplicates) stimulated by the receptor-specific agonists i.e. N/OFQ, SNC80, DAMGO, or U69,593
  • TB obs [%] percent total binding
  • the percentage efficacies of test compounds at the hDOP, hMOP, or hKOP receptor are determined versus the calculated maximal enhancement of [ 35 S]GTP ⁇ S binding by the full agonists SNC80 (B1 calc-SNC80 [%]), DAMGO (B1 calc-DAMGO [%]) and U69,593 (B1 calc-U69,593 [%]) which are set as 100% relative efficacy at each receptor, respectively.

Abstract

The invention relates to 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.

Description

  • This application is a continuation of U.S. Nonprovisional patent application Ser. No. 16/265,080, filed Feb. 1, 2019, allowed; which is a continuation of U.S. Nonprovisional patent application Ser. No. 15/984,919, filed May 21, 2018, abandoned, which is a continuation of U.S. Nonprovisional patent application Ser. No. 15/405,896, filed Jan. 13, 2017, abandoned, which claims foreign priority benefit under 35 U.S.C. § 119 of European Patent Application No. 16 151 013.6, filed Jan. 13, 2016, the disclosures of which are incorporated herein by reference.
  • The invention relates to 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and use in medicine, particularly in various neurological disorders, including but not limited to pain, neurodegenerative disorders, neuroinflammatory disorders, neuropsychiatric disorders, substance abuse/dependence.
  • Opioid receptors are a group of Gi/o protein-coupled receptors which are widely distributed in the human body. The opioid receptors are currently subdivided into four major classes, i.e. the three classical opioid receptors mu-opioid (MOP) receptor, kappa-opioid (KOP) receptor, and delta-opioid (DOP) receptor as well as the opioid receptor-like (ORL-1) receptor, which was more recently discovered based on its high homology with said classical opioid receptors. After identification of the endogenous ligand of the ORL-1 receptor, known as nociceptin/orphanin FQ, a highly basic 17 amino acid peptide isolated from tissue extracts in 1995, the ORL-1 receptor was renamed “nociceptin opioid peptide receptor” and abbreviated as “NOP-receptor”.
  • The classical opioid receptors (MOP, KOP and DOP) as well as the NOP receptor are widely distributed/expressed in the human body, including in the brain, the spinal cord, on peripheral sensory neurons and the intestinal tract, wherein the distribution pattern differs between the different receptor classes.
  • Nociceptin acts at the molecular and cellular level in very much the same way as opioids. However, its pharmacological effects sometimes differ from, and even oppose those of opioids. NOP-receptor activation translates into a complex pharmacology of pain modulation, which, depending on route of administration, pain model and species involved, leads to either pronociceptive or antinociceptive activity. Furthermore, the NOP receptor system is upregulated under conditions of chronic pain. Systemic administration of selective NOP receptor agonists was found to exert a potent and efficacious analgesia in non-human primate models of acute and inflammatory pain in the absence of side effects. The activation of NOP receptors has been demonstrated to be devoid of reinforcing effects but to inhibit opioid-mediated reward in rodents and non-human primates (Review: Schroeder et al, Br J Pharmacol 2014; 171 (16): 3777-3800, and references therein).
  • Besides the involvement of the NOP receptor in nociception, results from preclinical experiments suggest that NOP receptor agonists might be useful inter alia in the treatment of neuropsychiatric disorders (Witkin et al, Pharmacology & Therapeutics, 141 (2014) 283-299; Jenck et al., Proc. Natl. Acad. Sci. USA 94, 1997, 14854-14858). Remarkably, the DOP receptor is also implicated to modulate not only pain but also neuropsychiatric disorders (Mabrouk et al, 2014; Pradhan et al., 2011).
  • Strong opioids acting at the MOP receptor site are widely used to treat moderate to severe acute and chronic pain. However, the therapeutic window of strong opioids is limited by severe side effects such as nausea and vomiting, constipation, dizziness, somnolence, respiratory depression, physical dependence and abuse. Furthermore, it is known that MOP receptor agonists show only reduced effectiveness under conditions of chronic and neuropathic pain.
  • It is known that some of the above mentioned side-effects of strong opioids are mediated by activation of classic opioid-receptors within the central nervous system. Furthermore, peripheral opioid receptors, when activated, can inhibit transmission of nociceptive signals shown in both, clinical and animal studies (Gupta et al., 2001; Kalso et al., 2002; Stein et al., 2003; Zollner et al., 2008).
  • Thus, to avoid CNS-mediated adverse effects after systemic administration, one approach has been to provide peripherally restricted opioid receptor ligands that do not easily cross the blood-brain barrier and therefore distribute poorly to the central nervous system (see for instance WO 2015/192039). Such peripherally acting compounds might combine effective analgesia with limited side-effects.
  • Another approach has been to provide compounds which interact with both the NOP receptor and the MOP receptor. Such compounds have for instance been described in WO 2004/043967, WO 2012/013343 and WO 2009/118168.
  • A further approach has been to provide multi-opioid receptor analgesics that modulate more than one of the opioid receptor subtypes to provide additive or synergistic analgesia and/or reduced side effects like abuse liability or tolerance.
  • On the one hand, it would be desirable to provide analgesics that selectively act on the NOP receptor system but less pronounced on the classic opioid receptor system, especially MOP receptor system, whereas it would be desirable to distinguish between central nervous activity and peripheral nervous activity. On the other hand, it would be desirable to provide analgesics that act on the NOP receptor system and also to a balanced degree on the MOP receptor system, whereas it would be desirable to distinguish between central nervous activity and peripheral nervous activity.
  • There is a need for medicaments which are effective in the treatment of pain and which have advantages compared to the compounds of the prior art. Where possible, such medicaments should contain such a small dose of active ingredient that satisfactory pain therapy can be ensured without the occurrence of intolerable treatment-emergent adverse events.
  • It is an object of the invention to provide pharmacologically active compounds, preferably analgesics that have advantages compared to the prior art.
  • This object has been achieved by the subject-matter of the patent claims.
  • A first aspect of the invention relates to 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives according to general formula (I)
  • Figure US20200399252A1-20201224-C00001
  • wherein
    n means 1, 2 or 3;
    R1 and R2 independently of one another mean
    • —H;
  • —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —OH, —OCH3, —CN and —CO2CH3;
    a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —OH, —OCH3, —CN and —CO2CH3; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted; or
    a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —OH, —OCH3, —CN and —CO2CH3; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted;
    or
    R1 and R2 together with the nitrogen atom to which they are attached form a ring and mean —(CH2)3-6—; —(CH2)2—O—(CH2)2—; or —(CH2)2—NRA(CH2)2—, wherein RA means —H or —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br and —I;
    preferably with the proviso that R1 and R2 do not simultaneously mean —H;
    R3 means
    —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
    a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
    a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
    a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or
    a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
    R4 means
    • —H;
  • —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said —C1-C6-alkyl is optionally connected through —C(═O)—, —C(═O)O—, or —S(═O)2—;
    a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C(═O)—, —C(═O)O—, —C(═O)O—CH2—, or —S(═O)2—;
    a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C(═O)—, —C(═O)O—, —C(═O)O—CH2—, or —S(═O)2—;
    a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 6-14-membered aryl moiety is optionally connected through —C(═O)—, —C(═O)O—, —C(═O)O—CH2—, or —S(═O)2—; or
    a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 5-14-membered heteroaryl moiety is optionally connected through —C(═O)—, —C(═O)O—, —C(═O)O—CH2—, or —S(═O)2—;
    R5 means
    a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; or
    a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted;
    R7, R8, R11, R12, R13, R14, R15, R16, R17, R18, R19, and R20 independently of one another mean —H, —F, —Cl, —Br, —I, —OH, or —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
    or wherein R7 and R8 together with the carbon atom to which they are attached form a ring and mean —(CH2)2— or —(CH2)3—;
    wherein “mono- or polysubstituted” means that one or more hydrogen atoms are replaced by a substituent independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —R21, —C(═O)R21, —C(═O)OR21, —C(═O)NR21R22, —O—(CH2CH2—O)1-30—H, —O—(CH2CH2—O)1-30—CH3, ═O, —OR21, —OC(═O)R21, —OC(═O)OR21, —OC(═O)NR21R22, —NO2, —NR21R22, —NR21—(CH2)1-6C(═O)R22, —NR21—(CH2)1-6—C(═O)OR22, —NR23—(CH2)1-6—C(═O)NR21R22, —NR21C(═O)R22, —NR21C(═O)—OR22, —NR23C(═O)NR21R22, —NR21S(═O)2R22, —SR21, —S(═O)R21, —S(═O)2R21, —S(═O)2OR21, and —S(═O)2NR21R22;
    wherein
    R21, R22 and R23 independently of one another mean
    • —H;
  • —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH2, and —O—C1-C6-alkyl;
    a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH2, —C1-C6-alkyl and —O—C1-C6-alkyl;
    a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH2, —C1-C6-alkyl and —O—C1-C6-alkyl;
    a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH2, —C1-C6-alkyl and —O—C1-C6-alkyl;
    a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH2, —C1-C6-alkyl and —O—C1-C6-alkyl;
    or R21 and R22 within —C(═O)NR21R22, —OC(═O)NR21R22, —NR21R22, —NR23—(CH2)1-6—C(═O)NR21R22, —NR23C(═O)NR21R22, or —S(═O)2NR21R22 together with the nitrogen atom to which they are attached form a ring and mean —(CH2)3-6—; —(CH2)2—O—(CH2)2—; or —(CH2)2—NRB—(CH2)2—, wherein RB means —H or —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br and —I;
    or a physiologically acceptable salt thereof.
  • Preferably, aryl includes but is not limited to phenyl and naphthyl. Preferably, heteroaryl includes but is not limited to -1,2-benzodioxole, -pyrazinyl, -pyridazinyl, -pyridinyl, -pyrimidinyl, -thienyl, -imidazolyl, -benzimidazolyl, -thiazolyl, -1,3,4-thiadiazolyl, -benzothiazolyl, -oxazolyl, -benzoxazolyl, -pyrazolyl, -quinolinyl, -isoquinolinyl, -quinazolinyl, -indolyl, -indolinyl, -benzo[c][1,2,5]oxadiazolyl, -imidazo[1,2-a]pyrazinyl, or -1H-pyrrolo[2,3-b]pyridinyl. Preferably, cycloalkyl includes but is not limited to -cyclopropyl, -cyclobutyl, -cyclopentyl and -cyclohexyl. Preferably, heterocycloalkyl includes but is not limited to -aziridinyl, -azetidinyl, -pyrrolidinyl, -piperidinyl, -piperazinyl, -morpholinyl, -sulfamorpholinyl, -oxiridinyl, -oxetanyl, -tetrahydropyranyl, and -pyranyl.
  • When a moiety is connected through an asymmetric group such as —C(═O)O— or —C(═O)O—CH2—, said asymmetric group may be arranged in either direction. For example, when R4 is connected to the core structure through —C(═O)O—, the arrangement may be either R4—C(═O)O-core or core —C(═O)O—R4.
  • In preferred embodiments of the compound according to the invention, R7, R8, R11, R12, R13, R14, R15, R16, R17, R18, R19, and R20 independently of one another mean —H, —F, —OH, or —C1-C6-alkyl; preferably —H.
  • In preferred embodiments of the compound according to the invention, R7 and R8 together with the carbon atom to which they are attached form a ring and mean —(CH2)2— (i.e. form a cyclopropyl ring) or —(CH2)3— (i.e. form a cyclobutyl ring).
  • In a preferred embodiment of the compound according to the invention, R1 means —H; and R2 means —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R1 means —H and R2 means —CH3.
  • In another preferred embodiment of the compound according to the invention, R1 means —CH3; and R2 means —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R1 means —CH3 and R2 means —CH3.
  • In still another preferred embodiment of the compound according to the invention, R1 and R2 together with the nitrogen atom to which they are attached form a ring and mean —(CH2)3-6—. Preferably, R1 and R2 together with the nitrogen atom to which they are attached form a ring and mean —(CH2)3—.
  • In yet another preferred embodiment,
      • R1 means —H or —CH3; and
      • R2 means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted; wherein said 3-12-membered cycloalkyl moiety is connected through —CH2—, unsubstituted; preferably —CH2-cycloalkyl, —CH2-cyclobutyl or —CH2-cyclopentyl; or R2 means a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted; wherein said 3-12-membered heterocycloalkyl moiety is connected through —CH2—, unsubstituted; preferably —CH2-oxetanyl or —CH2-tetrahydrofuranyl.
  • In a preferred embodiment of the compound according to the invention, R3 means —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R3 means —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with —OCH3.
  • In another preferred embodiment of the compound according to the invention, R3 means a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted, optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted. In a preferred embodiment, R3 means -phenyl unsubstituted, mono- or polysubstituted. More preferably, R3 means -phenyl unsubstituted, mono- or disubstituted with —F, —Cl, —CH3, —CF3, —OH, —OCH3, —OCF3 or —OCH2OCH3, preferably —F. In another preferred embodiment, R3 means -benzyl unsubstituted, mono- or polysubstituted. More preferably, R3 means -benzyl unsubstituted, mono- or disubstituted with —F, —Cl, —CH3, —CF3, —OH, —OCH3, —OCF3 or —OCH2OCH3, preferably —F.
  • In still another preferred embodiment of the compound according to the invention, R3 means a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted. Preferably, R3 means -thienyl or -pyridinyl, in each case unsubstituted, mono- or polysubstituted. More preferably, R3 means -thienyl, -pyridinyl, -imidazolyl or benzimidazolyl, in each case unsubstituted or monosubstituted with —F, —Cl or —CH3.
  • In a preferred embodiment of the compound according to the invention, R4 means —H.
  • In another preferred embodiment of the compound according to the invention, R4 means —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R4 means —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with a substituent selected from the group consisting of —F, —Cl, —Br, —I, —CN, —CF3, —OH, —O—C1-C4-alkyl, —OCF3, —O—(CH2CH2—O)1-30—H, —O—(CH2CH2—O)1-30—CH3, —OC(═O)C1-C4-alkyl, —C(═O)C1-C4-alkyl, —C(═O)OH, —C(═O)OC1-C4-alkyl, —C(═O)NH2, —C(═O)NHC1-C4-alkyl, —C(═O)NHC1-C4-alkylene-CN, —C(═O)NHC1-C4-alkylene-O—C1-C4-alkyl, —C(═O)N(C1-C4-alkyl)2; —S(═O)C1-C4-alkyl, and —S(═O)2C1-C4-alkyl; or with —C(═O)NR21R22 wherein R21 and R22 together with the nitrogen atom to which they are attached form a ring and mean —(CH2)3-6—, —(CH2)2—O—(CH2)2—, or —(CH2)2—NRB—(CH2)2—, wherein RB means —H or —C1-C6-alkyl; or with —C(═O)NH-3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted or monosubstituted with —F, —Cl, —Br, —I, —CN, or —OH; or with —C(═O)NH-3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted or monosubstituted with —F, —Cl, —Br, —I, —CN, or —OH. More preferably, R4 means —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with —O—C1-C4-alkyl or —C(═O)N(C1-C4-alkyl)2.
  • In still another preferred embodiment of the compound according to the invention, R4 means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein the 3-12-membered cycloalkyl moiety is connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R4 means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is connected through —CH2— or —CH2CH2—. More preferably, R4 means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —C1-C4-alkyl, —O—C1-C4-alkyl, —C(═O)OH, —C(═O)OC1-C4-alkyl, —C(═O)NH2, —C(═O)NHC1-C4-alkyl, —C(═O)N(C1-C4-alkyl)2, —S(═O)C1-C4-alkyl and —S(═O)2C1-C4-alkyl; wherein said 3-12-membered cycloalkyl moiety is connected through —CH2— or —CH2CH2—.
  • In a preferred embodiment of the compound according to the invention, R4 means a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R4 means a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is connected through —CH2— or —CH2CH2—. More preferably, R4 means -oxetanyl, -tetrahydrofuranyl or -tetrahydropyranyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —C1-C4-alkyl, —O—C1-C4-alkyl, —C(═O)OH, —C(═O)OC1-C4-alkyl, —C(═O)NH2, —C(═O)NHC1-C4-alkyl, —C(═O)N(C1-C4-alkyl)2, —S(═O)C1-C4-alkyl and —S(═O)2C1-C4-alkyl; wherein said -oxetanyl, -tetrahydrofuranyl or -tetrahydropyranyl is connected through —CH2— or —CH2CH2—.
  • In yet another preferred embodiment of the compound according to the invention, R4 means a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R4 means -phenyl, unsubstituted, mono- or polysubstituted; wherein said -phenyl is connected through —CH2— or —CH2CH2—. More preferably, R4 means -phenyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —C1-C4-alkyl, —O—C1-C4-alkyl, —C(═O)OH, —C(═O)OC1-C4-alkyl, —C(═O)NH2, —C(═O)NHC1-C4-alkyl, —C(═O)N(C1-C4-alkyl)2, —S(═O)C1-C4-alkyl and —S(═O)2C1-C4-alkyl; wherein said -phenyl is connected through —CH2— or —CH2CH2—.
  • In a further preferred embodiment of the compound according to the invention, R4 means a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R4 means a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said -phenyl is connected through —CH2— or —CH2CH2—. More preferably, R4 means -pyridinyl, -pyrimidinyl, -pyrazinyl, or -pyrazolinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —C1-C4-alkyl, —O—C1-C4-alkyl, —C(═O)OH, —C(═O)OC1-C4-alkyl, —C(═O)NH2, —C(═O)NHC1-C4-alkyl, —C(═O)N(C1-C4-alkyl)2, —S(═O)C1-C4-alkyl and —S(═O)2C1-C4-alkyl; wherein said -pyridinyl, -pyrimidinyl, -pyrazinyl, or -pyrazolinyl is connected through —CH2— or —CH2CH2—.
  • In a preferred embodiment of the compound according to the invention, n means 1 or 2. Preferably, n means 1.
  • In a preferred embodiment of the compound according to the invention, R means -phenyl, unsubstituted, mono- or polysubstituted. Preferably, R5 means -phenyl unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F; —Cl; —Br; —I; —CN; —OH; —C1-C4-alkyl; —CF3; -3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; preferably -cyclopropyl, saturated, unsubstituted; -3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; preferably -pyrrolidinyl, -piperidinyl, -morpholinyl, -piperazinyl, -thiomorpholinyl, or -thiomorpholinyl dioxide, in each case saturated, unsubstituted or monosubstituted with —C1-C4-alkyl; —O—CH2—O— (such that it is condensed with a dioxolanyl ring); —O—C1-C4-alkyl; —O—(CH2CH2—O)1-30—H; —O—(CH2CH2—O)1-30—CH3; —C(═O)OH; —C(═O)OC1-C4-alkyl; —C(═O)NH2; —C(═O)NHC1-C4-alkyl; —C(═O)N(C1-C4-alkyl)2; —S(═O)C1-C4-alkyl and —S(═O)2C1-C4-alkyl.
  • In another preferred embodiment of the compound according to the invention, R5 means -pyrazinyl, -pyridazinyl, -pyridinyl, -pyrimidinyl, -thienyl, -imidazolyl, triazolyl, or -1,3-benzodioxolyl, in each case unsubstituted, mono- or polysubstituted. Preferably, R5 means -pyrazinyl, -pyridazinyl, -pyridinyl, -pyrimidinyl, -thienyl, -imidazolyl, triazolyl, or -1,3-benzodioxolyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F; —Cl; —Br; —I; —CN; —OH; —C1-C4-alkyl; —CF3; —C1-C4-alkyl-OH; —C1-C4-alkyl-C(═O)NH2; -3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; preferably -cyclopropyl, saturated, unsubstituted; -3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; preferably -pyrrolidinyl, -piperidinyl, -morpholinyl, -piperazinyl, -thiomorpholinyl, or -thiomorpholinyl dioxide, in each case saturated, unsubstituted or monosubstituted with —C1-C4-alkyl; —O—CH2—O— (such that it is condensed with a dioxolanyl ring); —O—C1-C4-alkyl; —O—(CH2CH2—O)1-30—H; —O—(CH2CH2—O)1-30—CH3; —C(═O)OH; —C(═O)OC1-C4-alkyl; —C(═O)NH2; —C(═O)NHC1-C4-alkyl; —C(═O)N(C1-C4-alkyl)2; —SC1-C4-alkyl; —S(═O)C1-C4-alkyl and —S(═O)2C1-C4-alkyl.
  • In preferred embodiments, the compound according to the invention has a structure according to any of general formulas (II-A) to (VIII-C):
  • Figure US20200399252A1-20201224-C00002
    Figure US20200399252A1-20201224-C00003
    Figure US20200399252A1-20201224-C00004
    Figure US20200399252A1-20201224-C00005
  • wherein in each case
    R1, R2, R3, R4, and R5 are defined as above,
    RC means —H, —OH, —F, —CN or —C1-C4-alkyl; preferably —H or —OH;
    RD means —H or —F;
    or a physiologically acceptable salt thereof.
  • Preferably, in the compounds according to general formula (I) or any of the compounds according to general formulas (II-A) to (VIII-C), R5 is selected from the group consisting of:
  • Figure US20200399252A1-20201224-C00006
    Figure US20200399252A1-20201224-C00007
  • In a particularly preferred embodiment of the compound according to the invention,
  • n means 1 or 2;
    R1 means —H or —CH3;
    R2 means —H or —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with —OH, —OCH3, —C(═O)OCH3, or —CN;
    R3 means
    —C1-C4-alkyl, optionally monosubstituted with —OCH3;
    -phenyl, -thienyl or -pyridinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —CN, —CH3, —CH2CH3, —CH2F, —CHF2, —CF3, —OCF3, —OH, —OCH3, —O—CH2—O—CH3, —C(═O)NH2, C(═O)NHCH3, —C(═O)N(CH3)2, —NH2, —NHCH3, —N(CH3)2, —NHC(═O)CH3, —CH2OH, SOCH3 and SO2CH3; or
    R means
    • —H;
  • —C1-C6-alkyl, linear or branched, saturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, ═O, —OH, —O—C1-C4-alkyl, —CO2H, —C(═O)O—C1-C4-alkyl, —C(═O)NH2, —C(═O)NH—C1-C4-alkyl, —C(═O)N(C1-C4-alkyl)2, —C(═O)NH—C1-C4-alkyl-CN, —C(═O)NCH3—C1-C4-alkyl-CN, —C(═O)NH-cyclopropyl-CN, —C(═O)NCH3-cyclopropyl-CN, —C(═O)NH—C1-C4-alkyl-OH, —C(═O)NCH3—C1-C4-alkyl-OH, —C(═O)NH—C1-C4-alkyl-OCH3, —C(═O)NCH3—C1-C4-alkyl-OCH3, —C(═O)NRR′ wherein R and R′ together with the nitrogen atom to which they are attached form a ring and mean —(CH2)2-4—;
    3-6-membered cycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, and —O—C1-C4-alkyl, wherein said 3-6-membered cycloalkyl is connected through —C1-C6-alkylene;
    3-6-membered heterocycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —CO2H, —C(═O)O—C1-C4-alkyl, —OH, and —O—C1-C4-alkyl, wherein said 3-6-membered heterocycloalkyl is connected through —C1-C6-alkylene;
    6-14-membered aryl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —CO2H, —C(═O)O—C1-C4-alkyl, —OH, and —O—C1-C4-alkyl; wherein said 6-14-membered aryl is connected through —C1-C6-alkylene- or —S(═O)2—;
    5-14-membered heteroaryl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —CO2H, —C(═O)O—C1-C4-alkyl, —OH, and —O—C1-C4-alkyl; wherein said 5-14-membered heteroaryl is connected through —C1-C6-alkylene- or —S(═O)2—;
    R5 means -phenyl, -pyrazinyl, -pyridazinyl, -pyridinyl, -pyrimidinyl, -thienyl, -imidazolyl, triazolyl, or -1,3-benzodioxolyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F; —Cl; —Br; —I; —CN; —OH; —C1-C4-alkyl; —CF3; —C1-C4-alkyl-OH; —C1-C4-alkyl-C(═O)NH2; -3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; preferably -cyclopropyl, saturated, unsubstituted; -3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; —O—CH2—O—; —O—C1-C4-alkyl; —O—(CH2CH2-0)1-30—H; —O—(CH2CH2—O)1-30—CH3; —C(═O)OH; —C(═O)OC1-C4-alkyl; —C(═O)NH2; —C(═O)NHC1-C4-alkyl; —C(═O)N(C1-C4-alkyl)2; —SC1-C4-alkyl; —S(═O)C1-C4-alkyl and —S(═O)2C1-C4-alkyl; and
    R7, R8, R11, R12, R13, R14, R15, R16, R17, R18, R19, and R20 mean —H.
  • In a particularly preferred embodiment of the compound according to the invention,
  • n means 1 or 2; and/or
    R1 means —H or —CH3; and/or
    R2 means —C1-C6-alkyl, linear or branched, saturated, unsubstituted; preferably, R2 means —CH3 or —CH2CH3; more preferably, R1 and R2 both mean —CH3; and/or
    R3 means -phenyl, -thienyl or -pyridinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —CN, —CH3, —CH2CH3, —CH2F, —CHF2, —CF3, —OCF3, —OH, —OCH3, —C(═O)NH2, C(═O)NHCH3, —C(═O)N(CH3)2, —NH2, —NHCH3, —N(CH3)2, —NHC(═O)CH3, —CH2OH, SOCH3 and SO2CH3; preferably R3 means -phenyl, -thienyl or -pyridinyl, in each case unsubstituted or substituted with —F; more preferably, R3 means phenyl, unsubstituted; and/or
    R4 means
    • —H;
  • —C1-C6-alkyl, linear or branched, saturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, and —O—C1-C4-alkyl; or
    3-6-membered cycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, and —O—C1-C4-alkyl, wherein said 3-6-membered cycloalkyl is connected through —C1-C6-alkylene; preferably R4 means 3-6-membered cycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, and —O—C1-C4-alkyl, wherein said 3-6-membered cycloalkyl is connected through —CH2— or —CH2CH2—; more preferably, R4 means -cyclobutyl, unsubstituted or monosubstituted with —OH, wherein said -cyclobutyl is connected through —CH2—; and/or
    R5 means -phenyl, -pyridazinyl, -pyridinyl, or -pyrimidinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F; —Cl; —Br; —I; —CN; —OH; —C1-C4-alkyl; —CF3; -3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; preferably -cyclopropyl, saturated, unsubstituted; -3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; preferably -pyrrolidinyl, -piperidinyl, -morpholinyl, -piperazinyl, -thiomorpholinyl, or -thiomorpholinyl dioxide, in each case saturated, unsubstituted or monosubstituted with —C1-C4-alkyl; —O—CH2—O— (such that it is condensed with a dioxolanyl ring); —O—C1-C4-alkyl; —O—(CH2CH2—O)1-30—H; —O—(CH2CH2—O)1-30—CH3; —C(═O)OH; —C(═O)OC1-C4-alkyl; —C(═O)NH2; —C(═O)NHC1-C4-alkyl; —C(═O)N(C1-C4-alkyl)2; —S(═O)C1-C4-alkyl and —S(═O)2C1-C4-alkyl; and/or
    R7, R8, R11, R12, R13, R14, R15, R16, R17, R18, R19, and R20 mean —H.
  • In preferred embodiments, the compound according to the invention is selected from the group consisting of
  •
    SC_2001 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(4-methylsulfonyl-phenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2002 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(3-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2003 CIS-8-Dimethylamino-1-isopropyl-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2004 CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2005 CIS-1-(Cyclobutyl-methyl)-3-[(4-methoxyphenyl)-methyl]-8-[methyl-(2-methyl-propyl)-
    amino]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2006 CIS-2-[[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-3-yl]-methyl]-benzamide
    SC_2007 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-(pyrazin-2-yl-methyl)-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2008 CIS-8-(Allyl-methyl-amino)-1-(cyclobutyl-methyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2009 CIS-4-[[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-3-yl]-methyl]-benzamide
    SC_2010 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2011 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(4-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2012 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-methoxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2013 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(4-methoxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2014 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1-(2-methyl-propyl)-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2015 CIS-1-Butyl-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2016 CIS-8-Dimethylamino-8-(4-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2017 CIS-8-Dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2018 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-hydroxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2019 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-(pyridin-3-yl-methyl)-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2020 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[[3-[2-[2-[2-[2-[2-(2-methoxy-
    ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-phenyl]-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2021 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(4-hydroxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-
    diazaspiro[4.5]decan-2-one hydrochloride
    SC_2022 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[(3-methoxyphenyl)-methyl]-8-
    phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2023 CIS-1-(Cyclopentyl-methyl)-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2024 CIS-8-Dimethylamino-1-(2-hydroxy-2-methyl-propyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2025 CIS-8-Dimethylamino-1-(2-methoxy-2-methyl-propyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2026 CIS-1-(Cyclobutyl-methyl)-3-[(3-methoxyphenyl)-methyl]-8-methylamino-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2027 CIS-3-[[1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-3-yl]-methyl]-benzonitrile
    SC_2028 CIS-1-(Cyclobutyl-methyl)-3-[(3-methoxyphenyl)-methyl]-8-(methyl-propyl-amino)-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2029 CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-3-[(3-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2030 CIS-3-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-1-yl]-propionitrile
    SC_2031 CIS-1-(Cyclobutyl-methyl)-8-methylamino-8-phenyl-3-(pyridin-3-yl-methyl)-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2032 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1-(oxetan-3-yl-methyl)-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2033 CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-3-(pyridin-3-yl-methyl)-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2034 CIS-8-Dimethylamino-1-(2-hydroxy-ethyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2035 CIS-8-Dimethylamino-1-(2,2-dimethyl-propyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2036 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1-(3-methyl-butyl)-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2037 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1-[3-(trifluoromethyloxy)-
    propyl]-1,3-diazaspiro[4.5]decan-2-one
    SC_2038 CIS-1-(2-Cyclobutyl-ethyl)-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2039 CIS-1-[(3,3-Difluoro-cyclobutyl)-methyl]-8-dimethylamino-3-[(4-methoxyphenyl)-
    methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2040 CIS-2-[[1-(Cyclobutyl-methyl)-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-8-yl]-methyl-amino]-acetonitrile
    SC_2041 CIS-1-(Cyclobutyl-methyl)-8-[(2-methoxy-ethyl)-methyl-amino]-3-[(4-methoxyphenyl)-
    methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2042 CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-1-yl]-acetic acid tert-butyl ester
    SC_2043 CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-1-yl]-acetic acid; 2,2,2-trifluoro-acetic acid salt
    SC_2044 CIS-1-(Cyclobutyl-methyl)-3-[(4-methoxyphenyl)-methyl]-8-methylamino-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2045 CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-1-yl]-acetic acid methyl ester
    SC_2046 CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-1-yl]-acetamide
    SC_2047 CIS-1-Benzyl-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2048 CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-1-yl]-N-methyl-acetamide
    SC_2049 CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-1-yl]-N-propyl-acetamide
    SC_2050 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1-(3-methoxy-propyl)-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2051 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[(4-methoxyphenyl)-methyl]-
    8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2052 CIS-8-Dimethylamino-1-(2-methoxy-ethyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2053 CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-1-yl]-acetonitrile
    SC_2054 CIS-8-Dimethylamino-1-hexyl-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2055 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1-(tetrahydro-pyran-4-yl-methyl)-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2056 CIS-1-(Cyclohexyl-methyl)-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2057 CIS-N-(Cyano-methyl)-2-[8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-1-yl]-acetamide
    SC_2058 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1-(pyridin-3-yl-methyl)-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2059 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-(3-methoxy-propyl)-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2060 CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-1-yl]-N-(2-methoxy-ethyl)-acetamide
    SC_2062 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-8-phenyl-
    1,3-diazaspiro[4.5]decan-2-one
    SC_2063 CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-1-yl]-N,N-dimethyl-acetamide
    SC_2064 CIS-N-(1-Cyano-cyclopropyl)-2-[8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-
    1,3-diazaspiro[4.5]decan-1-yl]-acetamide
    SC_2065 CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-1-yl]-N-methyl-N-propyl-acetamide
    SC_2066 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-(3-methoxy-propyl)-
    1,3-diazaspiro[4.5]decan-2-one
    SC_2067 CIS-8-Dimethylamino-1-(3-hydroxy-propyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2068 CIS-8-Dimethylamino-1-(4-methoxy-butyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2069 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1-[(1-methyl-cyclobutyl)-methyl]-8-
    phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2070 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclohexyl)-methyl]-3-[(4-methoxyphenyl)-methyl]-8-
    phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2071 CIS-5-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-1-yl]-pentanenitrile
    SC_2072 CIS-3-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-1-yl]-propionamide
    SC_2073 CIS-1-(Cyclobutyl-methyl)-8-[(2-hydroxy-ethyl)-methyl-amino]-3-[(4-methoxyphenyl)-
    methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2074 CIS-1-[[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-1-yl]-methyl]-cyclobutane-1-carbonitrile
    SC_2075 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclopentyl)-methyl]-3-[(4-methoxyphenyl)-methyl]-
    8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2076 CIS-3-[(2-Bromophenyl)-methyl]-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2077 CIS-3-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-1-yl]-N-methyl-propionamide
    SC_2078 CIS-3-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-1-yl]-N-propyl-propionamide
    SC_2079 CIS-8-Dimethylamino-1-[(1-fluoro-cyclobutyl)-methyl]-3-[(4-methoxyphenyl)-methyl]-8-
    phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2080 CIS-1-(2-Cyclohexyl-ethyl)-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2081 CIS-3-[[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-
    3-yl]-methyl]-benzonitrile
    SC_2082 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1-methyl-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2083 CIS-8-Dimethylamino-1-[2-[2-[2-[2-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-
    ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethyl]-3-[(4-methoxyphenyl)-
    methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2084 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1-(2-tetrahydro-pyran-4-yl-ethyl)-
    1,3-diazaspiro[4.5]decan-2-one
    SC_2085 CIS-4-[[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-
    3-yl]-methyl]-benzonitrile
    SC_2086 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[[6-(trifluoromethyl)-pyridin-3-yl]-
    methyl]-1,3-diazaspiro[4.5]decan-2-one
    SC_2087 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[[4-[2-[2-[2-[2-[2-[2-[2-(2-
    methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-
    phenyl]-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2088 CIS-3-[[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-
    3-yl]-methyl]-benzamide
    SC_2089 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(4-hydroxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2090 CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2091 CIS-8-Dimethylamino-1-[(1-methoxy-cyclobutyl)-methyl]-3-[(4-methoxyphenyl)-methyl]-8-
    phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2092 CIS-2-[[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-
    3-yl]-methyl]-benzonitrile
    SC_2093 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(3-methylsulfonyl-phenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2094 CIS-8-Dimethylamino-1-ethyl-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2095 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1-propyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2096 CIS-3-Benzyl-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2097 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2099 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1-(pyrimidin-4-yl-methyl)-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2100 CIS-3-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-1-yl]-2,2-dimethyl-propionitrile
    SC_2101 CIS-2-[[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-1-yl]-methyl]-benzoic acid methyl ester
    SC_2102 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-(pyridin-2-yl-methyl)-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2103 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-(pyridin-4-yl-methyl)-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2104 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1-(tetrahydro-furan-3-yl-methyl)-
    1,3-diazaspiro[4.5]decan-2-one
    SC_2105 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-(pyrimidin-2-yl-methyl)-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2106 CIS-3-[[1-[(5-Cyano-2-methoxy-phenyl)-methyl]-8-dimethylamino-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-3-yl]-methyl]-4-methoxy-benzonitrile
    SC_2107 CIS-8-Dimethylamino-1-(3-hydroxy-3-methyl-butyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-
    1,3-diazaspiro[4.5]decan-2-one
    SC_2108 CIS-8-Dimethylamino-1-(3-methoxy-3-methyl-butyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-
    1,3-diazaspiro[4.5]decan-2-one
    SC_2109 CIS-2-[[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-3-yl]-methyl]-benzamide
    SC_2110 CIS-3-[[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-3-yl]-methyl]-benzamide
    SC_2111 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2112 CIS-1-[(1-Hydroxy-cyclobutyl)-methyl]-3-[(4-methoxyphenyl)-methyl]-8-methylamino-8-
    phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2113 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1-(tetrahydro-furan-2-yl-methyl)-
    1,3-diazaspiro[4.5]decan-2-one
    SC_2114 CIS-3-Benzyl-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2115 CIS-3-Benzyl-8-dimethylamino-1-ethyl-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2117 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1-[2-(methylsulfonyl)-ethyl]-8-
    phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2118 CIS-8-Dimethylamino-1-[(2R)-2-hydroxy-propyl]-3-[(4-methoxyphenyl)-methyl]-8-
    phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2119 CIS-8-Dimethylamino-1-[(2S)-2-hydroxy-propyl]-3-[(4-methoxyphenyl)-methyl]-8-
    phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2120 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1-(tetrahydro-furan-3-yl-methyl)-
    1,3-diazaspiro[4.5]decan-2-one
    SC_2122 CIS-8-Dimethylamino-1-ethyl-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2123 CIS-8-Amino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[(4-methoxyphenyl)-methyl]-8-
    phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2124 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-(2-phenyl-ethyl)-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2125 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[(4-methoxyphenyl)-methyl]-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2126 CIS-3-[[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-3-yl]-methyl]-4-methoxy-benzonitrile
    SC_2127 CIS-8-Dimethylamino-1-ethyl-8-phenyl-3-(pyridin-3-yl-methyl)-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2129 CIS-8-Dimethylamino-1-[2-(1-methoxy-cyclobutyl)-ethyl]-3-[(4-methoxyphenyl)-methyl]-8-
    phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2130 CIS-8-Dimethylamino-8-[3-(methoxymethyloxy)-phenyl]-3-[(4-methoxyphenyl)-methyl]-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2131 CIS-8-Dimethylamino-8-[4-(methoxymethyloxy)-phenyl]-3-[(4-methoxyphenyl)-methyl]-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2132 CIS-3-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-1-yl]-propionic acid
    SC_2133 CIS-3-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-1-yl]-propionic acid tert-butyl ester
    SC_2134 CIS-2-[[1-(Cyclobutyl-methyl)-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-8-yl]-methyl-amino]-acetic acid methyl ester
    SC_2135 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1-(3-methyl-but-2-enyl)-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2136 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(3-methylsulfanyl-phenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2137 CIS-3-[(3-Bromophenyl)-methyl]-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2138 CIS-2-((8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-3-yl)methyl)benzonitrile
    SC_2139 CIS-8-Dimethylamino-8-(3-methoxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2140 CIS-8-Dimethylamino-8-(4-methoxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2141 CIS-3-((8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-3-yl)methyl)benzonitrile
    SC_2142 CIS-3-((8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)methyl)-4-
    methoxybenzonitrile
    SC_2143 CIS-8-Dimethylamino-8-phenyl-3-(1H-[1,2,3]triazol-4-yl-methyl)-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2144 CIS-8-Dimethylamino-3-[[1-(2-hydroxy-ethyl)-1H-[1,2,3]triazol-4-yl]-methyl]-
    8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2145 CIS-2-[4-[(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-methyl]-
    1H-[1,2,3]triazol-1-yl]-acetamide
    SC_2146 CIS-8-Methylamino-8-phenyl-3-(1H-[1,2,3]triazol-4-yl-methyl)-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2147 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1-(p-tolylsulfonyl)-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2148 CIS-2-[4-[(8-Methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-methyl]-
    1H-[1,2,3]triazol-1-yl]-acetamide
    SC_2149 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decane-1-carboxylic acid benzyl ester
    SC_2150 CIS-3-[[1-(2-Hydroxy-ethyl)-1H-[1,2,3]triazol-4-yl]-methyl]-8-methylamino-8-
    phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2152 CIS-8-Dimethylamino-8-phenyl-3-(2-pyridin-2-yl-ethyl)-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2153 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[[1-(2-hydroxy-ethyl)-1H-
    [1,2,3]triazol-4-yl]-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2155 CIS-2-[4-[[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-3-yl]-methyl]-1H-[1,2,3]triazol-1-yl]-acetamide
    SC_2156 CIS-1-[(1-Hydroxy-cyclobutyl)-methyl]-3-[[1-(2-hydroxy-ethyl)-1H-[1,2,3]triazol-
    4-yl]-methyl]-8-methylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2159 CIS-2-[4-[[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-3-yl]-methyl]-1H-[1,2,3]triazol-1-yl]-acetamide
    SC_2160 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[[1-(2-hydroxy-ethyl)-1H-[1,2,3]triazol-
    4-yl]-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2161 CIS-2-[4-[[1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-3-yl]-methyl]-1H-[1,2,3]triazol-1-yl]-acetamide
    SC_2162 CIS-1-(Cyclobutyl-methyl)-3-[[1-(2-hydroxy-ethyl)-1H-[1,2,3]triazol-4-yl]-methyl]-
    8-methylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2163 CIS-2-[4-[[1-(Cyclobutyl-methyl)-8-methylamino-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-3-yl]-methyl]-1H-[1,2,3]triazol-1-yl]-acetamide
    SC_2164 CIS-8-Dimethylamino-8-phenyl-3-(2-pyridin-3-yl-ethyl)-1,3-diazaspiro[4.5]decan-2-one
    SC_2165 CIS-8-Dimethylamino-3-[2-(1H-imidazol-1-yl)-ethyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2166 CIS-8-Dimethylamino-8-phenyl-3-(2-pyridin-4-yl-ethyl)-1,3-diazaspiro[4.5]decan-2-one
    SC_2167 CIS-8-Dimethylamino-8-phenyl-3-(2-pyrimidin-2-yl-ethyl)-1,3-diazaspiro[4.5]decan-2-one
    SC_2168 CIS-8-Dimethylamino-8-phenyl-3-(2-pyrimidin-5-yl-ethyl)-1,3-diazaspiro[4.5]decan-2-one
    SC_2169 CIS-8-Dimethylamino-1-ethyl-3-[(4-methylsulfonyl-phenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2170 CIS-8-Dimethylamino-3-(1-methyl-1-phenyl-ethyl)-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2171 CIS-8-Dimethylamino-8-phenyl-3-(1-phenyl-cyclopropyl)-1,3-diazaspiro[4.5]decan-2-one
    SC_2172 CIS-8-Dimethylamino-1,3-bis[(2-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2173 CIS-8-Dimethylamino-3-[(3-methylsulfonyl-phenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2174 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(1-methyl-1-phenyl-ethyl)-8-phenyl-
    1,3-diazaspiro[4.5]decan-2-one
    SC_2175 CIS-3-[(3-Cyclopropyl-phenyl)-methyl]-8-dimethylamino-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2176 CIS-3-(1,3-Benzodioxol-4-yl-methyl)-8-dimethylamino-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2177 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-(1-phenyl-cyclopropyl)-
    1,3-diazaspiro[4.5]decan-2-one
    SC_2178 CIS-4-[[8-Dimethylamino-3-[(2-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-
    diazaspiro[4.5]decan-1-yl]-methyl]-benzonitrile
    SC_2179 CIS-8-Dimethylamino-3-[(2-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2180 CIS-8-Dimethylamino-8-phenyl-3-(pyridin-4-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one
    SC_2181 CIS-8-Dimethylamino-8-phenyl-3-(pyridin-2-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one
    SC_2182 CIS-8-Dimethylamino-8-phenyl-3-(pyridin-3-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one
    SC_2183 CIS-8-Dimethylamino-3-[[2-(4-methyl-piperazin-1-yl)-pyridin-4-yl]-methyl]-8-phenyl-
    1,3-diazaspiro[4.5]decan-2-one
    SC_2184 CIS-8-Dimethylamino-8-phenyl-3-[(2-piperidin-1-yl-pyridin-4-yl)-methyl]-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2185 CIS-8-Dimethylamino-3-[(2-morpholin-4-yl-pyridin-4-yl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2186 CIS-8-Dimethylamino-8-phenyl-3-[(2-piperazin-1-yl-pyridin-4-yl)-methyl]-1,3-
    diazaspiro[4.5]decan-2-one

    and the physiologically acceptable salts thereof.
  • According to the invention, unless expressly stated otherwise, “—C1-C4-alkyl”, “—C1-C6-alkyl” and any other alkyl residues can be linear or branched, saturated or unsaturated. Linear saturated alkyl includes methyl, ethyl, n-propyl, n-butyl, n-pentyl and n-hexyl. Examples of branched saturated alkyl include but are not limited to iso-propyl, sc-butyl, and tert-butyl. Examples of linear unsaturated alkyl include but are not limited to vinyl, propenyl, allyl, and propargyl.
  • According to the invention, unless expressly stated otherwise, “—C1-C4-alkyl”, “—C1-C6-alkyl” and any other alkyl residues can be unsubstituted, mono- or polysubstituted. Examples of substituted alkyl include but are not limited to —CH2CH2OH, —CH2CH2CH3, —CH2CH2CH2OCH3, —CH2CH2S(═O)2CH3, —CH2C(═O)NH2, —C(CH3)2C(═O)NH2, —CH2C(CH3)2C(═O)NH2, and —CH2CH2C(═O)N(CH3)2.
  • According to the invention, unless expressly stated otherwise, “—C1-C6-alkylene-”, “—C1-C4-alkylene” and any other alkylene residue can be unsubstituted, mono- or polysubstituted. Examples of saturated alkylene include but are not limited to —CH2—, —CH(CH3)—, —C(CH3)2—, —CH2CH2—, —CH(CH3)CH2—, —CH2CH(CH3)—, —CH(CH3)—CH(CH3)—, —C(CH3)2CH2—, —CH2C(CH3)2—, —CH(CH3)C(CH3)2—, —C(CH3)2CH(CH3)—, C(CH3)2C(CH3)2—, —CH2CH2CH2—, and —C(CH3)2CH2CH2—. Examples of unsaturated alkylene include but are not limited to —CH═CH—, —C≡C—, —C(CH3)═CH—, —CH═C(CH3)—, —C(CH3)═C(CH3)—, —CH2CH═CH—, —CH═CHCH2—, —CH═CH—CH═CH—, and —CH═CH—C═C—.
  • According to the invention, unless expressly stated otherwise, “—C1-C6-alkylene-”, “—C1-C4-alkylene” and any other alkylene residue can be unsubstituted, mono- or polysubstituted. Examples of substituted —C1-C6-alkylene- include but are not limited to —CHF—, —CF2—, —CHOH— and —C(═O)—.
  • According to the invention, moieties may be connected through —C1-C6-alkylene-, i.e. the moieties may not be directly bound to the core structure of compound according to general formula (I), but may be connected to the core structure of compound according to general formula (I) or its periphery through a —C1-C6-alkylene- linker.
  • According to the invention, “3-12-membered cycloalkyl moiety” means a non-aromatic, monocyclic, bicyclic or tricyclic moiety comprising 3 to 12 ring carbon atoms but no heteroatoms in the ring. Examples of preferred saturated 3-12-membered cycloalkyl moieties according to the invention include but are not limited to cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, hydrindane, and decaline. Examples of preferred unsaturated 3-12-membered cycloalkyl moiety moieties according to the invention include but are not limited to cyclopropene, cyclobutene, cyclopentene, cyclopentadiene, cyclohexene, 1,3-cyclohexadiene, and 1,4-cyclohexadiene. The 3-12-membered cycloalkyl moiety, which is bonded to the compound according to the invention, in its periphery may optionally be condensed with a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; and/or with a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted. Under these circumstances, the ring atoms of the condensed moieties are not included in the 3 to 12 ring atoms of the 3-12-membered cycloalkyl moiety. Examples of 3-12-membered cycloalkyl moieties condensed with 3-12-membered heterocycloalkyl moieties include but are not limited to octahydro-1H-indol, decahydroquinoline, decahydroisoquinoline, octahydro-2H-benzo[b][1,4]oxazin, and decahydro-quinoxalin, which in each case are connected through the 3-12-membered cycloalkyl moiety. Examples of 3-12-membered cycloalkyl moieties condensed with 6-14-membered aryl moieties include but are not limited to 2,3-dihydro-1H-indene and tetraline, which in each case are connected through the 3-12-membered cycloalkyl moiety. Examples of 3-12-membered cycloalkyl moieties condensed with 5-14-membered heteroaryl moieties include but are not limited to 5,6,7,8-tetrahydroquinoline and 5,6,7,8-tetrahydroquinazoline, which in each case are connected through the 3-12-membered cycloalkyl moiety.
  • According to the invention, the 3-12-membered cycloalkyl moiety may optionally be connected through —C1-C6-alkylene-, i.e. the 3-12-membered cycloalkyl moiety may not be directly bound to the compound according to general formula (I) but may be connected thereto through a —C1-C6-alkylene- linker. Examples include but are not limited to —CH2-cyclopropyl, —CH2-cyclobutyl, —CH2-cyclopentyl, —CH2-cyclohexyl, —CH2CH2-cyclopropyl, —CH2CH2-cyclobutyl, —CH2CH2-cyclopentyl, and —CH2CH2-cyclohexyl.
  • According to the invention, unless expressly stated otherwise, the 3-12-membered cycloalkyl moiety can be unsubstituted, mono- or polysubstituted. Examples of substituted 3-12-membered cycloalkyl moieties include but are not limited to —CH2-1-hydroxy-cyclobutyl.
  • According to the invention, “3-12-membered heterocycloalkyl moiety” means a non-aromatic, monocyclic, bicyclic or tricyclic moiety comprising 3 to 12 ring atoms, wherein each cycle comprises independently of one another 1, 2, 3, 4 or more heteroatoms independently of one another selected from the group consisting of nitrogen, oxygen and sulfur, whereas sulfur may be oxidized (S(═O) or (S(═O)2), whereas the remaining ring atoms are carbon atoms, and whereas bicyclic or tricyclic systems may share common heteroatom(s). Examples of preferred saturated 3-12-membered heterocycloalkyl moieties according to the invention include but are not limited to aziridin, azetidine, pyrrolidine, imidazolidine, pyrazolidine, piperidine, piperazine, triazolidine, tetrazolidine, oxiran, oxetane, tetrahydrofurane, tetrahydropyrane, thiirane, thietane, tetra-hydrothiophene, diazepane, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazoli-dine, morpholine, thiomorpholine. Examples of preferred unsaturated 3-12-membered heterocycloalkyl moiety moieties according to the invention include but are not limited to oxazoline, pyrazoline, imidazoline, isoxazoline, thiazoline, isothiazoline, and dihydropyran. The 3-12-membered heterocycloalkyl moiety, which is bonded to the compound according to the invention, in its periphery may optionally be condensed with a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; and/or with a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted. Under these circumstances, the ring atoms of the condensed moieties are not included in the 3 to 12 ring atoms of the 3-12-membered heterocycloalkyl moieties. Examples of 3-12-membered heterocycloalkyl moieties condensed with 3-12-membered cycloalkyl moieties include but are not limited to octahydro-1H-indol, decahydroquinoline, decahydroisoquinoline, octahydro-2H-benzo[b][1,4]oxazin, and decahydro-quinoxalin, which in each case are connected through the 3-12-membered heterocycloalkyl moiety. An examples of a 3-12-membered heterocycloalkyl moiety condensed with a 6-14-membered aryl moiety includes but is not limited to 1,2,3,4-tetrahydroquinoline, which is connected through the 3-12-membered heterocycloalkyl moiety. An example of a 3-12-membered heterocycloalkyl moiety condensed with a 5-14-membered heteroaryl moieties includes but is not limited to 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine, which is connected through the 3-12-membered heterocycloalkyl moiety.
  • According to the invention, the 3-12-membered heterocycloalkyl moiety may optionally be connected through —C1-C6-alkylene-, i.e. the 3-12-membered heterocycloalkyl moiety may not be directly bound to the compound according to general formula (I) but may be connected thereto through a —C1-C6-alkylene- linker. Said linker may be connected to a carbon ring atom or to a hetero ring atom of the 3-12-membered heterocycloalkyl moiety. Examples include but are not limited to —CH2-oxetane, —CH2-pyrrolidine, —CH2-piperidine, —CH2-morpholine, —CH2CH2-oxetane, —CH2CH2-pyrrolidine, —CH2CH2-piperidine, and —CH2CH2-morpholine.
  • According to the invention, unless expressly stated otherwise, the 3-12-membered heterocycloalkyl moiety can be unsubstituted, mono- or polysubstituted. Examples of substituted 3-12-membered heterocycloalkyl moieties include but are not limited to 2-carboxamido-N-pyrrolidinyl-, 3,4-dihydroxy-N-pyrrolidinyl, 3-hydroxy-N-pyrimidinyl, 3,4-dihydroxy-N-pyrimidinyl, 3-oxo-N-piperazinyl, -tetrahydro-2H-thiopyranyl dioxide and thiomorpholinyl dioxide.
  • According to the invention, “6-14-membered aryl moiety” means an aromatic, monocyclic, bicyclic or tricyclic moiety comprising 6 to 14 ring carbon atoms but no heteroatoms in the ring. Examples of preferred 6-14-membered aryl moieties according to the invention include but are not limited to benzene, naphthalene, anthracen, and phenanthren. The 6-14-membered aryl moiety, which is bonded to the compound according to the invention, in its periphery may optionally be condensed with a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted. Under these circumstances, the ring atoms of the condensed moieties are not included in the 6 to 14 ring carbon atoms of the 6-14-membered heterocycloalkyl moieties. Examples of 6-14-membered aryl moieties condensed with 3-12-membered cycloalkyl moieties include but are not limited to 2,3-dihydro-1H-indene and tetraline, which in each case are connected through the 6-14-membered aryl moiety. An example of a 6-14-membered aryl moiety condensed with a 3-12-membered heterocycloalkyl moiety includes but is not limited to 1,2,3,4-tetrahydroquinoline, which is connected through the 6-14-membered aryl moiety. Examples of 6-14-membered aryl moieties condensed with 5-14-membered heteroaryl moieties include but are not limited to quinoline, isoquinoline, phenazine and phenoxacine, which in each case are connected through the 6-14-membered aryl moiety.
  • According to the invention, the 6-14-membered aryl moiety may optionally be connected through —C1-C6-alkylene-, i.e. the 6-14-membered aryl moiety may not be directly bound to the compound according to general formula (I) but may be connected thereto through a —C1-C6-alkylene- linker. Said linker may be connected to a carbon ring atom or to a hetero ring atom of the 6-14-membered aryl moiety. Examples include but are not limited to —CH2—C6H5, —CH2CH2—C6H5 and —CH═CH—C6H5.
  • According to the invention, unless expressly stated otherwise, the 6-14-membered aryl moiety can be unsubstituted, mono- or polysubstituted. Examples of substituted 6-14-membered aryl moieties include but are not limited to 2-fluorophenyl, 3-fluorophenyl, 2-methoxyphenyl and 3-methoxyphenyl.
  • According to the invention, “5-14-membered heteroaryl moiety” means an aromatic, monocyclic, bicyclic or tricyclic moiety comprising 6 to 14 ring atoms, wherein each cycle comprises independently of one another 1, 2, 3, 4 or more heteroatoms independently of one another selected from the group consisting of nitrogen, oxygen and sulfur, whereas the remaining ring atoms are carbon atoms, and whereas bicyclic or tricyclic systems may share common heteroatom(s). Examples of preferred 5-14-membered heteroaryl moieties according to the invention include but are not limited to pyrrole, pyrazole, imidazole, triazole, tetrazole, furane, thiophene, oxazole, isoxazole, thiazole, isothiazole, pyridine, pyridazine, pyrimidine, pyrazine, indolicine, 9H-chinolicine, 1,8-naphthyridine, purine, imidazo[1,2-a]pyrazine, and pteridine. The 5-14-membered heteroaryl moiety, which is bonded to the compound according to the invention, in its periphery may optionally be condensed with a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted. Under these circumstances, the ring atoms of the condensed moieties are not included in the 6 to 14 ring carbon atoms of the 6-14-membered heterocycloalkyl moieties. Examples of 5-14-membered heteroaryl moieties condensed with 3-12-membered cycloalkyl moieties include but are not limited to 5,6,7,8-tetrahydroquinoline and 5,6,7,8-tetrahydroquinazoline, which in each case are connected through the 5-14-membered heteroaryl moiety. An examples of a 5-14-membered heteroaryl moiety condensed with a 3-12-membered heterocycloalkyl moiety includes but is not limited to 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine, which is connected through the 5-14-membered heteroaryl moiety. Examples of 5-14-membered heteroaryl moieties condensed with 6-14-membered aryl moieties include but are not limited to quinoline, isoquinoline, phenazine and phenoxacine, which in each case are connected through the 5-14-membered heteroaryl moiety.
  • According to the invention, the 5-14-membered heteroaryl moiety may optionally be connected through —C1-C6-alkylene-, i.e. the 5-14-membered heteroaryl moiety may not be directly bound to the compound according to general formula (I) but may be connected thereto through a —C1-C6-alkylene- linker. Said linker may be connected to a carbon ring atom or to a hetero ring atom of the 5-14-membered heteroaryl moiety. Examples include but are not limited to —CH2-oxazole, —CH2-isoxazole, —CH2-imidazole, —CH2-pyridine, —CH2-pyrimidine, —CH2-pyridazine, —CH2CH2-oxazole, —CH2CH2-isoxazole, —CH2CH2-imidazole, —CH2CH2-pyridine, —CH2CH2-pyrimidine, and —CH2CH2-pyridazine.
  • According to the invention, unless expressly stated otherwise, the 5-14-membered heteroaryl moiety can be unsubstituted, mono- or polysubstituted. Examples of 5-14-membered heteroaryl moieties include but are not limited to 2-methoxy-4-pyridinyl, 2-methoxy-5-pyridinyl, 3-methoxy-4-pyridinyl, 3-methoxy-6-pyridinyl, 4-methoxy-2-pyridinyl, 2-methylsulfonyl-5-pyridinyl, 3-methylsulfonyl-6-pyridinyl, 3-methoxy-6-pyridazinyl, 2-nitrilo-5-pyrimidinyl, 4-hydroxy-2-pyrimidinyl, 4-methoxy-pyrimidinyl, and 2-methoxy-6-pyrazinyl.
  • Preferably, the compounds according to the invention have a structure according to general formula (I′)
  • Figure US20200399252A1-20201224-C00008
  • wherein R1 to R5, R7, R8, R10 to R20 and n are defined as above, or a physiologically acceptable salt thereof.
  • In one preferred embodiment, the excess of the cis-isomer so designated is at least 50% de, more preferably at least 75% de, yet more preferably at least 90% de, most preferably at least 95% de and in particular at least 99% de.
  • In a preferred embodiment, the compound according to the invention has a structure according to general formula (IX)
  • Figure US20200399252A1-20201224-C00009
  • wherein
    RC means —H or —OH;
    R3 means -phenyl or -3-fluorophenyl; and
    R5 means
    6-14-membered aryl, unsubstituted, mono- or polysubstituted; or
    5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted;
    or a physiologically acceptable salt thereof.
  • Preferably, R5 is selected from -phenyl, -pyridyl, pyrimidinyl, or -triazolyl, in each case unsubstituted, mono- or polysubstituted.
  • In a preferred embodiment, the compounds according to the invention are in the form of the free bases.
  • In another preferred embodiment, the compounds according to the invention are in the form of the physiologically acceptable salts.
  • For the purposes of the description, a “salt” is to be understood as being any form of the compound in which it assumes an ionic form or is charged and is coupled with a counter-ion (a cation or anion) or is in solution. The term is also to be understood as meaning complexes of the compound with other molecules and ions, in particular complexes which are associated via ionic interactions. Preferred salts are physiologically acceptable, in particular physiologically acceptable salts with anions or acids or also a salt formed with a physiologically acceptable acid.
  • Physiologically acceptable salts with anions or acids are salts of the particular compound in question with inorganic or organic acids which are physiologically acceptable, in particular when used in humans and/or mammals. Examples of physiologically acceptable salts of particular acids include but are not limited to salts of hydrochloric acid, sulfuric acid, and acetic acid.
  • The invention also includes isotopic isomers of a compound according to the invention, wherein at least one atom of the compound is replaced by an isotope of the respective atom which is different from the naturally predominantly occurring isotope, as well as any mixtures of isotopic isomers of such a compound. Preferred isotopes are 2H (deuterium), 3H (tritium), 3C and 14C.
  • Certain compounds according to the invention are useful for modulating a pharmacodynamic response from one or more opioid receptors (mu, delta, kappa, NOP/ORL-1) either centrally or peripherally, or both. The pharmacodynamic response may be attributed to the compound either stimulating (agonizing) or inhibiting (antagonizing) the one or more receptors. Certain compounds according to the invention may antagonize one opioid receptor, while also agonizing one or more other receptors. Compounds according to the invention having agonist activity may be either full agonists or partial agonists.
  • As used herein, compounds that bind to receptors and mimic the regulatory effects of endogenous ligands are defined as “agonists”. Compounds that bind to a receptor but produce no regulatory effect, but rather block the binding of ligands to the receptor, are defined as “antagonists”.
  • In certain embodiments, the compounds according to the invention are agonists at the mu opioid (MOP) and/or kappa opioid (KOP) and/or delta opioid (DOP) and/or nociceptin opioid (NOP/ORL-1) receptors.
  • The compounds according to the invention potently bind to the MOP and/or KOP and/or DOP and/or NOP receptors.
  • The compounds according to the invention can be modulators at the MOP and/or KOP and/or DOP and/or NOP receptors, and therefore the compounds according to the invention can be used/administered to treat, ameliorate, or prevent pain.
  • In some embodiments, the compounds according to the invention are agonists of one or more opioid receptors. In some embodiments, the compounds according to the invention are agonists of the MOP and/or KOP and/or DOP and/or NOP receptors.
  • In some embodiments, the compounds according to the invention are antagonists of one or more opioid receptors. In some embodiments, the compounds according to the invention are antagonists of the MOP and/or KOP and/or DOP and/or NOP receptors.
  • In some embodiments, the compounds according to the invention have both, (i) agonist activity at the NOP receptor; and (ii) agonist activity at one or more of the MOP, KOP, and DOP receptors.
  • In some embodiments, the compounds according to the invention have both, (i) agonist activity at the NOP receptor; and (ii) antagonist activity at one or more of the MOP, KOP, and DOP receptors.
  • In some embodiments, the compounds according to the invention have both, (i) antagonist activity at the NOP receptor; and (ii) agonist activity at one or more of the MOP, KOP, and DOP receptors.
  • In some embodiments, the compounds according to the invention have both, (i) antagonist activity at the NOP receptor; and (ii) antagonist activity at one or more of the MOP, KOP, and DOP receptors.
  • In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have selective agonist activity at the NOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention
      • have agonist activity at the NOP receptor, but no significant activity at the MOP receptor;
      • have agonist activity at the NOP receptor, but no significant activity at the KOP receptor;
      • have agonist activity at the NOP receptor, but no significant activity at the DOP receptor;
      • have agonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor;
      • have agonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the DOP receptor; or
      • have agonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor as well as no significant activity at the DOP receptor.
  • In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have balanced agonist activity at the NOP receptor as well as at the MOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention
      • have agonist activity at the NOP receptor as well as agonist activity at the MOP receptor;
      • have agonist activity at the NOP receptor as well as agonist activity at the MOP receptor as well as agonist activity at the KOP receptor;
      • have agonist activity at the NOP receptor as well as agonist activity at the MOP receptor as well as agonist activity at the DOP receptor;
      • can be regarded as opioid pan agonists, i.e. have agonist activity at the NOP receptor as well as agonist activity at the MOP receptor as well as agonist activity at the KOP receptor as well as agonist activity at the DOP receptor;
      • have agonist activity at the NOP receptor as well as agonist activity at the MOP receptor, but no significant activity at the KOP receptor;
      • have agonist activity at the NOP receptor as well as agonist activity at the MOP receptor, but no significant activity at the DOP receptor; or
      • have agonist activity at the NOP receptor as well as agonist activity at the MOP receptor, but no significant activity at the KOP receptor as well as no significant activity at the DOP receptor.
  • In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have balanced agonist activity at the NOP receptor as well as at the KOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention
      • have agonist activity at the NOP receptor as well as agonist activity at the KOP receptor;
      • have agonist activity at the NOP receptor as well as agonist activity at the KOP receptor as well as agonist activity at the MOP receptor;
      • have agonist activity at the NOP receptor as well as agonist activity at the KOP receptor as well as agonist activity at the DOP receptor;
      • have agonist activity at the NOP receptor as well as agonist activity at the KOP receptor, but no significant activity at the MOP receptor;
      • have agonist activity at the NOP receptor as well as agonist activity at the KOP receptor, but no significant activity at the DOP receptor; or
      • have agonist activity at the NOP receptor as well as agonist activity at the KOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the DOP receptor.
  • In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have balanced agonist activity at the NOP receptor as well as at the DOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention
      • have agonist activity at the NOP receptor as well as agonist activity at the DOP receptor;
      • have agonist activity at the NOP receptor as well as agonist activity at the DOP receptor, but no significant activity at the MOP receptor;
      • have agonist activity at the NOP receptor as well as agonist activity at the DOP receptor, but no significant activity at the KOP receptor; or
      • have agonist activity at the NOP receptor as well as agonist activity at the DOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor.
  • In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have selective agonist activity at the KOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention
      • have agonist activity at the KOP receptor, but no significant activity at the MOP receptor;
      • have agonist activity at the KOP receptor, but no significant activity at the NOP receptor;
      • have agonist activity at the KOP receptor, but no significant activity at the DOP receptor;
      • have agonist activity at the KOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the NOP receptor;
      • have agonist activity at the KOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the DOP receptor; or
      • have agonist activity at the KOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the NOP receptor as well as no significant activity at the DOP receptor.
  • In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have agonist activity at the MOP receptor, agonist activity at the KOP receptor, and antagonist activity at the DOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention
      • have agonist activity at the MOP receptor as well as agonist activity at the KOP receptor as well as antagonist activity at the DOP receptor;
      • have agonist activity at the MOP receptor as well as agonist activity at the KOP receptor as well as antagonist activity at the DOP receptor as well as agonist activity at the NOP receptor;
      • have agonist activity at the MOP receptor as well as agonist activity at the KOP receptor as well as antagonist activity at the DOP receptor as well as antagonist activity at the NOP receptor; or
      • have agonist activity at the MOP receptor as well as agonist activity at the KOP receptor as well as antagonist activity at the DOP receptor, no significant activity at the NOP receptor.
  • In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention have selective agonist activity at the NOP receptor. In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention
      • have agonist activity at the NOP receptor, but no significant activity at the MOP receptor;
      • have agonist activity at the NOP receptor, but no significant activity at the KOP receptor;
      • have agonist activity at the NOP receptor, but no significant activity at the DOP receptor;
      • have agonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor;
      • have agonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the DOP receptor; or
      • have agonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor as well as no significant activity at the DOP receptor.
  • In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention have selective antagonist activity at the NOP receptor. In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention
      • have antagonist activity at the NOP receptor, but no significant activity at the MOP receptor;
      • have antagonist activity at the NOP receptor, but no significant activity at the KOP receptor;
      • have antagonist activity at the NOP receptor, but no significant activity at the DOP receptor;
      • have antagonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor;
      • have antagonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the DOP receptor; or
      • have antagonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor as well as no significant activity at the DOP receptor.
  • In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention have antagonist activity at the NOP receptor as well as agonist activity at the DOP receptor. In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention
      • have antagonist activity at the NOP receptor as well as agonist activity at the DOP receptor;
      • have antagonist activity at the NOP receptor as well as agonist activity at the DOP receptor, but no significant activity at the MOP receptor;
      • have antagonist activity at the NOP receptor as well as agonist activity at the DOP receptor, but no significant activity at the KOP receptor: or
      • have antagonist activity at the NOP receptor as well as agonist activity at the DOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor.
  • For the purpose of the specification, “no significant activity” means that the activity (agonist/antagonist) of the given compound at this receptor is lower by a factor of 1000 or more compared to its activity (agonist/antagonist) at one or more of the other opioid receptors.
  • A further aspect of the invention relates to the compounds according to the invention as medicaments.
  • A further aspect of the invention relates to the compounds according to the invention for use in the treatment of pain. A further aspect of the invention relates to a method of treating pain comprising the administration of a pain alleviating amount of a compound according to the invention to a subject in need thereof, preferably to a human. The pain is preferably acute or chronic. The pain is preferably nociceptive or neuropathic.
  • A further aspect of the invention relates to the compounds according to the invention for use in the treatment of neurodegenerative disorders, neuroinflammatory disorders, neuropsychiatric disorders, and substance abuse/dependence. A further aspect of the invention relates to a method of treating any one of the aforementioned disorders, diseases or conditions comprising the administration of a therapeutically effective amount of a compound according to the invention to a subject in need thereof, preferably to a human.
  • Another aspect of the invention relates to a pharmaceutical composition which contains a physiologically acceptable carrier and at least one compound according to the invention.
  • Preferably, the composition according to the invention is solid, liquid or pasty; and/or contains the compound according to the invention in an amount of from 0.001 to 99 wt. %, preferably from 1.0 to 70 wt. %, based on the total weight of the composition.
  • The pharmaceutical composition according to the invention can optionally contain suitable additives and/or auxiliary substances and/or optionally further active ingredients.
  • Examples of suitable physiologically acceptable carriers, additives and/or auxiliary substances are fillers, solvents, diluents, colorings and/or binders. These substances are known to the person skilled in the art (see H. P. Fiedler, Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik and angrenzende Gebiete, Editio Cantor Aulendoff).
  • The pharmaceutical composition according to the invention contains the compound according to the invention in an amount of preferably from 0.001 to 99 wt. %, more preferably from 0.1 to 90 wt. %, yet more preferably from 0.5 to 80 wt. %, most preferably from 1.0 to 70 wt. % and in particular from 2.5 to 60 wt. %, based on the total weight of the pharmaceutical composition.
  • The pharmaceutical composition according to the invention is preferably for systemic, topical or local administration, preferably for oral administration.
  • Another aspect of the invention relates to a pharmaceutical dosage form which contains the pharmaceutical composition according to the invention.
  • In one preferred embodiment, the pharmaceutical dosage form according to the invention is produced for administration twice daily, for administration once daily or for administration less frequently than once daily. Administration is preferably systemic, in particular oral.
  • The pharmaceutical dosage form according to the invention can be administered, for example, as a liquid dosage form in the form of injection solutions, drops or juices, or as a semi-solid dosage form in the form of granules, tablets, pellets, patches, capsules, plasters/spray-on plasters or aerosols. The choice of auxiliary substances etc. and the amounts thereof to be used depend on whether the form of administration is to be administered orally, perorally, parenterally, intravenously, intraperitoneally, intradermally, intramuscularly, intranasally, buccally, rectally or locally, for example to the skin, the mucosa or into the eyes.
  • Pharmaceutical dosage forms in the form of tablets, dragees, capsules, granules, drops, juices and syrups are suitable for oral administration, and solutions, suspensions, readily reconstitutable dry preparations and also sprays are suitable for parenteral, topical and inhalatory administration. Compounds according to the invention in a depot, in dissolved form or in a plaster, optionally with the addition of agents promoting penetration through the skin, are suitable percutaneous administration preparations.
  • The amount of the compounds according to the invention to be administered to the patient varies in dependence on the weight of the patient, on the type of administration, on the indication and on the severity of the disease. Usually, from 0.00005 mg/kg to 50 mg/kg, preferably from 0.001 mg/kg to 10 mg/kg, of at least one compound according to the invention is administered.
  • Another aspect of the invention relates to a process for the preparation of the compounds according to the invention. Suitable processes for the synthesis of the compounds according to the invention are known in principle to the person skilled in the art.
  • Preferred synthesis routes are described below:
  • The compounds according to the invention can be obtained via different synthesis routes. Depending on the synthesis route, different intermediates are prepared and subsequently further reacted.
  • In a preferred embodiment, the synthesis of the compounds according to the invention proceeds via a synthesis route which comprises the preparation of an intermediate according to general formula (IIIa):
  • Figure US20200399252A1-20201224-C00010
  • wherein R1, R2 and R3 are defined as above.
  • In another preferred embodiment, the synthesis of the compounds according to the invention proceeds via a synthesis route which comprises the preparation of an intermediate according to general formula (IIIb):
  • Figure US20200399252A1-20201224-C00011
  • wherein R1, R2 and R3 are defined as above and PG is a protecting group.
  • Preferably the protecting group is -p-methoxybenzyl. Therefore, in another preferred embodiment, the synthesis of the compounds according to the invention proceeds via a synthesis route which comprises the preparation of an intermediate according to general formula (IIIc):
  • Figure US20200399252A1-20201224-C00012
  • wherein R1, R2 and R3 are defined as above.
  • As already indicated, in general formula (IIIc), the -p-methoxybenzyl moiety represents a protecting group which can be cleaved in the course of the synthesis route.
  • In yet another preferred embodiment, the synthesis of the compounds according to the invention proceeds via a synthesis route which comprises the preparation of
      • an intermediate according to general formula (IIIa) and according to general formula (IIIb); or
      • an intermediate according to general formula (IIIa) and according to general formula (IIIc); or
      • an intermediate according to general formula (IIIb) and according to general formula (IIIc); or
      • an intermediate according to general formula (IIIa), according to general formula (IIIb) and according to general formula (IIIc).
  • The following examples further illustrate the invention but are not to be construed as limiting its scope.
    • EXAMPLES
  • “RT” means room temperature (23±7° C.), “M” are indications of concentration in mol/l, “aq.” means aqueous, “sat.” means saturated, “sol.” means solution, “conc.” means concentrated.
  • Further abbreviations:
  • brine saturated aqueous sodium chloride solution
    CC column chromatography
    cHex cyclohexane
    DCM dichloromethane
    • DIPEA N,N-diisopropylethylamine DMF N,N-dimethylformamide Et Ethyl
  • ether diethyl ether
    EE ethyl acetate
    EtOAc ethyl acetate
    EtOH ethanol
    h hour(s)
    H2O water
    HATU O-(7-aza-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate
    LDA Lithium-di-isoproyl-amid
    • Me Methyl
  • m/z mass-to-charge ratio
    MeOH methanol
    MCCN acetonitrile
    min minutes
    MS mass spectrometry
    NBS N-bromo-succinimide
    NEt3 triethylamine
    • PE Petrol Ether (60-80° C.)
  • RM reaction mixture
    RT room temperature
    T3P 2,4,6-Tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide
    tBME tert-.butyl methyl ether
    THF tetrahydrofuran
    v/v volume to volume
    w/w weight to weight
  • The yields of the compounds prepared were not optimised. All temperatures are uncorrected.
  • All starting materials, which are not explicitly described, were either commercially available (the details of suppliers such as for example Acros, Aldrich, Bachem, Butt park, Enamine, Fluka, Lancaster, Maybridge, Merck, Sigma, TCI, Oakwood, etc. can be found in the Symyx® Available Chemicals Database of MDL, San Ramon, US or the SciFinder® Database of the ACS, Washington D.C., US, respectively, for example) or the synthesis thereof has already been described precisely in the specialist literature (experimental guidelines can be found in the Reaxys® Database of Elsevier, Amsterdam, NL or the SciFinder® Database of the ACS, Washington D.C., US, respectively, for example) or can be prepared using the conventional methods known to the person skilled in the art.
  • The mixing ratios of solvents or eluents for chromatography are specified in v/v.
  • All the intermediate products and exemplary compounds were analytically characterised by mass spectrometry (MS, m/z for [M+H]+). In addition 1H-NMR and 13C spectroscopy was carried out for all the exemplary compounds and selected intermediate products.
  • Remark Regarding Stereochemistry
  • CIS refers to the relative configuration of compounds described herein, in which both nitrogen atoms are drawn on the same face of the cyclohexane ring as described in the following exemplary structure. Two depictions are possible:
  • Figure US20200399252A1-20201224-C00013
  • TRANS refers to compounds, in which both nitrogen atoms are on opposite faces of the cyclohexane ring as described in the following exemplary structure. Two depictions are possible:
  • Figure US20200399252A1-20201224-C00014
  • Synthesis of Intermediates
    • Synthesis of INT-795: CIS-8-Dimethylamino-8-phenyl-3-(2-phenyl-ethyl)-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00015
    • Step 1: CIS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4,5]decane-2,4-dione
  • A diastereomeric mixture of 8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione (20 g) (INT-976 step 1) was suspended in methanol (200 mL) and was heated to 80° C. for 1 h. The resulting suspension was filtered hot and the precipitate was washed with methanol (100 mL). Solid obtained was dried under reduced pressure to afford major isomer CIS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4,5]decane-2,4-dione (15 g) as an off-white solid. Chiral HPLC purity 98.93%, HPLC purity 98.61%.
    • Step 2: CIS-8-Dimethylamino-8-phenyl-3-(2-phenyl-ethyl)-1,3-diazaspiro[4.5]decane-2,4-dione
  • Cs2CO3 (3.9 g, 10.98 mmol) was added to the solution of CIS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4,5]decane-2,4-dione (1.5 g, 5.49 mmol) in MeCN (20 mL) under argon atmosphere and the reaction mixture was stirred for 30 min. (2-Bromoethyl)benzene (1.5 g, 8.24 mmol) was added and the reaction mixture was stirred under reflux for 16 h. The reaction completion was monitored by TLC. The reaction mixture was quenched with water (25 mL) and the organic product was extracted with DCM (2×150 mL). The combined organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo. Purification of the residue by flash column chromatography on silica gel (230-400 mesh) (5-10% methanol in DCM) further by washing with pentane yielded 1.6 g (78%) of CIS-8-dimethylamino-8-phenyl-3-(2-phenyl-ethyl)-1,3-diazaspiro[4.5]decane-2,4-dione as white solid. (TLC system: 10% MeOH in DCM; Rf: 0.4).
    • Step 3: CIS-8-Dimethylamino-8-phenyl-3-(2-phenyl-ethyl)-1,3-diazaspiro[4.5]decan-2-one
  • Anhydrous AlCl3 (1.27 g, 9.59 mmol) was added to the solution of LiAlH4 (1M in THF) (7.6 mL, 7.67 mmol) in THF at 0° C. under argon atmosphere. The reaction was stirred at RT for 1 h. CIS-8-(Dimethylamino)-3-phenethyl-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione (1.5 g, 4.60 mmol) was added to the reaction mixture at 0° C. and stirred at RT for 16 h. The reaction completion was monitored by TLC. The mixture was cooled to 0° C.; quenched with sat. aq. Na2SO4 (10 mL) and filtered through celite. The filtrate was dried over anhydrous Na2SO4 and concentrated in vacuo. Purification of the residue by flash column chromatography on silica gel (230-400 mesh) (5-10% methanol in DCM) and further by washing with pentane yielded 1 g (69%) of CIS-8-dimethylamino-8-phenyl-3-(2-phenyl-ethyl)-1,3-diazaspiro[4.5]decan-2-one (INT-795) as a white solid. (TLC system: 10% MeOH in DCM; Rf: 0.3). [M+H]+ 378.
    • Synthesis of INT-799: CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00016
    • Step 1: CIS-1-((1-(benzyloxy)cyclobutyl)methyl)-3-(3,4-dimethoxybenzyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • NaOH (1.42 g, 35.5 mmol) was added to a solution of CIS-3-(3,4-dimethoxybenzyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-794) (3 g, 7.09 mmol) in DMSO (90 mL) under argon atmosphere and the reaction mixture was stirred at 80° C. for 30 min. ((1-(Bromomethyl)cyclobutoxy)methyl)benzene (5.4 g, 21.3 mmol) was added and stirring was continued for 2 days at 80° C. The reaction completion was monitored by TLC. The reaction mixture was diluted with water (500 mL) and extracted with diethyl ether (4×300 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (230-400 mesh silica gel; 65-70% EtOAc in petroleum ether as eluent) to afford 2.5 g (59%) of CIS-1-((1-(benzyloxy)cyclobutyl)methyl)-3-(3,4-dimethoxybenzyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (TLC system: 10% MeOH in DCM; Rf: 0.8).
    • Step 2: CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • TFA (12 mL) was added to CIS-1-((1-(benzyloxy)cyclobutyl)methyl)-3-(3,4-dimethoxybenzyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (2.5 g, 4.18 mmol) at 0° C. and the resulting mixture was stirred at 70° C. for 6 h. The reaction completion was monitored by LCMS. The reaction mixture was concentrated under reduced pressure. To the residue sat. aq. NaHCO3 was added (until pH 10) and the organic product was extracted with DCM (3×150 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (230-400 mesh silica gel; 5% MeOH in DCM as eluent) to afford 500 mg (33%) of CIS-8-dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-799) (TLC system: 10% MeOH in DCM; Rf: 0.5). [M+H]+ 358.2
    • Synthesis of INT-951: CIS-1-[(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-methyl]-cyclobutane-1-carbonitrile
  • Figure US20200399252A1-20201224-C00017
    • Step 1: 1-((CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl)cyclobutanecarbonitrile
  • NaH (50% in mineral oil) (2.44 g, 50.89 mmol) was added to a solution of CIS-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro [4.5]decan-2-one (INT-975) (5 g, 12.72 mmol) in DMF (100 mL) at 0° C. portionwise over 10 min. 1-(Bromomethyl)cyclobutanecarbonitrile (4.4 g, 25.44 mmol) was added dropwise over 10 minutes at 0° C. The reaction mixture was allowed to stir at RT for 3 h, then quenched with water and the organic product was extracted with ethyl acetate (3×200 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford 5 g (crude) of 1-((CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl)cyclobutane-carbonitrile as gummy brown liquid. The material was used for the next step without further purification.
    • Step 2: 1-((CIS-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl) cyclobutanecarboxamide
  • TFA (100 mL) was added to 1-((CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl)cyclobutanecarbonitrile (5 g, 10.28 mmol) at 0° C. and the reaction mixture at mixture was stirred at RT for 2 days. The reaction mixture was concentrated in vacuo. To the residue sat. aq. NaHCO3 was added (until pH 10) and the organic product was extracted with dichloromethane (3×150 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford 3.5 g (crude) of 1-((CIS-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl) cyclobutanecarboxamide. The material was used for the next step without further purification.
    • Step 3: 1-((cis-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl)cyclobutane Carbonitrile
  • Thionyl chloride (35 mL) was added to 1-((cis-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl)cyclobutanecarboxamide (3.5 g, 9.11 mmol) at RT and the resulting mixture was stirred at reflux for 2 h. The reaction mixture was concentrated in vacuo. To the residue sat. aq. NaHCO3 was added (until pH 10) and the organic product was extracted with dichloromethane (3×150 mL). The combined organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography to afford 1.3 g (34% after three steps) of CIS-1-[(8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-methyl]-cyclobutane-1-carbonitrile (INT-951). [M+H]+ 367.2.
    • Synthesis of INT-953: CIS-1-(Cyclobutyl-methyl)-8-(methyl-(2-methyl-propyl)-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00018
    • Step 1: 1-Cyclobutylmethyl-3-(4-methoxy-benzyl)-9,12-dioxa-1,3-diazadispiro[4.2.4.2]tetradecan-2-one
  • To a stirred solution of 3-(4-methoxy-benzyl)-9,12-dioxa-1,3-diazadispiro[4.2.4.2]tetradecan-2-one (4 g, 12.04 mmol) in anhydrous DMF (60 ml) was added NaH (1.38 g, 60% dispersion in oil, 36.14 mmol) at RT. The reaction mixture was stirred for 10 min, bromomethylcyclobutane (3 ml, 26.5 mmol) was added dropwise and stirring was continued for 50 h. TLC analysis showed complete consumption of the starting material. The reaction mixture was quenched with sat. aq. NH4Cl (50 ml) and extracted with EtOAc (3×200 ml). The combined organic phase was dried over Na2SO4 and concentrated under reduced pressure. The resulting residue was purified column chromatography (neutral aluminum oxide, EtOAc-petroleum ether (2:8)) to give 1-cyclobutylmethyl-3-(4-methoxy-benzyl)-9,12-dioxa-1,3-diazadispiro[4.2.4.2]tetradecan-2-one (2.4 g, 50%, white solid). TLC system: EtOAc-pet ether (6:4); Rf=0.48.
    • Step 2: 1-Cyclobutylmethyl-3-(4-methoxy-benzyl)-1,3-diaza-spiro[4.5]decane-2,8-dione
  • To a stirred solution of 1-cyclobutylmethyl-3-(4-methoxy-benzyl)-9,12-dioxa-1,3-diazadispiro[4.2.4.2]tetradecan-2-one (1 g, 2.5 mmol) in MeOH (7 ml) was added 10% aq. HCl (8 ml) at 0° C. The reaction mixture was warmed up to RT and stirred for 16 h. TLC analysis showed complete consumption of the starting material. The reaction mixture was quenched with sat. aq. NaHCO3 (30 ml) and extracted with EtOAc (3×50 ml). The combined organic phase was dried over Na2SO4 and concentrated under reduced pressure. The resulting residue was purified by column chromatography (silica gel, 230-400 mesh, EtOAc-pet ether (1:3)→(3:7)) to give 1-cyclobutylmethyl-3-(4-methoxy-benzyl)-1,3-diaza-spiro[4.5]decane-2,8-dione (650 mg, 73%, colorless viscous oil). TLC system: EtOAc-pet ether (6:4); Rf=0.40.
    • Step 3: 1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile
  • To a stirred solution of N-isobutyl-N-methylamine (1.34 ml, 11.23 mmol) and MeOH/H2O (8 ml, 1:1, v/v) was added 4N aq. HCl (1.5 ml) and the reaction mixture was stirred for 10 min at 0° C. (ice bath). A solution of 1-cyclobutylmethyl-3-(4-methoxy-benzyl)-1,3-diaza-spiro[4.5]decane-2,8-dione (1 g, 2.80 mmol) in MeOH (7 ml) and KCN (548 mg, 8.42 mmol) were added and the reaction mixture was stirred at 45° C. for 20 h. TLC analysis showed complete consumption of the starting material. The reaction mixture was diluted with water (30 ml), extracted with EtOAc (3×30 ml), the combined organic phase was dried over Na2SO4 and concentrated under reduced pressure to give 1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (1.3 g, viscous yellow oil). TLC system: EtOAc-pet ether (1:1); Rf=0.45. The product was used for the next step without additional purification.
    • Step 4: CIS-1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • A round bottom flask containing 1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (1.3 g, 2.81 mmol) was cooled in an ice bath (˜0° C.) and a solution of phenylmagnesium bromide (26 ml, -2M in THF) was added slowly at 0° C.-5° C. The ice bath was removed and the reaction mixture was stirred for 30 min, then diluted with sat. aq. NH4Cl (25 ml) and extracted with EtOAc (4×30 ml). The combined organic phase was dried over Na2SO4 and concentrated under reduced pressure to give pale yellow viscous oil. This residue was purified by column chromatography (silica gel, 230-400 mesh, eluent: EtOAc-pet ether (15:85)→(2:4)) to give CIS-1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (135 mg, 10%, white solid). TLC system: EtOAc-pet ether (1:1); Rf=0.6
    • Step 5: CIS-1-(cyclobutyl-methyl)-8-(methyl-(2-methyl-propyl)-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • A round bottom flask containing CIS-1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (130 mg, 0.25 mmol) was cooled in an ice bath and a mixture of TFA/CH2Cl2 (2.6 ml, 1:1, v/v) was added slowly at 0° C.-5° C. The reaction mixture was warmed to RT and stirred for 20 h, then quenched with methanolic NH3 (10 ml, ˜10% in MeOH) and concentrated under reduced pressure to give pale yellow viscous oil. This residue was purified twice by column chromatography (silica gel, 230-400 mesh, eluent: MeOH—CHCl3 (1:99)→(2:98)) to give CIS-1-(cyclobutyl-methyl)-8-(methyl-(2-methyl-propyl)-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-953) (65 mg, 66%, white solid). TLC system: MeOH—CHCl3 (5:95); Rf=0.25; [M+H]+ 384.3
    • Synthesis of INT-958: 4-oxo-1-pyridin-2-yl-cyclohexane-1-carbonitrile
  • Figure US20200399252A1-20201224-C00019
    • Step 1: Ethyl 5-cyano-2-oxo-5-(pyridin-2-yl)cyclohexanecarboxylate
  • KOtBu (57.0 g, 508.4 mmol) was added to the solution of 2-(pyridin-2-yl)acetonitrile (50.0 g, 423.7 mmol) and ethyl acrylate (89.0 g, 889.8 mmol) in THF (500 mL) at 0° C. and stirred for 16 h at RT. The reaction mixture was quenched with sat. aq. NH4Cl and extracted with EtOAc (2×500 mL). The combined organic layer was washed with brine, dried over Na2SO4 and concentrated under reduced pressure to afford 68.0 g (60%; crude) of ethyl 5-cyano-2-oxo-5-(pyridin-2-yl)cyclohexanecarboxylate as a brown liquid (TLC system: 50% ethyl acetate in petroleum ether; Rf: 0.65).
    • Step 2: 4-Oxo-1-pyridin-2-yl-cyclohexane-1-carbonitrile
  • A solution of ethyl 5-cyano-2-oxo-5-(pyridin-2-yl)cyclohexanecarboxylate (68.0 g, 250.0 mmol) was added to a mixture of conc. aq. HCl and glacial acetic acid (7 mL/510 mL) at 0° C. The reaction mixture was heated to 100° C. for 16 h. All volatiles were evaporated under reduced pressure. The residue was diluted with sat. aq. NaHCO3 and extracted with ethyl acetate (3×300 mL). The combined organic layer was washed with brine, dried over Na2SO4 and concentrated under reduced pressure to afford 44.0 g (88%) of 4-oxo-1-pyridin-2-yl-cyclohexane-1-carbonitrile INT-958 as a brown solid (TLC system: 50% ethyl acetate in pet ether; Rf: 0.45). [M+H]+ 201.1
    • Synthesis of INT-%1: 4-Dimethylamino-4-pyridin-2-yl-cyclohexan-1-one
  • Figure US20200399252A1-20201224-C00020
    • Step 1: 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carbonitrile
  • A solution of 4-oxo-1-pyridin-2-yl-cyclohexane-1-carbonitrile (INT-958) (44.0 g, 220.0 mmol), ethylene glycol (27.0 g, 440.0 mmol) and PTSA (4.2 g, 22.0 mmol) in toluene (450 mL) was heated to 120° C. for 16 h using Dean Stark apparatus. All volatiles were evaporated under reduced pressure. The residue was diluted with sat. aq. NaHCO3 and extracted with ethyl acetate (3×300 mL). The combined organic layer was washed with brine, dried over Na2SO4 and concentrated under reduced pressure to afford 45.0 g (85%) of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carbonitrile as a light brown solid (TLC system: 50% ethyl acetate in petroleum ether; Rf: 0.55).
    • Step 2: 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carboxamide
  • Potassium carbonate (50.0 g, 368.84 mmol) and 30% aq. H2O2 (210.0 mL, 1844.2 mmol) were added to the solution of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carbonitrile (45.0 g, 184.42 mmol) in DMSO (450 mL) at 0° C. and the resulting mixture was stirred at RT for 14 h. The reaction mixture was diluted with water (1.5 L) and stirred for 1 h. The precipitated solid was separated by filtration, washed with water, petroleum ether and dried under reduced pressure to get 32.0 g (66%) of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carboxamide as a white solid. (TLC system: 10% MeOH in DCM R 0.35).
    • Step 3: methyl 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-ylcarbamate
  • A mixture of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carboxamide (25.0 g, 95.41 mmol), sodium hypochlorite (5 wt % aq. solution, 700 mL, 477.09 mmol) and KF—Al2O3 (125.0 g) in methanol (500 mL) was heated to 80° C. for 16 h. The reaction mixture was filtered through celite and the solid residue was washed with methanol. The combined filtrate was concentrated under reduced pressure. The residue was diluted with water and extracted with ethyl acetate (3×500 mL). The combined organic layer was washed with brine, dried over Na2SO4 and concentrated under reduced pressure to afford 18.0 g (66%) of methyl 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-ylcarbamate as a light brown solid. (TLC system: 5% MeOH in DCM R 0.52.)
    • Step 4: 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-amine
  • A suspension of methyl 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-ylcarbamate (18.0 g, 61.64 mmol) in 10 wt % aq. NaOH (200 mL) was heated to 100° C. for 24 h. The reaction mixture was filtered through celite pad, the solid residue was washed with water and the combined filtrate was extracted with EtOAc (4×200 mL). The combined organic layer washed with brine, dried over Na2SO4 and concentrated under reduced pressure to afford 12.5 g (88%) of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-amine as a light brown semi-solid. (TLC system: 5% MeOH in DCM Rf: 0.22.).
    • Step 5: 4-Dimethylamino-4-pyridin-2-yl-cyclohexan-1-one
  • Sodium cyanoborohydride (13.7 g, 0.213 mol) was added portionwise to a solution of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-amine (12.5 g, 53.418 mmol) and 35 wt % aq. formaldehyde (45 mL, 0.534 mol) in acetonitrile (130 mL) at 0° C. The reaction mixture was warmed up to room temperature and stirred for 16 h. The reaction mixture was quenched with sat. aq. NH4Cl and concentrated under reduced pressure. The residue was dissolved in water and extracted with EtOAc (3×200 mL). The combined organic layer was washed with brine, dried over Na2SO4 and concentrated under reduced pressure to afford 10.5 g (72%) of 4-dimethylamino-4-pyridin-2-yl-cyclohexan-1-one (INT-%1) as a light brown solid. (TLC system: 5% MeOH in DCM Rf: 0.32.). [M+H]+ 219.1
    • Synthesis of INT-%5: 4-Dimethylamino-4-phenyl-cyclohexan-1-one
  • Figure US20200399252A1-20201224-C00021
    • Step 1: 8-(Dimethylamino)-1,4-dioxaspiro 4.5] decane-8-carbonitrile
  • Dimethylamine hydrochloride (52 g, 0.645 mol) was added to the solution of 1,4-dioxaspiro-[4.5]-decan-8-one (35 g, 0.224 mmol) in MeOH (35 mL) at RT under argon atmosphere. The solution was stirred for 10 min and 40 wt % aq. dimethylamine (280 mL, 2.5 mol) and KCN (32 g, 0.492 mol) were sequentially added. The reaction mixture was stirred for 48 h at RT, then diluted with water (100 mL) and extracted with EtOAc (2×200 mL). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford 44 g of 8-(dimethylamino)-1,4-dioxaspiro-[4.5]-decane-8-carbonitrile (93%) as a white solid.
    • Step 2: N,N-dimethyl-8-phenyl-1,4-dioxaspiro [4.5] decan-8-amine
  • 8-(Dimethylamino)-1,4-dioxaspiro[4.5]decane-8-carbonitrile (35 g, 0.167 mol) in THF (350 mL) was added to the solution of 3M phenylmagnesium bromide in diethyl ether (556 mL, 1.67 mol) dropwise at −10° C. under argon atmosphere. The reaction mixture was stirred for 4 h at -10° C. to 0° C. and then at RT for 18 h. The reaction completion was monitored by TLC. The reaction mixture was cooled to 0° C., diluted with sat. aq. NH4Cl (1 L) and extracted with EtOAc (2×600 mL). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford 60 g of, N N-dimethyl-8-phenyl-1, 4-dioxaspiro-[4.5]-decan-8-amine as a liquid.
    • Step 3: 4-(dimethylamino)-4-phenylcyclohexanone
  • A solution of N,N-dimethyl-8-phenyl-1,4-dioxaspiro[4.5]decan-8-amine (32 g, 0.123 mol) in 6N aq. HCl (320 mL) was stirred at 0° C. for 2 h and then at RT for 18 h. The reaction completion was monitored by TLC. The reaction mixture was extracted with DCM (2×150 mL). The aqueous layer was basified to pH 10 with solid NaOH and extracted with ethyl acetate (2×200 mL). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The solid residue was washed with hexane and dried in vacuo to afford 7 g of 4-dimethylamino-4-phenyl-cyclohexan-1-one (INT-965) (25% over 2 steps) as a brown solid. [M+H]+ 218.1
    • Synthesis of INT-966: 3-[(4-Methoyphenyl)-methyl]-1,3-diazaspiro[4.5]decane-2,8-dione
  • Figure US20200399252A1-20201224-C00022
    • Step 1: 9,12-Dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}.2{circumflex over ( )}{5}]tetradecane-1,3-dione
  • KCN (93.8 g, 1441.6 mmol) and (NH4)2CO3 (271.8 g, 1729.9 mmol) were added to the solution of 1,4-dioxaspiro[4.5]decan-8-one (150 g, 961 mmol) in MeOH:H2O (1:1 v/v) (1.92 L) at RT under argon atmosphere. The reaction mixture was stirred at 60° C. for 16 h. The reaction completion was monitored by TLC. The reaction mixture was cooled to 0° C., the precipitated solid was filtered off and dried in vacuo to afford 120 g (55%) of 9,12-dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}.2{circumflex over ( )}{5}]tetradecane-1,3-dione. The filtrate was extracted with DCM (2×1.5 L). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford additional 30 g (14%) of 9,12-dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}. 2{circumflex over ( )}{5}]tetradecane-1,3-dione (TLC system: 10% Methanol in DCM; Rf: 0.4).
    • Step 2: 2-[(4-Methoxyphenyl)-methyl]-9,12-dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}.2{circumflex over ( )}{5}]tetradecane-1,3-dione
  • Cs2CO3 (258.7 g, 796.1 mmol) was added to the solution of 73a (150 g, 663.4 mmol) in MCCN (1.5 L) under argon atmosphere and the reaction mixture was stirred for 30 min. A solution of p-methoxybenzyl bromide (96 mL, 663.4 mmol) was added. The reaction mixture was stirred at RT for 48 h. The reaction completion was monitored by TLC. The reaction mixture was quenched with sat. aq. NH4Cl (1.0 L) and the organic product was extracted with EtOAc (2×1.5 L). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was washed with diethyl ether and pentane and dried under reduced pressure to afford 151 g (65%) of 2-[(4-Methoxyphenyl)-methyl]-9,12-dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}.2{circumflex over ( )}{5}]tetradecane-1,3-dione as an off white solid (TLC system: 10% MeOH in DCM; Rf: 0.6).
    • Step 3: 2-[(4-Methoxyphenyl)-methyl]-9,12-dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}.2{circumflex over ( )}{5}]tetradecan-3-one
  • AlCl3 (144.3 g, 1082.6 mmol) was added to a solution of LiAlH4 (2M in THF) (433 mL, 866.10 mmol) in THF (4.5 L) at 0° C. under argon atmosphere and the resulting mixture was stirred at RT for 1 h. 2-[(4-Methoxyphenyl)-methyl]-9,12-dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}.2{circumflex over ( )}{5}]tetradecane-1,3-dione (150 g, 433.05 mmol) was added at 0° C. The reaction mixture was stirred at RT for 16 h. The reaction completion was monitored by TLC. The reaction mixture was cooled to 0° C., quenched with sat. aq. NaHCO3 (500 mL) and filtered through celite pad. The filtrate was extracted with EtOAc (2×2.0 L). The combined organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo to afford 120 g (84%) of 2-[(4-methoxyphenyl)-methyl]-9,12-dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}.2{circumflex over ( )}{5}]tetradecan-3-one as an off-white solid. (TLC system: 10% MeOH in DCM, Rf: 0.5).
    • Step 4: 3-[(4-Methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decane-2,8-dione
  • A solution of 2-[(4-methoxyphenyl)-methyl]-9,12-dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}. 2{circumflex over ( )}{5}] tetradecan-3-one (120 g, 361.03 mmol) in 6N aq. HCl (2.4 L) was stirred at 0° C. for 2 h and then at RT for 18 h. The reaction completion was monitored by TLC. The reaction mixture was extracted with DCM (2×2.0 L). The aqueous layer was basified to pH 10 with 50% aq. NaOH and then extracted with DCM (2×2.0 L). Combined organic extracts were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The solid residue was washed with hexane and dried in vacuo to afford 90 g of 3-[(4-Methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decane-2,8-dione (INT-966) as an off-white solid (TLC system: 10% MeOH in DCM; Rf: 0.4) [M+H]+ 289.11.
    • Synthesis of INT-975: CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00023
  • KOtBu (M in THF) (29.30 mL, 29.30 mmol) was added to the solution of CIS-8-Dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one INT-976 (8.0 g, 29.30 mmol) in THF (160 mL) under argon atmosphere and the reaction mixture was stirred for 30 min. 4-Methoxybenzyl bromide (4.23 mL, 29.30 mmol) was added and stirring was continued at RT for 4 h. The reaction completion was monitored by TLC. The reaction mixture was diluted with sat. aq. NH4Cl (150 mL) and the organic product was extracted with EtOAc (2×150 mL). The combined organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo. The reaction was carried out in 2 batches (8 g×2) and the batches were combined for purification. Purification of the crude product by flash column chromatography on silica gel (0-10% methanol in DCM) and subsequently by washing with pentane yielded 11 g (47%) of CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-975) as a white solid. [M+H]+ 394.2
    • Synthesis of INT-976: CIS-8-Dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00024
    • Step 1: 8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4,5]decane-2,4-dione
  • In a sealed tube 4-dimethylamino-4-phenyl-cyclohexan-1-one (INT-965) (2 g, 9.22 mmol) was suspended in 40 mL EtOH/H2O (1:1 v/v) at RT under argon atmosphere. (NH42CO3 (3.62 g, 23.04 mmol) and KCN (0.6 g, 9.22 mmol) were added. The reaction mixture was stirred at 60° C. for 18 h. The reaction mixture was cooled to 0° C. and diluted with ice-water and filtered through a glass filter. The solid residue was dried under reduced pressure to afford 8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4,5]decane-2,4-dione (1.8 g, 86%) as an off white crystalline solid (TLC: 80% EtOAc in hexane; Rf: 0.25).
    • Step 2: 8-(dimethylamino)-8-phenyl-1, 3-diazaspiro [4, 5] decan-2-one
  • LiAlH4 (2M in THF) (70 mL, 139.4 mmol) was added to the solution of 8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4,5]decane-2,4-dione (10 g, 34.8 mmol) in THF/Et2O (2:1 v/v) (400 mL) at 0° C. under argon atmosphere. The reaction mixture was stirred for 4 h at 60° C. The reaction completion was monitored by TLC. The reaction mixture was cooled to 0° C., quenched with saturated Na2SO4 solution (100 mL) and filtered through Celite pad. The filtrate was dried over anhydrous Na2SO4 and concentrated in vacuo to afford 5.7 g (59%) of 8-(dimethylamino)-8-phenyl-1, 3-diazaspiro [4, 5] decan-2-one as an off white solid. (TLC system: 10% MeOH in DCM, Rf: 0.3).
    • Step 3: CIS-8-Dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • A mixture of CIS- and TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4,5]decan-2-one (8 g, 29.30 mmol) was purified by preparative chiral SFC (column: Chiralcel AS-H, 60% CO2, 40% (0.5% DEA in MeOH)) to get 5 g of CIS-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-976) as a white solid. [M+H]+ 274.2.
    • Synthesis of INT-977: CIS-2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-acetic Acid; 2,2,2-trifluoro-acetic Acid Salt
  • Figure US20200399252A1-20201224-C00025
    • Step 1: CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5] decan-1-yl]-acetic Acid Tert-Butyl Ester
  • A solution of CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro [4.5]decan-2-one (INT-975) (5.0 g, 12.7 mmol) in THF (18 mL) was cooled to 0° C. and treated with LDA solution (2M in THF/heptane/ether, 25.4 mL, 50.8 mmol). The resulting mixture was allowed to warm up to RT over 30 min. The solution was then cooled to 0° C. again and tert-butyl-bromoacetate (5.63 mL, 38.1 mmol) was added. The reaction mixture was stirred at RT for 16 h, quenched with water and extracted with DCM (3×). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. Purification of the residue by column chromatography on silica gel provided CIS-2-[8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5] decan-1-yl]-acetic acid tert-butyl ester (4.4 g).
    • Step 2: cis-2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-acetic Acid Trifluoroacetic Acid Salt
  • CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5] decan-1-yl]-acetic acid tert-butyl ester (200 mg, 0.4 mmol) was dissolved in TFA (5 mL) and heated to reflux overnight. After cooling to RT all volatiles are removed in vacuo. The residue was taken up in THF (1 mL) and added dropwise to diethyl ether (20 mL). The resulting precipitate was filtered off and dried under reduced pressure to give CIS-2-(8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-acetic acid; 2,2,2-trifluoro-acetic acid salt (INT-977) (119 mg) as a white solid. [M+H]+ 332.2
    • Synthesis of INT-978: CIS-2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-N,N-dimethyl-acetamide
  • Figure US20200399252A1-20201224-C00026
  • CIS-2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-acetic acid (INT-977) trifluoroacetic acid salt (119 mg, 0.35 mmol) was dissolved in DCM (5 mL). Triethylamine (0.21 mL, 1.6 mmol), dimethylamine (0.54 mL, 1.1 mmol) and T3P (0.63 mL, 1.1 mmol) were sequentially added. The reaction mixture was stirred at RT overnight, then diluted with 1 M aq. Na2CO3 (5 mL). The aqueous layer was extracted with DCM (3×5 mL), the combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel to yield CIS-2-(8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-N,N-dimethyl-acetamide (INT-978) (39 mg) as a white solid. [M+H]+ 359.2
    • Synthesis of INT-982: CIS-8-Dimethylamino-1-[(1-methyl-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00027
    • Step 1: CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-1-((1-methylcyclobutyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • A solution of NaOH (2.85 g, 71.2 mmol) in DMSO (25 mL) was stirred at RT for 10 min. CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5] decan-2-one (INT-975) (7.00 g, 17.8 mmol) was added and stirring was continued for 15 min. 1-(Bromo-methyl)-1-methyl-cyclobutane (8.7 g, 53.4 mmol) was added at 0° C. The reaction mixture was heated to 60° C. for 16 h. After cooling down to RT, water (100 mL) was added and the mixture was extracted with DCM (3×150 mL). The combined organic layers were washed with water (70 mL), brine (100 mL), dried over Na2SO4 and concentrated under reduced pressure. Purification of the residue by column chromatography on silica gel provided CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-1-((1-methylcyclobutyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (6.5 g) as a light yellow solid.
    • Step 2: CIS-8-Dimethylamino-1-[(1-methyl-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • To the solution of CIS-8-Dimethylamino-1-[(1-methyl-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro [4.5]decan-2-one (6.66 g, 14.0 mmol) in DCM (65 mL) was added TFA (65 mL) and the resulting mixture was stirred at RT for 16 h. The reaction mixture was concentrated under reduced pressure. The residue was taken up in DCM (100 mL) and water (60 mL) and basified with 2M aq. NaOH to pH 10. The organic layer was separated and washed with brine (40 mL), dried over MgSO4, filtered and concentrated under reduced pressure. Crystallization of the residue from EtOAc provided CIS-8-Dimethylamino-1-[(1-methyl-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5] decan-2-one (INT-982) (3.41 g) as an off-white solid. [M+H]+ 356.3
    • Synthesis of INT-984: CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00028
    • Step 1: CIS-8-(dimethylamino)-1-isobutyl-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • In analogy to the method described for INT-951 step 1 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-975) was converted into CIS-8-(dimethylamino)-1-isobutyl-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro [4.5]decan-2-one.
    • Step 2: CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • In analogy to the method described for INT-982 step 2 CIS-8-(dimethylamino)-1-isobutyl-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one was converted into CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-984).
    • Synthesis of INT-986: CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00029
    • Step 1: CIS-3-benzyl-1-(cyclobutylmethyl)-8-(methylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • N-Iodosuccinimide (3.11 g, 13.92 mmol) was added to the solution of CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[phenyl-methyl]-1,3-diazaspiro[4.5]decan-2-one (INT-950) (4 g, 9.28 mmol) in a mixture of acetonitrile and THF (1:1 v/v, 80 mL) and the resulting mixture was stirred at RT for 16 h. The reaction mixture was basified with 2N aq. NaOH to pH˜10 and the organic product was extracted with DCM (3×10 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was stirred vigorously with a mixture of 10 wt % aq. citric acid (5 mL) and DCM (10 mL) at RT for 10 min. The reaction mixture was basified with 5N aq. NaOH to pH˜10 and extracted with DCM (3×10 mL). The combined organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo to give 3.5 g (crude) of CIS-3-benzyl-1-(cyclobutylmethyl)-8-(methylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one as semi solid (TLC system: 10% MeOH in DCM; Rf: 0.60.).
    • Step 2: CIS-3-benzyl-1-(cyclobutylmethyl)-8-(ethyl(methyl)amino)-8-phenyl-1,3-diazaspiro [4.5]decan-2-one
  • Sodium cyanoborohydride (1.56 g, 25.17 mmol, 3 equiv.) was added to the solution of CIS-3-benzyl-1-(cyclobutylmethyl)-8-(methylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (3.5 g, 8.39 mmol), acetaldehyde (738 mg, 16.78 mmol, 2 equiv.) and acetic acid (0.5 mL) in methanol (20 mL). The reaction mixture was stirred at RT for 3 h, then quenched with sat. aq. NaHCO3 and the organic product was extracted with DCM (3×50 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated in vacuo. Purification of the residue by flash column chromatography on silica gel (230-400 mesh) (20-25% ethyl acetate in petroleum ether) yielded 2.3 g (62%) of CIS-3-benzyl-1-(cyclobutylmethyl)-8-(ethyl(methyl)amino)-8-phenyl-1,3-diazaspiro [4.5]decan-2-one as a solid. (TLC system: 50% EtOAc in Pet. Ether; Rf: 0.65).
    • Step 3: CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-986)
  • Sodium metal (1.18 g, 51.68 mmol, 10 equiv.) was added to liquid ammonia (˜25 mL) at -78° C. The resulting mixture was stirred for 10 min at −78° C. A solution of CIS-3-benzyl-1-(cyclobutylmethyl)-8-(ethyl(methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (2.3 g, 5.16 mmol) in THF (25 mL) was added at -78° C. The reaction mixture was stirred for 15 min, then quenched with sat. aq. NH4Cl, warmed to RT and stirred for 1 h. The organic product was extracted with DCM (3×50 mL). The combined organic layer was washed with water, brine and concentrated under reduced pressure to afford 1.30 g (72%) of CIS-1-(cyclobutylmethyl)-8-(ethyl(methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-986) as an off-white solid. (TLC system: 10% MeOH in DCM R 0.15.). [M+H]+ 356.3
    • Synthesis of INT-987: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00030
  • In analogy to the method as described for INT-982 step 2 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (INT-952) was converted into CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-987).
    • Synthesis of INT-988: CIS-8-(dimethylamino)-1-(2-(1-methoycyclobutyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00031
    • Step 1: CIS-8-(dimethylamino)-1-[2-(1-methoxycyclobutyl)ethyl]-3-[(4-methoxyphenyl)methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Sodium hydroxide (78.06 mg, 4.0 equiv.) was suspended in DMSO (3.5 mL), stirred for 10 minutes, 8-(dimethylamino)-3-[(4-methoxyphenyl)methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-975) (192.0 mg, 1.0 equiv.) was added, the reaction mixture was stirred for 5 min followed by addition of 2-(1-methoxycyclobutyl)ethyl 4-methylbenzenesulfonate (416.2 mg, 3.0 equiv.) in DMSO (1.5 mL). The resulting mixture was stirred overnight at 50° C. The reaction mixture was quenched with water and extracted with DCM (3×20 mL). The combined organic phases were washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The residue (283 mg yellow oil) was purified by column chromatography on silica gel (eluent DCM/EtOH 98/2 to 96/4) to give 8-(dimethylamino)-1-[2-(1-methoxycyclobutyl)ethyl]-3-[(4-methoxyphenyl)methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one 163 mg (66%).
    • Step 2: CIS-8-(dimethylamino)-1-(2-(1-methoxycyclobutyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5] decan-2-one (INT-988)
  • In analogy to the method described for INT-982 step 2 CIS-8-(dimethylamino)-1-[2-(1-methoxycyclobutyl)ethyl]-3-[(4-methoxyphenyl)methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one was converted into CIS-8-(dimethylamino)-1-(2-(1-methoxycyclobutyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5] decan-2-one (INT-988). Mass: m/z 386.3 (M+H)+.
    • Synthesis of INT-1008: CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00032
    • Step 1 and step 2: ethyl-(8-phenyl-1,4-dioxa-spiro[4.5]dec-8-yl)-amine Hydrochloride (INT-1004)
  • A mixture of 1,4-dioxa-spiro[4.5]decan-8-one (25.0 g, 160.25 mmol, 1.0 eq.) and 2M solution of EtNH2 in THF (200 ml, 2.5 eq. 400.64 mmol) in EtOH (30 ml) was stirred at RT for 48 h. The reaction mixture was concentrated under argon atmosphere and the residue was diluted with ether (60 ml), and a freshly prepared PhLi solution was added [prepared by addition of 2.5M n-BuLi in THF (70.5 ml, 1.1 eq. 176.27 mmol) to a solution of bromobenzene (27.675 g, 1.1 eq. 176.275 mmol) in ether (100 ml) at −30° C. and stirred at RT for 1 h). The reaction mixture was stirred at RT for 1.5 h, quenched with saturated NH4Cl solution (100 ml) at 0° C. and extracted with ethyl acetate (2×750 ml). The combined organic layer was washed with water (3×350 ml), brine (300 ml), dried over Na2SO4 and concentrated under reduced pressure. The resulting residue was dissolved in ethyl methyl ketone (100 ml) and trimethylsilyl chloride (37.5 ml) was added at 0° C. The resulting mixture was stirred at RT for 16 h. The precipitated solid was filtered off and washed with acetone followed by THF to get ethyl-(8-phenyl-1,4-dioxa-spiro[4.5]dec-8-yl)-amine hydrochloride as an off white solid. This reaction was done in 2 batches of 25 g scale and the yield is given for 2 combined batches. Yield: 18% (17.1 g, 57.575 mmol). LCMS: m/z 262.2 (M+H)+.
    • Step 3: 4-ethylamino-4-phenyl-cyclohexanone (INT-1005)
  • To a solution of ethyl-(8-phenyl-1,4-dioxa-spiro[4.5]dec-8-yl)-amine hydrochloride (10.1 g, 34.0 mmol, 1 eq.) in water (37.5 ml) was added conc. aq. HCl (62.5 ml) at 0° C. and the resulting mixture was stirred at RT for 16 h. The reaction mixture was basified with aq. NaOH (pH -14) at 0° C. and extracted with DCM (2×750 ml). Organic layer was washed with water (400 ml), brine (400 ml), dried over Na2SO4 and concentrated under reduced pressure to yield 4-ethylamino-4-phenyl-cyclohexanone which was used in the next step without further purification. This reaction was carried out in another batch of 15.1 g scale and the yield is given for 2 combined batches. Yield: 92% (17.0 g, 78.34 mmol).
    • Step 4: Cis and Trans Mixture of 8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (INT-1006 and INT-1007)
  • To a solution of 4-ethylamino-4-phenyl-cyclohexanone (17 g, 78.341 mmol, 1.0 eq.) in EtOH (250 ml) and water (200 ml) was added (NH4)CO3 (18.8 g, 195.85 mmol, 2.5 eq.) and the reaction mixture was stirred at RT for 15 min. KCN (5.09 g, 78.341 mmol, 1.0 eq.) was added and stirring was continued at 60° C. for 18 h. The reaction mixture was cooled down to RT. The precipitated solid was filtered off, washed with water (250 ml), EtOH (300 ml), hexane (200 ml) and dried under reduced pressure to yield cis and trans mixture of 8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (13.0 g, 45.29 mmol, 58%) as a white solid. Yield: 58% (13 g, 45.296 mmol). LC-MS: m/z [M+1]+=288.2.
    • Step 5: CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (INT-1006)
  • To a solution of cis and trans mixture of 8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (12 g) in MeOH-DCM (1:1, 960 ml) was added a solution of L-tartaric acid in MeOH (25 ml) and the resulting mixture stirred at RT for 2 h and then kept in refrigerator for 16 h. The precipitated solid was filtered off and washed with MeOH-DCM (1:5, 50 ml) to get tartrate salt of 8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (7.5 g) as a white solid. To this solid sat. aq. NaHCO3 was added (pH˜8) and the resulting mixture was extracted with 25% MeOH-DCM (2×800 ml). Combined organic layer was washed with water (300 ml), brine (300 ml), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was triturated with 20% DCM-hexane and the resulting solid was dried under reduced pressure to afford CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione as white solid. This step was done in 2 batches (12 g & 2.4 g) and the yield is given for 2 combined batches. Yield: 31.2% (5.0 g, 17.421 mmol). LC-MS: m/z [M+1]+=288.0.
    • Step 6: CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (INT-1008)
  • To a slurry of LiAlH4 (793 mg, 20.91 mmol, 3.0 eq.) in THF (15 ml) was added a suspension of CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (2.0 g, 6.97 mmol, 1.0 eq.) in THF (60 ml) at 0° C. and the reaction mixture was heated to 65° C. for 16 h. The reaction mixture was cooled to 0° C., quenched with sat. aq. Na2SO4 (20 ml), stirred at RT for 1 h and filtered through celite pad. The residue was washed with 15% MeOH-DCM (500 ml). The combined filtrate was dried over anhydrous Na2SO4 and concentrated under reduced pressure to give crude product which was triturated with 15% DCM-Hexane to afford CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (INT-1008) (1.6 g, 5.86 mmol, 84%) as a white solid. Yield: 84% (1.6 g, 5.86 mmol). LC-MS: m/z [M+1]+=274.2.
    • Synthesis of INT-1010: CIS-8-(dimethylamino)-8-phenyl-3-(prop-2-yn-1-yl)-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00033
  • To a solution of CIS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-976) (5.0 g, 18.31 mmol, 1.0 eq.) in dry THF (500 ml) was added t-BuOK (3.07 g, 27.46 mmol, 1.5 eq.) and the reaction mixture was stirred at RT for 15 min. 3-Bromo-propyne (3.24 g, 13.18 mmol, 1.2 eq., 80% in toluene) was added and stirring was continued at RT for 18 h. The reaction mixture was poured into ice-water and extracted with DCM (800 ml). The organic layer was dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (neutral alumina; 1% MeOH/Hexane) to yield CIS-8-(dimethylamino)-8-phenyl-3-(prop-2-yn-1-yl)-1,3-diazaspiro[4.5]decan-2-one (INT-1010) (3.0 g, 9.64 mmol, 52%) as an off white solid. Yield: 52% (3.0 g, 9.64 mmol). Mass: m/z 312.3 (M+H)+.
    • Synthesis of INT-1011: ethyl CIS-2-(4-((8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)methyl)-1H-1,2,3-triazol-1-yl)acetate
  • Figure US20200399252A1-20201224-C00034
  • To a suspension of CIS-8-dimethylamino-8-phenyl-3-prop-2-ynyl-1,3-diaza-spiro[4.5]decan-2-one (INT-1010) (1.0 g, 3.21 mmol, 1.0 eq.) and azidoacetic acid ethyl ester (0.37 ml, 3.21 mmol, 1.0 eq.) in t-BuOH:H2O (1:1, 18 ml) and 1M aq. CuSO4 (0.19 ml) was added sodium ascorbate (191 mg, 0.963 mmol, 0.3 eq.). The reaction mixture was stirred at RT for 18 h, then quenched with water and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel neutralized with TEA; 10% MeOH/DCM) to yield ethyl CIS-2-(4-((8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)methyl)-1H-1,2,3-triazol-1-yl)acetate (INT-1011) (1.0 g, 2.27 mmol, 70%) as an off white solid. Yield: 70% (1.0 g, 2.27 mmol). Mass: m/z 441.4 (M+H)+.
    • Synthesis of INT-1012: Methyl CIS-2-(4-((8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)methyl)-1H-1,2,3-triazol-1-yl)acetate
  • Figure US20200399252A1-20201224-C00035
  • To a solution of CIS-2-(4-((8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)methyl)-1H-1,2,3-triazol-1-yl)acetate (INT-1011) (2.0 g, 4.54 mmol, 1.0 eq.) in DMSO (30 ml) was added NaOH (727 mg, 18.18 mmol, 4.0 eq.) at RT and the reaction mixture was heated to 70° C. for 30 min. The resulting mixture was cooled down to RT and a solution of 1-oxa-spiro[2.3]hexane (953 mg, 11.35 mmol, 2.5 eq.) in DMSO (5 ml) was added. The reaction mixture was stirred at 50° C. for 16 h, then cooled down to RT and diluted with MeOH (40 ml). Thionyl chloride (1.32 ml, 18.18 mmol, 4.0 eq.) was added at 0° C. and stirring was continued at RT for 16 h. The reaction mixture was concentrated under reduced pressure, then diluted with DCM (300 ml), sat. NaHCO3 solution (200 ml) was added slowly at 0° C. and the resulting mixture was stirred at RT for 1 h. The organic layer was separated, dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; 4% MeOH/DCM) to yield methyl CIS-2-(4-((8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)methyl)-1H-1,2,3-triazol-1-yl)acetate (INT-1012) (950 mg, 1.86 mmol, 41%) as brown sticky solid. After purification, isolated compound was 60% pure and was used in the next steps without further purification. Yield: 41% (950 mg, 1.86 mmol). Mass: m/z 509.4 (M+H)+.
    • Synthesis of INT-1021: CIS-1-(2-methoxybenzyl)-8-(methylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00036
    • Step 1: CIS-3-benzyl-8-(dimethylamino)-1-(2-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • NaH (0.15 g, 3.30 mmol) was added to a solution of CIS-3-benzyl-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-%3) (0.4 g, 1.10 mmol) in DMF (8 mL) at 0° C. over 15 min. The reaction mixture was stirred for 5 min, 1-(bromomethyl)-2-methoxybenzene (0.33 g, 1.65 mmol) was added portionwise, ice bath was removed and stirring was continued at RT for 3 h. The resulting mixture was quenched with cold water (precipitation observed), the precipitate was filtered off and dried under reduced pressure to give 450 mg (84%) of CIS-3-benzyl-8-(dimethylamino)-1-(2-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one. The crude material was used in the next step without further purification. (TLC system: 10% MeOH in DCM; Rf: 0.7).
    • Step 2: CIS-8-(dimethylamino)-1-(2-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1021)
  • CIS-3-benzyl-8-(dimethylamino)-1-(2-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (0.45 g, 0.93 mmol) in THF (10 mL) was added to sodium metal (0.21 g, 9.316 mmol) in liquid ammonia (10 mL) at −78° C. The reaction mixture was stirred at -78° C. for 15 min, quenched with sat. aq. NH4Cl and the organic product was extracted with EtOAc (2×20 mL). The combined organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo. Purification of the residue by preparative TLC using 2% methanol in DCM as eluent gave 170 mg of solid material, which was washed with pentane to give 150 mg (40%) of CIS-8-(dimethylamino)-1-(2-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1021) as an off white solid. (TLC system: 10% MeOH in DCM; Rf: 0.3). 1H NMR (DMSO-d6): δ 7.34-7.18 (m, 7H), 6.96 (d, 1H), 6.90 (t, 1H), 6.33 (s, 1H), 4.19 (s, 2H), 3.83 (s, 3H), 3.20 (s, 2H), 2.59-2.55 (m, 2H), 1.98-1.90 (m, 8H), 1.37-1.30 (m, 4H). Mass: m/z 394.3 [M+H]+
    • Synthesis of INT-1022: CIS-8-(dimethylamino)-1-(2-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00037
  • In analogy to the method described for INT-986 (step 1) CIS-8-(dimethylamino)-1-(2-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one was reacted with N-iodosuccinimide to be converted into CIS-1-(2-methoxybenzyl)-8-(methylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1022). 1H NMR (DMSO-d6): δ 7.39 (d, 2H), 7.29 (t, 2H), 7.23-7.15 (m, 3H), 6.96 (d, 1H), 6.89 (t, 1H), 6.36 (s, 1H), 4.21 (s, 2H), 3.84 (s, 3H), 3.25 (s, 2H), 2.13 (m, 1H), 2.03-1.98 (m, 2H), 1.82-1.80 (m, 5H), 1.64-1.58 (m, 2H), 1.34-1.31 (m, 2H). Mass: m/z 380.2 [M+H]+
    • Synthesis of INT_1023: CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00038
    • Step 1: Synthesis of CIS-1-amino-4-(dimethylamino)-4-phenylcycloheanecarboylic Acid
  • Ba(OH)2×8H2O (36.87 g, 117.07 mmol) was added to the solution of CIS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione (12 g, 41.81 mmol) in water (450 mL) at RT. The reaction mixture was stirred at 150° C. for 8 h. The resulting mixture was cooled down to RT and (NH4)2CO3 (22.97 g, 146.34 mmol) was added. The reaction mixture was stirred at 65° C. for 8 h, then filtered through celite and the precipitate was washed with water. The combined filtrate was concentrated in vacuo to afford 6.5 g of crude CIS-1-amino-4-(dimethylamino)-4-phenylcyclohexanecarboxylic acid. The product was used in the next step without further purification. (TLC system: 10% MeOH in DCM; Rf: 0.1).
    • Step 2: Synthesis of CIS-1-(tert-butoxycarbonylamino)-4-(dimethylamino)-4-phenylcyclohexanecarboxylic Acid (INT-1023)
  • K2CO3 (4.74 g, 34.34 mmol) was added to a solution of CIS-1-amino-4-(dimethylamino)-4-phenylcyclohexanecarboxylic acid (3.0 g, 11.4 mmol) in water-THF (40 mL, 1:1 v/v) at RT. After 15 min, Boc2O (3.24 g, 14.85 mmol) was added and the reaction mixture was stirred at RT for 16 h. The resulting mixture was diluted with water, acidified with glacial acetic acid (pH -4) and extracted with 10% MeOH in DCM (2×150 mL). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (neutral alumina, 10% methanol in DCM as eluent) and further purified by washing with pentane to give 1.0 g (24%) of CIS-1-(tert-butoxycarbonylamino)-4-(dimethylamino)-4-phenylcyclohexanecarboxylic acid (INT-1023) as a white solid. (TLC system: 10% MeOH in DCM; Rf: 0.10). Mass: m/z 361.2 (M−H)−.
    • Synthesis of INT-1028: CIS-8-(dimethylamino)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00039
  • In analogy to the method described for INT-982 step 2 CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one (SC-2147) was treated with TFA to be converted into CIS-8-(dimethylamino)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one (INT-1028).
    • Synthesis of INT-1026: CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00040
    • Step 1:2-methyl-N-(1,4-dioxaspiro[4.5]decan-8-ylidene)propane-2-sulfinamide
  • Titanium ethoxide (58.45 g, 256.4 mmol) was added to a solution of 1,4-dioxaspiro[4.5]decan-8-one (20 g, 128.20 mmol) and 2-methylpropane-2-sulfinamide (15.51 g, 128.20 mmol) in THF (200 mL) at RT and the reaction mixture was stirred at RT for 18 h. The reaction mixture was cooled to 0° C. and quenched by dropwise addition of sat aq. NaHCO3 (500 mL) over a period of 30 min. The organic product was extracted with EtOAc (3×100 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated in vacuo to afford 10 g (crude) of 2-methyl-N-(1,4-dioxaspiro[4.5]decan-8-ylidene)propane-2-sulfamide as a white solid (TLC system: 30% Ethyl acetate in hexane; Rf: 0.30).
    • Step 2: 2-methyl-N-(8-phenyl-1,4-dioxaspiro[4.5]decan-8-yl)propane-2-sulfinamide
  • Phenylmagnesium bromide (M in THF, 116 mL, 116 mmol) was added dropwise to a solution of 2-methyl-N-(1,4-dioxaspiro[4.5]decan-8-ylidene)propane-2-sulfamide (10 g, 38.61 mmol) in THF (500 mL) at −10° C. under argon atmosphere. The reaction mixture was stirred for 2 h at −10° C. to 0° C. The reaction completion was monitored by TLC. The reaction mixture was quenched with sat. aq. NH4Cl (50 mL) at 0° C. and the organic product was extracted with EtOAc (3×100 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography (silica gel 230-400 mesh; 40-60% ethyl acetate in hexane) to yield 6.0 g (46%) of 2-methyl-N-(8-phenyl-1,4-dioxaspiro[4.5]decan-8-yl)propane-2-sulfinamide as a liquid (TLC system: 70% Ethyl acetate in hexane; Rf: 0.30).
    • Step 3: 8-phenyl-1,4-dioxaspiro[4.5]decan-8-amine Hydrochloride
  • 2N solution of HCl in diethyl ether (17.80 mL, 35.60 mmol) was added to a solution of 2-methyl-N-(8-phenyl-1,4-dioxaspiro[4.5]decan-8-yl)propane-2-sulfamide (6.0 g, 17.80 mmol) in DCM (60 mL) at 0° C. The reaction mixture was stirred at RT for 2 h. The reaction mixture was concentrated in vacuo. The residue was washed with diethyl ether to yield 3 g (crude) of 8-phenyl-1,4-dioxaspiro[4.5]decan-8-amine hydrochloride as a brown solid (TLC system: 5% MeOH in DCM; Rf: 0.10).
    • Step 4: 8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine
  • Sodium cyanoborohydride (2.17 g, 33.45 mmol) was added to a solution of 8-phenyl-1,4-dioxaspiro[4.5]decan-8-amine hydrochloride (3.0 g, 11.15 mmol) and tetrahydrofuran-3-carbaldehyde (4.46 mL, 22.30 mmol) and acetic acid (0.05 mL) in methanol (30 mL) at 0° C. The reaction mixture was stirred at RT for 16 h. The reaction mixture was concentrated in vacuo at 30° C. and to the residue sat. aq. NaHCO3 was added. The organic product was extracted with DCM (3×30 mL). The combined organic extracts were dried over anhydrous Na2SO4 and solvent was concentrated under reduced pressure to get 3 g (crude) of 8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine as a semi-solid (TLC system: 10% MeOH in DCM; Rf: 0.22).
    • Step 5: N-methyl-8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine)
  • Sodium cyanoborohydride (1.76 g, 28.39 mmol) was added to a solution of 8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine (3.0 g, 9.46 mmol), 37% formaldehyde in water (7.70 mL, 94.60 mmol) and acetic acid (0.05 mL) in methanol (30 mL) at 0° C. The reaction mixture was stirred at RT for 16 h. The reaction mixture was concentrated in vacuo and to the residue sat. aq. NaHCO3 was added. The organic product was extracted with DCM (3×30 mL). The combined organic extracts were dried over anhydrous Na2SO4 and solvent was concentrated under reduced pressure. The resulting residue was purified by column chromatography (silica gel 230-400 mesh; 5-6% MeOH in DCM) to yield 2.50 g (83%) of N-methyl-8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine as a semi solid (TLC system: 10% MeOH in DCM; Rf: 0.25).
    • Step 6: 4-(methyl((tetrahydrofuran-3-yl)methyl)amino)-4-phenylcyclohexanone
  • 5% sulfuric acid in water (25 mL) was added to N-methyl-8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine (2.50 g, 7.55 mmol) at 0° C. and the resulting mixture was stirred at RT for 24 h. The reaction mixture was quenched with sat. aq. NaHCO3 and the organic product was extracted with DCM (2×50 mL). The combined organic layers were dried over anhydrous Na2SO4 and concentrated in vacuo to afford 2.0 g (crude) of 4-(methyl((tetrahydrofuran-3-yl)methyl)amino)-4-phenylcyclohexanone as a thick liquid (TLC system: 10% MeOH in DCM, Rf: 0.20).
    • Step 7: 8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione
  • 4-(methyl((tetrahydrofuran-3-yl)methyl)amino)-4-phenylcyclohexanone (1.50 g, 5.22 mmol) was suspended in 30 mL of EtOH:H2O (1:1 v/v) at RT under argon atmosphere. (NH4)2CO3 (1.9 g, 13.05 mmol) and KCN (0.34 g, 5.22 mmol) were added. The reaction mixture was heated to 70° C. for 16 h. The reaction mixture was diluted with ice-water and the organic product was extracted with DCM (2×50 mL). The combined organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo to give 1.0 g (crude) of 8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione as a solid (TLC system: 70% Ethyl acetate in hexane; Rf: 0.18).
    • Step 8: CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione
  • Diastereomeric mixture of 8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione (1.0 g) was separated by reverse phase preparative HPLC to afford 400 mg of isomer 1 (CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione) and 60 mg of isomer 2 (TRANS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazasiro[4.5]decane-2,4-dione) and 300 mg of mixture of both isomers. Reverse phase preparative HPLC conditions: mobile phase: 10 mM ammonium bicarbonate in H2O/acetonitrile, column: X-BRIDGE-C18 (150*30), 5 μm, gradient (T/B %): 0/35, 8/55, 8.1/98, 10/98, 10.1/35, 13/35, flow rate: 25 ml/min, diluent: mobile phase+THF.
    • Step 9: CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1026)
  • LiAlH4 (M in THF) (4.48 mL, 4.48 mmol) was added to a solution of CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione (isomer-1) (0.4 g, 1.12 mmol) in THF:Et2O (2:1 v/v, 15 mL) at 0° C. under argon atmosphere. The reaction mixture was stirred at 65° C. for 16 h. The mixture was cooled to 0° C., quenched with sat. aq. Na2SO4 (1000 mL) and filtered through celite pad. The filtrate was dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography (silica gel 230-400 mesh; 5-6% MeOH in DCM) to yield 0.3 g (78%) of CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1026) as an off white solid. (TLC system: 10% MeOH in DCM, Rf: 0.2). LC-MS: m/z [M+1]+=344.2.
    • Synthesis of INT-1031: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00041
    • Step 1: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one
  • In analogy to the method described for INT-952 CIS-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (INT-974) was converted into CIS-1-(cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one.
    • Step 2: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one
  • In analogy to the method described for INT-982 step 2 1-(cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one was converted into 1-(cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one (INT-1031).
    • Synthesis of INT-1037: 8-(dimethylamino)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile
  • Figure US20200399252A1-20201224-C00042
    • Step 1: 9,12-dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}.2{circumflex over ( )}{5}]tetradecan-3-one
  • Lithiumaluminiumhydride (2.2 equiv., 292 mmol) was suspended in THF (400 mL) and the suspension was cooled to 0° C. 8-(Dimethylamino)-8-(m-tolyl)-1,3-diazaspiro[4.5]decan-2-one (B, 75 mg, 0,261 mmol) (step 1 of INT-965) was added portionwise at 0° C. The reaction mixture was stirred 1.5 h at 0° C., then overnight at RT and then 2 h at 40° C. The reaction mixture was cooled down to 0° C., quenched carefully with sat. aq. Na2SO4, EtOAc (400 mL) was added and the resulting mixture was stirred for 2 h and then left without stirring for 2 h at RT. The precipitate was filtered off and washed with EtOAc and MeOH. The resulting solid residue was suspended in methanol and stirred at RT overnight. The precipitate was filtered off and disposed. The filtrate was concentrated under reduced pressure, the residue was suspended thoroughly in water (50 mL) at 40° C., the precipitate was filtered off and dried under reduced pressure to yield 9,12-dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}.2{circumflex over ( )}{5}]tetradecan-3-one (11.4 g, 41%). Mass: m/z 213.2 (M+H)+.
    • Step 2: 1,3-diazaspiro[4.5]decane-2,8-dione
  • In analogy to the method described for INT-1003 step 3 9,12-dioxa-2,4-diazadispiro[4.2.4{circumflex over ( )}{8}.2{circumflex over ( )}{5}]tetradecan-3-one was treated with conc. aq. HCl to be converted into 1,3-diazaspiro[4.5]decane-2,8-dione. Mass: m/z 169.1 (M+H)+.
    • Step 3: 8-(dimethylamino)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (INT-1037)
  • In analogy to the method described for INT-965 step 1 1,3-diazaspiro[4.5]decane-2,8-dione was treated with dimethyl amine and potassium cyanide to be converted into 8-(dimethylamino)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (INT-1037). Mass: m/z 223.2 (M+H)+.
    • Synthesis of INT-1038: CIS-8-(dimethylamino)-8-(m-tolyl)-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00043
  • To the suspension of 8-(dimethylamino)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (200 mg, 0.90 mmol) in THF (4 mL) at RT was added dropwise 1M bromo(m-tolyl)magnesium in THF (4 equiv., 3.6 mmol, 3.6 mL) and the reaction mixture was stirred for 1 h at RT. Additional portion of 1M bromo(m-tolyl)magnesium in THF (1 equiv., 0.8 mL) was added. The reaction mixture was stirred at RT overnight, then quenched with methanol/water. Solid NH4Cl and DCM were added to the resulting mixture and the precipitate was filtered off. The organic phase of the filtrate was separated and the aqueous phase was extracted with DCM (3×). The combined organic phases were dried over anhydr. Na2SO4 and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (DCM/MeOH, 100/0 to 65/35) to yield CIS-8-(dimethylamino)-8-(m-tolyl)-1,3-diazaspiro[4.5]decan-2-one (INT-1038) (81 mg, 31%). Mass: m/z 288.2 (M+H)+.
    • Synthesis of INT-1064: CIS-1-acetyl-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00044
    • Step 1: CIS-1-acetyl-8-(dimethylamino)-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • To a solution of CIS-8-dimethylamino-3-(4-methoxy-benzyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (INT-975) (19.5 g, 49.6 mmol, 1.0 eq.) in THF (180 ml) was added 2.5M solution of n-BuLi in hexane (39.7 ml, 99.23 mmol, 2.0 eq.) at 0° C. and the resulting mixture was stirred for 1 h. A solution of acetyl chloride (7.7 g, 99.23 mmol, 2.0 eq.) in THF (20 ml) was added dropwise at 0° C. The cooling bath was removed, the reaction mixture was stirred at RT for 16 h, then cooled down to 0° C. again, quenched with water and extracted with ethyl acetate (2×200 ml). The combined organic extracts were washed with brine (250 ml), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; 30% EtOAc/Hexane) to yield CIS-1-acetyl-8-dimethylamino-3-(4-methoxy-benzyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (6.1 g, 14.02 mmol, 28%) as a light yellow sticky solid. Mass: m/z 436.3 [M+H]+
    • Step 2: CIS-1-acetyl-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1064)
  • To a solution of CIS-1-acetyl-8-dimethylamino-3-(4-methoxy-benzyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (5.0 g, 11.5 mmol, 1.0 eq.) in acetonitrile (60 ml) was added a solution cerium(IV) ammonium nitrate (18.98 g, 34.5 mmol, 3.0 eq.) in water (60 ml) at 0° C. and the reaction mixture was stirred at RT for 2 h. The reaction mixture was quenched with aq. NaHCO3 solution (50 ml) and extracted with ethyl acetate (2×100 ml). The combined organic layer was washed with brine (2×100 ml), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel neutralized with TEA; 2/3 v/v EtOAc/Hexane) to yield CIS-1-acetyl-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (INT-1064) as an off white solid. Yield: 61% (4.9 g, 15.55 mmol). 1HNMR (DMSO-d6, 400 MHz), δ (ppm)=7.57 (s, 1H), 7.33-7.23 (m, 5H), 3.21 (s, 2H), 3.03 (t, 2H, J=12.78 Hz), 2.60 (d, 2H, J=13.32 Hz), 2.32 (s, 3H), 1.89 (s, 6H), 1.37-1.32 (m, 4H). Mass: m/z 316.2 [M+H]+
    • Synthesis of INT-1059: TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00045
    • Step 1: TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione
  • To a stirred solution of 4-dimethylamino-4-phenyl-cyclohexanone (250.0 g, 1.15 mol, 1.0 eq.) in EtOH (2.5 L) and water (2.1 L) was added (NH4)CO3 (276.2 g, 2.87 mol, 2.5 eq.) and the reaction mixture was stirred at RT for 15 min. KCN (74.92 g, 1.15 mol, 1.0 eq.) was added. The reaction mixture was stirred at 60° C. for 18 h and then filtered in hot condition to get white solid which was washed with water (2.5 L), ethanol (1 L) and hexane (2.5 L). The resulting solid was dried under reduced pressure to get CIS-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (223 g, 0.776 mol, 65%) as a white solid. The filtrate was collected from multiple batches (˜450 g) which contained a mixture of cis and trans isomers. The filtrate was concentrated under reduced pressure and solid obtained was filtered and washed with water (1 L) and hexane (1 L). Solid material was dried under reduced pressure to get -100 g of a mixture of cis and trans (major) isomers. Crude material was partially dissolved in hot MeOH (600 mL) and cooled to RT, filtered through sintered funnel, washed with MeOH (200 mL) followed by ether (150 mL) and dried to get TRANS-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (50 g, 0.174 mmol, ˜9-10%).
    • Step 2: TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1059)
  • In analogy to the method described for INT-976 step 2 TRANS-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione was treated with LiAlH4 to be converted into TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1059). Mass: m/z 274.2 (M+H)+.
    • Synthesis of INT-1065: CIS-3-((2-chloropyridin-4-yl)methyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00046
    • Step 1: CIS-1-acetyl-3-((2-chloropyridin-4-yl)methyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • To a solution of CIS-1-acetyl-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1064) (1 g, 3.17 mmol) in DMF (37 mL) was added sodium hydride (60 wt % in mineral oil, 1.25 equiv., 3.96 mmol, 159 mg) portionwise at 0° C. The reaction mixture was stirred for 15 min at 0° C. and 2-chloro-4-(chloromethyl)pyridine (1.25 equiv., 3.96 mmol, 0.485 mL) was added. The reaction mixture was stirred at RT for 2 h, then cooled down to 0° C., quenched with sat. aq. NaHCO3 (10 mL), water (10 mL) and extracted with EtOAc (2×50 mL). Combined organic phase was washed with brine, dried over anhydr. Na2SO4 and concentrated under reduced pressure. The resulting crude product was purified by flash chromatography on silica gel (eluent MeCN/DCM 98/2) to yield 1215 mg (87%) of CIS-1-acetyl-3-((2-chloropyridin-4-yl)methyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one. Mass: m/z 441.2 (M+H)+.
    • Step 2: CIS-3-((2-chloropyridin-4-yl)methyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1065)
  • To a solution of CIS-1-acetyl-3-((2-chloropyridin-4-yl)methyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (1140 mg, 2.59 mmol) in THF/MeOH (2:1 v/v, 15 mL) was added 3M aq. NaOH (26 mL). The reaction mixture was stirred for 1.5 h at RT and then extracted with EtOAc (2×50 mL). The combined organic phase was dried over anhydr. Na2SO4 and concentrated under reduced pressure to yield 932 mg (90%) of CIS-3-((2-chloropyridin-4-yl)methyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1065) which was used in the next steps without additional purification. Mass: m/z 399.2 (M+H)+.
    • Synthesis of INT-1068 and INT-1069: CIS- and TRANS-8-(dimethylamino)-8-phenyl-1-(2,2,2-trifluoroethyl)-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00047
    • Step 1: 1-amino-4-dimethylamino-4-phenyl-cyclohexanecarbonitrile
  • To a stirred solution of 4-dimethylamino-4-phenyl-cyclohexanone (50 g, 230.096 mmol) in MeOH (400 mL) was added NH4Cl (24.6 g, 460.8 mmol) followed by NH4OH (400 mL) at RT and the reaction mixture was stirred for 15 min. NaCN (22.5 g, 460.83 mmol) was added and the resulting mixture was stirred for 16 h at RT. The reaction mixture was extracted with DCM (3×750 mL). Combined organic layer was washed with water (750 mL), brine (750 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was triturated with DCM/hexane to get crude 1-amino-4-dimethylamino-4-phenyl-cyclohexanecarbonitrile (50 g, 90%) as an off white solid which was used in next step without further purification. LC-MS: m/z [M+H]+=244.2 (MW calc. 244.09).
    • Step 2: N-(1-cyano-4-dimethylamino-4-phenyl-cyclohexyl)-2,2,2-trifluoroacetamide
  • To a solution of 1-amino-4-dimethylamino-4-phenyl-cyclohexanecarbonitrile (5.0 g, 20.57 mmol, 1.0 eq.) in THF (100 ml) were added DIPEA (10.72 ml, 61.71 mmol, 3.0 eq), trifluoroacetic acid (1.89 ml, 24.69 mmol, 1.2 eq) and T3P (18.2 ml, 30.85 mmol, 1.5 eq) at 0° C. The reaction mixture was stirred at RT for 16 h, then diluted with water (100 ml) and extracted with 10% MeOH in DCM (2×250 mL). Combined organic layer was washed with brine (100 mL), dried over Na2SO4 and concentrated under reduced pressure to get crude N-(1-cyano-4-dimethylamino-4-phenyl-cyclohexyl)-2,2,2-trifluoroacetamide as a light yellow sticky material which was used in the next step without further purification. LC-MS: m/z [M+1]+=339.9 (MW calc. 339.36).
    • Step 3: 1-aminomethyl-N′,N′-dimethyl-4-phenyl-N-(2,2,2-trifluoroethyl)cyclohexane-1,4-diamine
  • To suspension of LiAlH4 (4.03 g, 106.19 mmol, 6.0 eq.) in dry THF (40 mL) was added N-(1-cyano-4-dimethylamino-4-phenyl-cyclohexyl)-2,2,2-trifluoro-acetamide (6.0 g, 17.69 mmol, 1.0 eq.) in dry THF (100 mL) dropwise at 0° C. The reaction mixture was stirred at RT for 16 h, then quenched with sat. aq. Na2SO4 at 0° C., excess THF was added and the resulting mixture was stirred at RT for 2 h. The resulting suspension was filtered through celite and the filter cake was washed with 10% MeOH in DCM (150 mL). Combined filtrate was concentrated under reduced pressure to yield crude 1-aminomethyl-N′,N′-dimethyl-4-phenyl-N-(2,2,2-trifluoro-ethyl)-cyclohexane-1,4-diamine (4.2 g, crude) as a light yellow sticky material which was directly used in the next step without further purification. LC-MS: m/z [M+1]+=330.0 (MW calc. 329.40).
    • Step 4: CIS- and TRANS-8-dimethylamino-8-phenyl-1-(2,2,2-trifluoro-ethyl)-1,3-diaza-spiro[4.5]decan-2-one (INT-1068 and INT-1069)
  • To a solution of 1-aminomethyl-N′,N′-dimethyl-4-phenyl-N-(2,2,2-trifluoro-ethyl)-cyclohexane-1,4-diamine (4.2 g, 12.76 mmol, 1.0 eq.) in toluene (60 ml) was added KOH (4.29 g, 76.56 mmol, 6.0 eq.) in water (120 ml) at 0° C. followed by addition of COCl2 (15.6 ml, 44.66 mmol, 3.5 eq., 20% in toluene) at 0° C. and stirred at RT for 16 h. Reaction mixture was basified with sat NaHCO3 solution and extracted with DCM (2×200 ml). Combined organic layer was dried over Na2SO4 and concentrated under reduced pressure to get crude product which was purified by prep HPLC to get CIS-8-dimethylamino-8-phenyl-1-(2,2,2-trifluoro-ethyl)-1,3-diaza-spiro[4.5]decan-2-one (INT-1068) (1.5 g) (major isomer, polar spot on TLC) and TRANS-8-dimethylamino-8-phenyl-1-(2,2,2-trifluoro-ethyl)-1,3-diaza-spiro[4.5]decan-2-one (INT-1069) as minor isomer (non-polar spot on TLC) (120 mg, 92.93% by HPLC) as off-white solids. CIS-isomer: LC-MS: m/z [M+1]+=356.2 (MW calc.=355.40). HPLC: 98.53%, Column: Xbridge C-18 (100×4.6), 5p, Diluent: MeOH, Mobile phase: A) 0.05% TFA in water; B) ACN flow rate: 1 ml/min, R=5.17 min. 1HNMR (DMSO-d6, 400 MHz), δ (ppm)=7.43-7.27 (m, 5H), 6.84 (s, 1H), 3.30-3.25 (m, 4H), 2.66-2.63 (d, 2H, J=12.72 Hz), 1.89 (s, 6H), 1.58-1.51 (m, 2H), 1.46-1.43 (m, 2H), 1.33-1.23 (m, 2H).
  • For further intermediates the synthesis in analogy to previously described methods is given in the following table. The syntheses of the building blocks and intermediates have either been described previously within this application or can be performed in analogy to the herein described methods or by methods known to the person, skilled in the art. Such a person will also know which building blocks and intermediates need to be chosen for synthesis of each exemplary compound.
  • in analogy m/z
    Intermediate Chemical Name to method [M + H]+
    INT-794 CIS-3-(3,4-dimethoxy- benzyl)-8-(dimethyl- amino)-8-phenyl-1,3- diazaspiro[4.5]decan- 2-one
    Figure US20200399252A1-20201224-C00048
         		SC_2097 424.3
    INT-796 CIS-8-Dimethylamino- 3-[(4-methoxyphenyl)- methyl]-8-(3-methoxy- propyl)-1,3-diazaspiro- [4.5]decan-2-one
    Figure US20200399252A1-20201224-C00049
         		SC_2017 390.3
    INT-797 CIS-8-(Ethyl-methyl- amino)-8-phenyl-1,3- diazaspiro-[4.5]decan- 2-one
    Figure US20200399252A1-20201224-C00050
         		INT-976 288.2
    INT-798 CIS-3-[[8-(Ethyl- methylamino)-2-oxo-8- phenyl-1,3-diazaspiro- [4.5]decan-3-yl]- methyl]benzonitrile
    Figure US20200399252A1-20201224-C00051
         		SC_2097 403.3
    INT-949 CIS-8-Dimethylamino- 1-ethyl-8-phenyl-1,3- diazaspiro[4.5]decan-2- one
    Figure US20200399252A1-20201224-C00052
         		INT-984 302.2
    INT-950 CIS-1-(Cyclobutyl- methyl)-8-dimethyl- amino-8-phenyl-3- [phenyl-methyl]-1,3- diazaspiro[4.5]decan- 2-one
    Figure US20200399252A1-20201224-C00053
         		SC_2125 432.3
    INT-954 4-Dimethylamino-4-(5- methyl-thiophen-2-yl)- cyclohexan-1-one
    Figure US20200399252A1-20201224-C00054
         		INT-965 238.1
    INT-955 4-Dimethylamino-4- thiophen-2-yl-cyclo- hexan-1-one
    Figure US20200399252A1-20201224-C00055
         		INT-965 224.1
    INT-956 1-(1-Methyl-1H- pyrazol-3-yl)-4-oxo- cyclohexane-1- carbonitrile
    Figure US20200399252A1-20201224-C00056
         		INT-958 204.1
    INT-957 4-Oxo-1-pyrazin-2- yl-cyclohexane-1- carbonitrile
    Figure US20200399252A1-20201224-C00057
         		INT-958 202.1
    INT-959 4-Dimethylamino-4- (1-methyl-1H-pyrazol- 3-yl)-cyclohexan-1-one
    Figure US20200399252A1-20201224-C00058
         		INT-961 222.2
    INT-960 4-Dimethylamino-4- pyrazin-2-yl-cyclo- hexan-1-one
    Figure US20200399252A1-20201224-C00059
         		INT-961 220.1
    INT-962 4-Dimethylamino-4- (3-methoxyphenyl)- cyclohexan-1-one
    Figure US20200399252A1-20201224-C00060
         		INT-965 248.2
    INT-963 CIS-3-Benzyl-8- dimethylamino-8- phenyl-1,3-diazaspiro- [4.5]decan-2-one
    Figure US20200399252A1-20201224-C00061
         		INT-975 364.2
    INT-964 4-(Ethyl-methyl- amino)-4-phenyl- cyclohexan-1-one
    Figure US20200399252A1-20201224-C00062
         		INT-965 232.2
    INT-967 CIS-8-Dimethylamino- 8-[4-(methoxymethyl- oxy)phenyl]-3-[(4- methoxyphenyl)- methyl]-1,3-diazaspiro- [4.5]decan-2-one
    Figure US20200399252A1-20201224-C00063
         		SC_2017 454.3
    INT-968 CIS-8-Dimethylamino- 8-[3-(methoxymethyl- oxy)phenyl]-3-[(4- methoxyphenyl)- methyl]-1,3-diazaspiro- [4.5]decan-2-one
    Figure US20200399252A1-20201224-C00064
         		SC_2017 454.3
    INT-969 CIS-1-(Cyclobutyl- methyl)-8-dimethyl- amino-8-(4-hydroxy- phenyl)-3-[(4-methoxy- phenyl)methyl]-1,3- diazaspiro[4.5]decan- 2-one
    Figure US20200399252A1-20201224-C00065
         		SC_2018 478.3
    INT-970 CIS-8-Dimethylamino- 8-(4-methoxyphenyl)- 3-[(4-methoxyphenyl)- methyl]-1,3-diazaspiro- [4.5]decan-2-one
    Figure US20200399252A1-20201224-C00066
         		SC_2017 424.3
    INT-972 CIS-8-Dimethylamino- 8-(3-methoxyphenyl)- 3-[(4-methoxyphenyl)- methyl]-1,3-diazaspiro- [4.5]decan-2-one
    Figure US20200399252A1-20201224-C00067
         		SC_2017 424.3
    INT-979 CIS-8-Dimethylamino- 1-(3-methoxy-propyl)- 8-phenyl-1,3-diazaspiro- [4.5]decan-2-one
    Figure US20200399252A1-20201224-C00068
         		INT-984 346.2
    INT-980 CIS-8-Dimethylamino- 1-(2-methoxy-ethyl)-8- phenyl-1,3-diazaspiro- [4.5]decan-2-one
    Figure US20200399252A1-20201224-C00069
         		INT-984 332.2
    INT-981 CIS-8-Dimethylamino- 8-phenyl-1-propyl-1,3- diazaspiro[4.5]decan-2- one
    Figure US20200399252A1-20201224-C00070
         		INT-984 316.2
    INT-983 CIS-1-(Cyclopropyl- methyl)-8-dimethyl- amino-8-phenyl-1,3- diazaspiro[4.5]decan- 2-one
    Figure US20200399252A1-20201224-C00071
         		INT-984 328.2
    INT-985 CIS-1-(Cyclobutyl- methyl)-8-(methyl- propylamino)-8- phenyl-1,3-diazaspiro- [4.5]decan-2-one
    Figure US20200399252A1-20201224-C00072
         		INT-986 370.3
    INT-993 4-benzyl-4-(dimethyl- amino)cyclohexanone
    Figure US20200399252A1-20201224-C00073
         		INT-965 232.3
    INT-994 CIS-8-benzyl-8- (dimethylamino)-1,3- diazaspiro[4.5]decan- 2-one
    Figure US20200399252A1-20201224-C00074
         		INT-976 288.2
    INT-995 TRANS-8-benzyl-8- (dimethylamino)-1,3- diazaspiro[4.5]decan- 2-one
    Figure US20200399252A1-20201224-C00075
         		INT-976 288.2
    INT-997 CIS-8-(dimethylamino)- 8-(thiophen-2-yl)-1,3- diazaspiro[4.5]decan-2- one
    Figure US20200399252A1-20201224-C00076
         		INT-976 280.1
    INT-998 TRANS-8-(dimethyl- amino)-8-(thiophen-2- yl)-1,3-diazaspiro[4.5]- decan-2-one
    Figure US20200399252A1-20201224-C00077
         		INT-976 280.1
    INT-999 4-(dimethylamino)-4-(1- methyl-1H-benzo[d]- imidazol-2-yl)cyclo- hexanone
    Figure US20200399252A1-20201224-C00078
         		INT-965 272.2
    INT-1000 CIS-8-(dimethylamino)- 8-(1-methyl-1H-benzo- [d]imidazol-2-yl)-1,3- diazaspiro[4.5]decan-2- one
    Figure US20200399252A1-20201224-C00079
         		INT-976 328.2
    INT-1001 TRANS-8-(dimethyl- amino)-8-(1-methyl- 1H-benzo[d]imidazol- 2-yl)-1,3-diazaspiro- [4.5]decan-2-one
    Figure US20200399252A1-20201224-C00080
         		INT-976 328.2
    INT-1009 TRANS-8-ethylamino- 8-phenyl-1,3-diazaspiro- [4.5]decan-2-one
    Figure US20200399252A1-20201224-C00081
         		INT-1008 274.2
    INT-1024 CIS-8-(dimethylamino)- 8-(3-fluorophenyl)-1,3- diazaspiro[4.5]decan-2- one
    Figure US20200399252A1-20201224-C00082
         		INT-977 (step 2) 292.2
    INT-1025 CIS-8-(dimethylamino)- 8-(4-fluorophenyl)-1,3- diazaspiro[4.5]decan-2- one
    Figure US20200399252A1-20201224-C00083
         		INT-974, INT-977 (step 2) 292.2
    INT-1029 CIS-1-(cyclobutyl- methyl)-8-(dimethyl- amino)-8-phenyl-3- (prop-2-yn-1-yl)-1,3- diazaspiro[4.5]-decan- 2-one
    Figure US20200399252A1-20201224-C00084
         		INT-1010 380.3
    INT-1030 ethyl CIS-2-(4-((1- (cyclobutylmethyl)-8- (dimethylamino)-2- oxo-8-phenyl-1,3- diazaspiro[4.5]decan- 3-yl)methyl)-1H-1,2,3- triazol-1-yl)acetate
    Figure US20200399252A1-20201224-C00085
         		INT-1011 509.3
    INT-1039 CIS-8-(dimethylamino)- 8-(3-(trifluoromethoxy)- phenyl)-1,3-diazaspiro- [4.5]decan-2-one
    Figure US20200399252A1-20201224-C00086
         		INT-1038 358.2
    INT-1040 (CIS)-8-(dimethyl- amino)-8-(3-(trifluoro- methyl)phenyl)-1,3- diazaspiro[4.5]-decan- 2-one
    Figure US20200399252A1-20201224-C00087
         		INT-1038 342.2
    INT-1041 (CIS)-8-(dimethyl- amino)-8-(3-methoxy- phenyl)-1,3-diazaspiro- [4.5]decan-2-one
    Figure US20200399252A1-20201224-C00088
         		INT-1038 304.2
    INT-1042 (CIS)-8-(5-chloro- thiophen-2-yl)-8- (dimethylamino)-1,3- diazaspiro[4.5]decan- 2-one
    Figure US20200399252A1-20201224-C00089
         		INT-1038 314.1
    INT-1043 (CIS)-8-(dimethyl- amino)-8-(3-fluoro-5- methylphenyl)-1,3- diazaspiro[4.5]decan- 2-one
    Figure US20200399252A1-20201224-C00090
         		INT-1038 306.2
    INT-1044 (CIS)-8-(3-chloro- phenyl)-8-(dimethyl- amino)-1,3-diazaspiro- [4.5]decan-2-one
    Figure US20200399252A1-20201224-C00091
         		INT-1038 308.2
    INT-1047 (CIS)-8-(methyl- (oxetan-3-ylmethyl)- amino)-8-phenyl-1,3- diazaspiro-[4.5]decan- 2-one
    Figure US20200399252A1-20201224-C00092
         		INT-1026 330.5
    INT-1061 TRANS-1-(cyclo- propylmethyl)-8- dimethylamino-8- phenyl-1,3-diazaspiro- [4.5]decan-2-one
    Figure US20200399252A1-20201224-C00093
         		INT-984 328.2
    INT-1063 CIS-1-(cyclopropyl- methyl)-8-(dimethyl- amino)-8-(3-fluoro- phenyl)-1,3-diazaspiro- [4.5]decan-2-one
    Figure US20200399252A1-20201224-C00094
         		INT-1031 346.2
    INT-1066 TRANS-1-(cyclobutyl- methyl)-8-(dimethyl- amino)-8-phenyl-1,3- diazaspiro-[4.5]decan- 2-one
    Figure US20200399252A1-20201224-C00095
         		INT-987 342.3
    INT-1070 CIS-8-(dimethylamino)- 8-phenyl-1-(3,3,3- trifluoropropyl)-1,3- diazaspiro[4.5]decan- 2-one
    Figure US20200399252A1-20201224-C00096
         		INT-1068 360.2
    INT-1074 CIS-8-(dimethylamino)- 8-(3-fluorophenyl)-1- ((1-hydroxycyclobutyl)- methyl)-1,3-diazaspiro- [4.5]decan-2-one
    Figure US20200399252A1-20201224-C00097
         		INT-1031 376.2
    • Synthesis of Exemplary Compounds Synthesis of SC_2002: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(3-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00098
  • NaH (60% in mineral oil) (70 mg, 2.93 mmol) and 1-(bromomethyl)-3-methoxy-benzene (58 mg, 0.29 mmol) were sequentially added to a suspension of CIS-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one INT-987 (100 mg, 0.29 mmol) in DMF (3 mL) at 0° C. and the reaction mixture was stirred at RT for 30 min. The reaction completion was monitored by TLC. The reaction mixture was quenched with sat. aq. NH4Cl solution and the organic product was extracted with EtOAc (2×12 mL). The combined organic layer was dried over anhydrous MgSO4 and concentrated in vacuo. Purification of the residue by flash column chromatography over silica gel (230-400 mesh) using 30-35% ethyl acetate in petroleum ether as eluent yielded 42 mg of CIS-1-(cyclobutyl-methyl)-8-dimethylamino-3-[(3-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_2002 as solid. [M+H]+ 462.3
    • Synthesis of SC_2008: CIS-8-(Allyl-methyl-amino)-1-(cyclobutyl-methyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00099
  • To the solution of CIS-1-(cyclobutyl-methyl)-3-[(4-methoxyphenyl)-methyl]-8-methylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_2044 (70 mg, 0.16 mmol) in MeCN (1 mL) was added potassium carbonate (216 mg, 1.56 mmol). The reaction mixture was stirred for 15 min, 3-bromo-prop-1-ene (41 μL, 0.47 mmol) was added and stirring was continued at RT for 3 days. The mixture was then diluted with DCM, filter through celite and the filtrate was concentrated in vacuo. Purification of the residue by flash column chromatography provided 44 mg of CIS-8-(allyl-methyl-amino)-1-(cyclobutyl-methyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_2008 as a solid. [M+H]+ 488.3.
    • Synthesis of SC_2010: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00100
  • CIS-8-Dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5] decan-2-one (SC_2017) (0.2 g, 0.48 mmol) was added to the solution of NaH (60% in mineral oil) (0.08 g, 1.94 mmol) in DMF (5 mL) and the reaction mixture was stirred at RT for 1 h. The reaction mixture was cooled to 0° C., (bromomethyl)cyclobutane (0.21 mL, 1.94 mmol) was added dropwise and stirring was continued for 30 min at 0° C. and then for 2 days at RT. The reaction completion was monitored by TLC. The reaction mixture was quenched with sat. aq. NH4Cl and the organic product was extracted with EtOAc (2×10 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated under reduced pressure. Purification of the residue by column chromatography on silica gel (100-200 mesh) using 0-50% EtOAc in petroleum ether as eluent gave 0.1 g of product which was further purified by preparative TLC using 30% EtOAc in petroleum ether as mobile phase to give 65 mg (28%) of CIS-1-(cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (SC_2010) as an off white solid. (TLC system: 30% EtOAc in petroleum ether; Rf: 0.6). [M+H]+ 480.3
    • Synthesis of SC_2014: CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1-(2-methyl-propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00101
  • A solution of NaOH (81 mg, 2.0 mmol) in DMSO (1 mL) was stirred at RT for 10 min. CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5] decan-2-one (SC_2097) (200 mg, 1.52 mmol) was added and stirring was continued for 15 min. Isobutyl-bromide (20 mg, 1.52 mmol) was added and the reaction mixture was heated to 60° C. for 16 h. After cooling to RT, water (100 mL) was added and the resulting mixture was extracted with DCM (3×150 mL). The combined organic layers were washed with water (70 mL) and brine (100 mL), dried over Na2SO4, filtered and concentrated in vacuo. Purification of the residue by column chromatography provided CIS-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-1-(2-methyl-propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_2014 (72 mg) as a solid. [M+H]+ 450.3
    • Synthesis of SC_2017: CIS-8-Dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00102
    • Step 1: 8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile
  • Dimethylamine hydrochloride (76.36 g, 936.39 mmol) was added to a solution of 3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decane-2,8-dione INT-966 (90 g, 312.13 mmol) in MeOH (180 mL) at RT under argon atmosphere. The solution was stirred for 15 min and 40% aq. dimethylamine (780 mL) and KCN (48.76 g, 749.11 mmol) were sequentially added. The reaction mixture was stirred for 48 h while being monitored by NMR. The reaction mixture was diluted with water (1.0 L) and the organic product was extracted with EtOAc (2×2.0 L). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford 90 g (85%) of 8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile as an off white solid (TLC system: TLC system: 10% MeOH in DCM; Rf: 0.35, 0.30).
    • Step 2: CIS-8-Dimethylamino-8-(3-fluorophenyl)-3-[(4-methoyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one
  • 3-Fluorophenylmagnesium bromide (M in THF) (220 mL, 219.17 mmol) was added dropwise to a solution of 8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (15 g, 43.83 mmol) in THF (300 mL) at 0° C. under argon atmosphere. The reaction mixture was stirred for 16 h at RT. The reaction completion was monitored by TLC. The reaction mixture was cooled to 0° C., quenched with sat. aq. NH4Cl (200 mL) and the organic product was extracted with EtOAc (2×200 mL). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The reaction was carried out in 4 batches (15 g×2 and 5 g×2) and the batches were purified together. Purification of the residue by flash column chromatography over silica gel (230-400 mesh) (2 times) by using 0-20% methanol in DCM as eluent and further purified by washing with pentane yielded 5.6 g (11%) of CIS-8-Dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one SC_2017 as off-white solid. (TLC system: 5% MeOH in DCM in presence of ammonia; Rf: 0.1). [M+H]+ 412.2
    • Synthesis of SC_2018: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-hydroxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00103
    • Step 1: CIS-8-(dimethylamino)-1-isobutyl-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • In analogy to the method described for INT-951 step 1 CIS-8-dimethylamino-8-[3-(methoxymethyloxy)-phenyl]-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (INT-968) was converted into CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(4-methoxybenzyl)-8-(3-(methoxymethoxy)phenyl)-1,3-diazaspiro[4.5]decan-2-one.
    • Step 2: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-hydroxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one
  • TFA (0.2 mL) was added to a solution of CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(4-methoxybenzyl)-8-(3-methoxyphenyl)-1,3-diazaspiro[4.5]decan-2-one (300 mg, 0.57 mmol) in DCM (1.5 mL) at 0° C. The reaction mixture was stirred at 0° C. for 3 h. The reaction completion was monitored by TLC. The reaction mixture was quenched with sat. aq. NaHCO3 and the organic product was extracted with DCM (3×10 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated under reduced pressure. Purification of the residue by preparative TLC using 3% MeOH in DCM as a mobile phase yielded 50 mg (18%) of CIS-1-(cyclobutyl-methyl)-8-dimethylamino-8-(3-hydroxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (SC_2018) as an off white solid. (TLC system: 10% MeOH in DCM; Rf: 0.20) [M+H]+ 478.3
    • Synthesis of SC_2019: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-(pyridin-3-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00104
  • KOtBu (411 mg, 3.66 mmol) was added to a solution of CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-987) (250 mg, 0.73 mmol) in THF (6 mL) under nitrogen atmosphere and the reaction mixture was stirred at RT for 30 min. After cooling to 0° C. 3-(chloromethyl)pyridine hydrochloride (180 mg, 1.10 mmol) was added and the reaction mixture was stirred at 0° C. for 30 min and then at RT for 3 days. The resulting mixture was diluted with water, extracted with DCM (3×), the combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. Purification of the residue by flash column chromatography provided 208 mg of CIS-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-(pyridin-3-yl-methyl)-1,3-di-azaspiro[4.5]decan-2-one (SC_2019). [M+H]+ 433.3
    • Synthesis of SC_2025: CIS-8-Dimethylamino-1-(2-methoxy-2-methyl-propyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00105
  • CIS-8-Dimethylamino-1-(2-hydroxy-2-methyl-propyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC 2024 (0.2 g, 0.42 mmol) was added to a solution of NaH (60% in mineral oil) (0.01 g, 0.42 mmol) in DMF (5 mL) at RT. The reaction mixture was stirred at RT for 30 min, then cooled to 0° C. and methyl iodide (0.08 g, 1.28 mmol) was added dropwise. the resulting mixture was stirred for 30 min at 0° C. and then for 16 h at RT. The reaction completion was monitored by TLC. The reaction mixture was quenched with sat. aq. NH4Cl and the organic product was extracted with EtOAc (2×10 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by preparative TLC using 30% EtOAc in petroleum ether as a mobile phase to give 40 mg (20%) of CIS-8-dimethylamino-1-(2-methoxy-2-methyl-propyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC 2025) as an off white solid. (TLC system: 30% EtOAc in Pet. Ether; Rf: 0.6). [M+H]+ 480.3.
    • Synthesis of SC_2026: CIS-1-(Cyclobutyl-methyl)-3-[(3-methoxyphenyl)-methyl]-8-methylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00106
  • N-Iodosuccinimide (437 mg, 1.95 mmol) was added to a suspension of CIS-1-(cyclobutyl-methyl)-8-dimethylamino-3-[(3-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_2002) (600 mg, 1.30 mmol) in a mixture of acetonitrile and THF (1:1 v/v, 20 mL) at RT and the resulting mixture was stirred at RT for 16 h. The reaction mixture was basified with 2N aq. NaOH to pH˜10 and the organic product was extracted with DCM (3×10 mL). The combined organic extracts were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was stirred vigorously with a mixture of 10% aqueous citric acid solution (5 mL) and DCM (10 mL) at RT for 10 min. The resulting mixture was basified with 5N aq. NaOH to pH˜10 and extracted with DCM (3×10 mL). The combined organic layer was dried over anhydrous sodium sulfate and was concentrated in vacuo. The residue was purified by preparative reverse phase HPLC [Column: KINETEX C-18 (150*21.2) 5μ and mobile phase: 10 mM ammonium bicarbonate-acetonitrile] to give 120 mg (20%) of CIS-1-(Cyclobutyl-methyl)-3-[(3-methoxyphenyl)-methyl]-8-methylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_2026) as semi solid (TLC system: 10% MeOH in DCM; R 0.20.). [M+H]+ 448.3
    • Synthesis of SC_2028: CIS-1-(Cyclobutyl-methyl)-3-[(3-methoxyphenyl)-methyl]-8-(methyl-propyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00107
  • Sodium cyanoborohydride (20 mg, 0.33 mmol) was added to a solution of CIS-1-(cyclobutyl-methyl)-3-[(3-methoxyphenyl)-methyl]-8-methylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_2026) (60 mg, 0.13 mmol), propionaldehyde (19 mg, 0.33 mmol) and acetic acid (0.05 mL) in methanol (5 mL) at RT. The reaction mixture was stirred at RT for 3 h. The reaction mixture was quenched with sat. aq. NaHCO3 and the organic product was extracted with DCM (10 mL3). The combined organic extracts were dried over anhydr. Na2SO4 and concentrated under reduced pressure. A second batch of this reaction was carried out starting from 100 mg of CIS-1-(Cyclobutyl-methyl)-3-[(3-methoxyphenyl)-methyl]-8-methylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_2026 in a similar manner. Both batches were combined and purified by preparative TLC to give 45 mg (25%) of CIS-1-(cyclobutyl-methyl)-3-[(3-methoxyphenyl)-methyl]-8-(methyl-propyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_2028) as semi solid (TLC system: 10% MeOH in DCM; R 0.25). [M+H]+ 490.3
    • Synthesis of SC_2034: CIS-8-Dimethylamino-1-(2-hydroxy-ethyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00108
  • NaH (55% in mineral oil) (0.26 g, 6.10 mmol) was added to a solution of CIS-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_2097) (0.4 g, 1.02 mmol) in DMF (10 mL) at 0° C. The reaction mixture was stirred at 0° C. for 15 min. To the reaction mixture (2-bromoethoxy)(tert-butyl)dimethylsilane (1.45 g, 6.10 mmol) was added dropwise over 5 min at 0° C. The reaction mixture was allowed to stir at RT for 16 h and then diluted with water (15 mL). The organic product was extracted with ethyl acetate (3×25 mL). The combined organic extracts were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was dissolved in THF (8 mL) and cooled to 0° C. Then a 1M TBAF solution in THF (1.8 mL, 1.81 mmol) was added at 0° C. The reaction mixture was allowed to stir at RT for 2 h. The reaction mixture was diluted with water (10 mL), the organic product was extracted with DCM (3×25 mL). The combined organic extracts were washed with sat. aq. NaHCO3, water and brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. Purification by prep HPLC using 10 Mm ammonium bicarbonate-acetonitrile as mobile phase yielded 93 mg of compound which was further washed with n-pentane (5 mL) to give 85 mg (19% after two steps) of CIS-8-dimethyl-amino-1-(2-hydroxy-ethyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro [4.5]decan-2-one (SC_2034) as off white solid. (TLC system: 5% MeOH in DCM Rf: 0.30). [M+H]+ 438.3
    • Synthesis of SC_2040: CIS-2-[[1-(Cyclobutyl-methyl)-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-8-yl]-methyl-amino]-acetonitrile
  • Figure US20200399252A1-20201224-C00109
  • NaH (50% in mineral oil) (24 mg, 0.6 mmol) was added to a stirred solution of CIS-1-(cyclobutyl-methyl)-3-[(4-methoxyphenyl)-methyl]-8-methylamino-8-phenyl-1,3-diazaspiro [4.5]decan-2-one (SC_2044) (134 mg, 0.3 mmol) in DMF (1 mL) at 0° C. Then iodoacetonitrile (0.11 mL, 1.5 mmol) was added dropwise at 0° C. over a period of 10 min. The reaction mixture was allowed to stir at RT for 16 h. The reaction mixture was quenched with water and the organic product was extracted with EtOAc (3×). The combined organic extracts were washed with brine, dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. Purification of the residue by flash column chromatography provided 13 mg of CIS-2-[[1-(cyclobutyl-methyl)-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-8-yl]-methyl-amino]-acetonitrile (SC_2040). [M+H]+ 487.3
    • Synthesis of SC_2042: CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-acetic Acid Tert-Butyl Ester
  • Figure US20200399252A1-20201224-C00110
  • CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_2097 (500 mg, 1.3 mmol) was dissolved in 1.7 mL THF and LDA (2M solution in THF, 2.5 mL) was added at 0° C. The reaction mixture was stirred at RT for 30 min, then cooled to 0° C. and tert-butylbromoacetate (0.5 mL, 3.8 mmol) was added. The reaction was stirred for 18 h, then diluted with water and extracted with DCM (3×10 ml). The combined organic layers were dried over Na2SO4, concentrated in vacuo and the residue was purified by flash chromatography to yield CIS-2-[8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-acetic acid tert-butyl ester (SC_2042) (470 mg) as a white solid. [M+H]+ 508.3
    • Synthesis of SC_2043: CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-acetic acid 2,2,2-trifluoroacetic Acid Salt
  • Figure US20200399252A1-20201224-C00111
  • CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5] decan-1-yl]-acetic acid tert-butyl ester SC_2042 (200 mg, 0.4 mmol) was dissolved in trifluoroacetic acid (5 mL) and stirred at RT for 30 min. All volatiles are removed in vacuo to yield CIS-2-[8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro [4.5]decan-1-yl]-acetic acid 2,2,2-trifluoro-acetic acid salt SC_2043 (190 mg) as a solid. [M+H]+ 452.3
    • Synthesis of SC_2049: CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N-propyl-acetamide
  • Figure US20200399252A1-20201224-C00112
  • To a mixture of CIS-2-[8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro [4.5]decan-1-yl]-acetic acid 2,2,2-trifluoro-acetic acid salt (SC_2043) (60 mg, 0.11 mmol), n-propylamine (35 μL, 0.43 mmol) and DIPEA (109 μL, 0.64 mmol) in DMF (1 ml) was added HATU (60 mg, 0.16 mmol) and the reaction mixture was stirred at RT for 16 h. The reaction mixture was quenched with a 1M aq. NaHCO3, diluted with water and extracted with DCM (3×). The combined organic layers were washed with water (3 mL), brine (3 ml), dried over Na2SO4, filtered and concentrated in vacuo. Flash column chromatography of the residue provided CIS-2-[8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N-propyl-acetamide (SC_2049) (20 mg). [M+H]+ 493.3
    • Synthesis of SC_2053: CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-acetonitrile
  • Figure US20200399252A1-20201224-C00113
  • CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5] decan-1-yl]-acetamide (SC_2046) (37 mg, 0.083 mmol) was dissolved in EtOAc (1 mL) and triethylamine (23 μL, 0.166 mmol) and T3P (59 μL, 0.099 mmol) were sequentially added. The reaction mixture was stirred at RT for 16 h and then heated at reflux for another 3 h. After cooling to RT the reaction mixture was partitioned between water and DCM. The organic layer was separated and the aqueous layers was extracted twice with DCM. The combined organic layers were dried over MgSO4, concentrated in vacuo and the residue was purified by flash chromatography to yield CIS-2-[8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-acetonitrile (SC 2053) (31 mg) as a solid. [M+H]+ 433.3
    • Synthesis of SC_2073: CIS-1-(Cyclobutyl-methyl)-8-[(2-hydroxy-ethyl)-methyl-amino]-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00114
  • To a solution of CIS-2-[[1-(cyclobutyl-methyl)-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-8-yl]-methyl-amino]-acetic acid methyl ester (SC_2134) (125 mg, 0.24 mmol) in THF (1 mL) was added lithium borohydride (2M in THF, 0.36 mL, 0.72 mmol) at RT. The reaction mixture was stirred at RT for 16 h followed by addition of another portion of lithium borohydride (2M in THF, 0.36 mL, 0.72 mmol). After stirring at RT for 16 h, the reaction mixture was quenched with water. The organic layer was separated, washed with a 1M aq. NaOH and water, dried over MgSO4, filtered and concentrated in vacuo. Purification of the residue by flash chromatography provided 37 mg of CIS-1-(cyclobutyl-methyl)-8-[(2-hydroxy-ethyl)-methyl-amino]-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_2073). [M+H]+ 492.3
    • Synthesis of SC_2067: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[[4-[2-[2-[2-[2-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-phenyl]-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00115
  • Powdered sodium hydroxide (21 mg, 0.5 mmol) was dissolved in 0.2 mL of dry DMSO. After stirring at RT for 30 min CIS-1-(cyclobutyl-methyl)-8-dimethylamino-3-[(4-hydroxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_2089)(60 mg, 0.13 mmol) was added and the resulting mixture was stirred for another 30 min. Then 2,5,8,11,14,17,20,23-octaoxapentacosan-25-yl 4-methylbenzenesulfonate (prepared via tosylation of 2,5,8,11,14,17,20,23-octaoxapentacosan-25-ol following standard procedures) (216 mg, 0.4 mmol) was added. The reaction mixture was stirred at 60° C. for 16 h. The reaction mixture was quenched with water and the organic product was extracted with DCM (2×20 mL). The combined organic extracts were dried over anhydrous Na2SO4, concentrated in vacuo and the residue was purified by flash chromatography to yield CIS-1-(cyclobutyl-methyl)-8-dimethylamino-3-[[4-[2-[2-[2-[2-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-phenyl]-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_2087) (25 mg) as a white solid. [M+H]+ 814.5
    • Synthesis of SC_2089: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(4-hydroxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00116
  • CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_2125) (153 mg, 0.33 mmol) was dissolved in DCM (7 mL) and boron tribromide (1M solution in DCM, 1.3 mL) was added at 0° C. The reaction was stirred for 18 h, then water and methanol (1:1 mixture, 6 mL) was added. The reaction mixture was extracted with DCM (3×10 ml). The combined organic layers were dried over Na2SO4, concentrated in vacuo and the residue was purified by flash chromatography to yield CIS-1-(cyclobutyl-methyl)-8-dimethylamino-3-[(4-hydroxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_2089) (21 mg) as a white solid. [M+H]+ 448.3
    • Synthesis of SC_2093: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(3-methylsulfonyl-phenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00117
  • CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(3-methylsulfanyl-phenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_2136) (109 mg) was dissolved in methanol (3 mL) and water (2 mL) and oxone (105 mg) was added at RT. The reaction mixture was stirred for 24 h, another portion of oxone (105 mg) was added, the reaction mixture was stirred for 12 h at RT, then diluted with water and extracted with DCM (3×10 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash chromatography to yield CIS-1-(cyclobutyl-methyl)-8-dimethylamino-3-[(3-methylsulfonyl-phenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC 2093) as a white solid. [M+H]+ 510.3
    • Synthesis of SC_2097: CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00118
  • KOtBu (1M in THF) (29.30 mL, 29.30 mmol) was added to the solution of CIS-8-Dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one INT-976 (8.0 g, 29.30 mmol) in THF (160 mL) under argon atmosphere and the reaction mixture was stirred for 30 min. 4-Methoxybenzyl bromide (4.23 mL, 29.30 mmol) was added and stirring was continued at RT for 4 h. The reaction completion was monitored by TLC. The reaction mixture was diluted with sat. aq. NH4Cl (150 mL) and the organic product was extracted with EtOAc (2×150 mL). The combined organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo. The reaction was carried out in 2 batches (8 g×2) and the batches were combined for purification. Purification of the crude product by flash column chromatography on silica gel (0-10% methanol in DCM) and subsequently by washing with pentane yielded 11 g (47%) of CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_2097) as a white solid. [M+H]+ 394.2
    • Synthesis of SC_2107: CIS-8-Dimethylamino-1-(3-hydroxy-3-methyl-butyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00119
  • 50 wt % aq. sulphuric acid (0.57 mL) was added to the solution of CIS-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-1-(3-methyl-but-2-enyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_2135) (0.25 g, 0.54 mmol) in 1,4-dioxane (5.75 mL) at RT and the reaction mixture was stirred for 3 h at RT. The reaction mixture was quenched with sat. aq. NaHCO3 and the organic product was extracted with ethyl acetate (2×10 mL). The combined organic extracts were dried over anhydr. Na2SO4 and concentrated under reduced pressure. The residue was purified by reverse phase preparative HPLC to give 0.04 g (15%) of CIS-8-dimethylamino-1-(3-hydroxy-3-methyl-butyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-on (SC_2107) as an off white solid. (TLC system: 10% MeOH in DCM; Rf: 0.4). [M+H]+ 480.3
    • Synthesis of SC_2109: CIS-2-[[8-dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-benzamide
  • Figure US20200399252A1-20201224-C00120
  • 30% aq. H2O2 (0.3 mL, 2.54 mmol) was added to a solution of CIS-2-((8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)methyl)benzonitrile (SC_2138) (0.4 g, 0.85 mmol) in DMSO (8 mL) at 0° C. A solution of potassium hydroxide (0.23 g, 4.23 mmol) in water (0.5 mL) was added dropwise. The reaction mixture was allowed to warm up to RT and stirred for 30 min and then quenched with cold water (20 mL). The precipitated product was filtered off and washed with water. Purification by preparative TLC using 5% methanol in DCM as mobile phase yielded 78 mg of target compound which was further washed with n-pentane (5 mL) to give 70 mg (17%) of CIS-2-[[8-dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-benzamide (SC_2109) as an off-white solid. (TLC system: 10% MeOH in DCM Rf 0.4). [M+H]+ 491.3
    • Synthesis of SC_2123: CIS-8-amino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00121
  • N-Iodosuccinimide (233 mg, 1.035 mmol) was added to a solution of CIS-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[(4-methoxyphenyl)-methyl]-8-methylamino-8-phenyl-1,3-diazaspiro [4.5]decan-2-one (SC_2026) (320 mg, 0.690 mmol) in a mixture of acetonitrile and THF (1:1 v/v, 30 mL) at 0° C. and the resulting mixture was stirred for 5 h at RT. The reaction mixture was cooled to 0° C. and another portion of N-Iodosuccinimide (233 mg, 1.035 mmol) was added. The reaction mixture was allowed to warm up to RT and was stirred for further 11 h. The reaction mixture was basified with 2N aq. NaOH to pH˜10 and the organic product was extracted with ethyl acetate (3×30 mL). The combined organic extracts were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by preparative TLC by using 3% methanol in DCM as a mobile phase to give 100 mg of target compound which was further purified by preparative reverse phase HPLC to give 65 mg (21%) of CIS-8-amino-1-((1-hydroxycyclobutyl)methyl)-3-(4-methoxybenzyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (SC_2123) as an off-white solid (TLC system: 5% MeOH in DCM; Rf: 0.40.). [M+H]+ 450.3
    • Synthesis of SC_2124: CIS-8-dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-(2-phenyl-ethyl)-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00122
  • NaOH (0.53 g, 13.26 mmol) was added to a solution of CIS-8-dimethylamino-8-phenyl-3-(2-phenyl-ethyl)-1,3-diazaspiro[4.5]decan-2-one INT-795 (1 g, 2.65 mmol) in DMSO (50 mL) under argon atmosphere at RT and the reaction mixture was stirred at 70° C. for 30 min. (1-(Tert-butyldimethylsilyloxy)cyclobutyl)methyl-4-methylbenzenesulfonate (2.94 g, 7.95 mmol) was added and stirring was continued for 2 days at 70° C. The reaction completion was monitored by TLC. The reaction mixture was diluted with sat. aq. NaHCO3 (20 mL) and the organic product was extracted with EtOAc (4×50 mL). The combined organic layer was dried over anhydr. Na2SO4 and concentrated in vacuo. The crude product was purified by column chromatography (using 230-400 mesh silica gel and 2-5% MeOH in DCM as eluent) to afford 250 mg of product which was further purified by prep. TLC (4% MeOH: DCM as an eluent) followed by washing with pentane to yield 133 mg (11%) of CIS-8-dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-(2-phenyl-ethyl)-1,3-diazaspiro[4.5]decan-2-one (SC_2124) as an off-white solid. (TLC system: 10% MeOH in DCM; Rf: 0.8). [M+H]+ 462.3
    • Synthesis of SC_2125: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00123
  • To a solution of CIS-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro [4.5]decan-2-one (SC_2097) (10 g, 25 mmol) in 500 mL THF was added KOtBu (7.1 g, 63 mmol) at 50° C. The reaction mixture was heated up to reflux and cyclobutylmethylbromide (11.3 g, 76 mmol) was added quickly in one portion. After 12 h new portions of KOtBu (7.1 g) and cyclobutylmethylbromide (11.3 g) were added and the reaction mixture was allowed to stir for 2 h at reflux and was then cooled to RT. Water (150 mL) was added and the organic layer separated. The aqueous layer was extracted with ethyl acetate (3×300 mL). The combined organic layers were dried over Na2SO4 and then concentrated in vacuo. The residue was filtered through a pad of silica gel using DCM/MeOH (19/1 v/v). The filtrate was concentrated in vacuo and the resulting solid was recrystallized from hot ethanol to yield 7.8 g of CIS-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (SC_2125). [M+H]+ 461.3
    • Synthesis of SC_2136: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(3-methylsulfanyl-phenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00124
  • CIS-3-[(3-Bromophenyl)-methyl]-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (SC_2137) (100 mg, 0.2 mmol), sodium thiomethoxide (20 mg, 0.3 mmol), Pd2(dba)3 (8 mg, 0.02 mmol) and 9,9-dimethyl-4,5-bis(diphenyl-phosphino)xanthene (10 mg, 0.02 mmol) were placed in an oven dried flask. After three vacuum/nitrogen purge cycles, toluene (2 mL) and DIPEA (66 μL, 0.4 mmol) were added and the resulting suspension was heated to 100° C. for 24 h. The reaction mixture was cooled to RT, water was added and the mixture was extracted with DCM (3×5 mL). The combined organic layers were dried over Na2SO4, concentrated in vacuo and the residue was purified by flash chromatography to yield CIS-1-(cyclobutyl-methyl)-8-dimethylamino-3-[(3-methylsulfanyl-phenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_2136) as a white solid. [M+H]+ 478.3
    • Synthesis of SC_2143: CIS-3-((1H-1,2,3-triazol-4-yl)methyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00125
  • To a solution of CIS-8-dimethylamino-8-phenyl-3-prop-2-ynyl-1,3-diaza-spiro[4.5]decan-2-one (INT-1010) (1.0 g, 3.21 mmol, 1.0 eq.) in dioxane/MeOH (50 ml, 9:1) were added sodium azide (418 mg, 6.42 mmol, 2.0 eq.) and cuprous chloride (32 mg, 0.32 mmol, 0.1 eq.) at RT. The reaction mixture was stirred at 80° C. for 18 h, then quenched with water and concentrated under reduced pressure. The resulting residue was purified by column chromatography (silica gel neutralized with aq. NH3; 0.5% aq NH3 in 10% MeOH/DCM) to yield CIS-3-((H-1,2,3-triazol-4-yl)methyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_2143) (600 mg, 1.69 mmol, 52%) as an off white solid. Yield: 52% (600 mg, 1.69 mmol). 1HNMR (DMSO-d6, 400 MHz), δ (ppm)=14.84 (bs, 1H), 7.65 (s, 1H), 7.32-7.24 (m, 5H), 6.93 (bs, 1H), 4.27 (s, 2H), 2.98 (s, 2H), 2.28 (bs, 2H), 1.92 (s, 6H), 1.76 (bs, 4H), 1.31 (bs, 2H). Mass: m/z 355.0 (M+H)+.
    • Synthesis of SC_2144: CIS-8-(dimethylamino)-3-((1-(2-hydroxyethyl)-1H-1,2,3-triazol-4-yl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00126
  • To a suspension of LiAlH4 (207 mg, 5.45 mmol, 3.0 eq.) in dry THF (20 ml) was added ethyl CIS-2-(4-((8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)methyl)-1H-1,2,3-triazol-1-yl)acetate (INT-1011) (800 mg, 1.82 mmol, 1.0 eq.) in dry THF (20 ml) dropwise at 0° C. and the resulting mixture was stirred at RT for 1 h. The reaction mixture was quenched with sat. aq. Na2SO4, excess THF was added and the resulting mixture was stirred at RT for 1 h. The reaction mixture was filtered through celite and washed with THF. The filtrate was concentrated under reduced pressure to get crude product which was purified by column chromatography (silica gel, neutralized with aq. NH3; 1% aq NH3 in 20% MeOH/DCM) to yield CIS-8-(dimethylamino)-3-((1-(2-hydroxyethyl)-1H-1,2,3-triazol-4-yl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_2144) (450 mg, 1.13 mmol, 62%) as a white solid. Yield: 62% (450 mg, 1.13 mmol). 1HNMR (DMSO-d6, 400 MHz), δ (ppm)=7.86 (s, 1H), 7.36-7.22 (m, 5H), 6.89 (bs, 1H), 4.97 (t, 1H, J=5.3 Hz), 4.34 (t, 2H, J=5.42 Hz), 4.24 (s, 2H), 3.72 (q, 2H, J=5.32 Hz), 3.01 (s, 2H), 2.30 (bs, 2H), 1.91 (s, 6H), 1.77-1.75 (m, 4H), 1.33-1.31 (m, 2H). Mass: m/z 399.1 (M+H)+.
    • Synthesis of SC_2145: CIS-2-(4-((8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)methyl)-1H-1,2,3-triazol-1-yl)acetamide
  • Figure US20200399252A1-20201224-C00127
  • To a solution of CIS-2-(4-((8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)methyl)-1H-1,2,3-triazol-1-yl)acetate (INT-1011) (300 mg, 0.68 mmol, 1.0 eq.) in MeOH (6 ml) was added 7 M NH3 solution in MeOH (2 ml) at RT and the reaction mixture was stirred at 80° C. in a sealed tube for 18 h. The reaction mixture was cooled down to RT and concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel, neutralized with TEA; 2% aq. NH3 in 20% MeOH/DCM) to yield CIS-2-(4-((8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)methyl)-1H-1,2,3-triazol-1-yl)acetamide (SC_2145) (220 mg, 0.54 mmol, 78%) as an off white solid. Yield: 78% (220 mg, 0.54 mmol). 1HNMR (DMSO-d6, 400 MHz), δ (ppm)=7.85 (s, 1H), 7.67 (s, 1H), 7.34-7.22 (m, 6H), 6.93 (bs, 1H), 5.00 (s, 2H), 4.25 (s, 2H), 3.01 (s, 2H), 2.30 (bs, 2H), 1.92 (s, 6H), 1.76 (bs, 4H), 1.31 (bs, 2H). Mass: m/z 412.3 (M+H)+.
    • Synthesis of SC_2147: CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00128
  • CIS-8-(dimethylamino)-3-[(4-methoxyphenyl)methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC 2097) (500 mg, 1.271 mmol) was dissolved in THF (8 mL) under nitrogen atmosphere and the solution was cooled down to −78° C. [Bis(trimethylsilyl)amino]lithium (1M in THF, 1.5 equiv., 1.906 mmol, 1.9 mL) was added dropwise and the reaction mixture was stirred at −78° C. for 30 min, then at 0° C. for 30 min. The reaction mixture was cooled down to −78° C. again and the solution of p-toluenesulfonyl chloride (1.5 equiv., 1.906 mmol) in THF (5 mL) was added. The reaction mixture was stirred further 2.5 h at −78° C. and then the temperature was allowed to increase to RT overnight. The reaction mixture was quenched by the addition of sat. aq. NaHCO3 (20 mL). The aqueous phase was extracted with EtOAc (3×40 mL). The combined organic extracts were washed with brine (30 mL), dried over MgSO4 and concentrated under reduced pressure. Purification by flash chromatography on silica gel (elution with gradient DCM/EtOH 100/0 to 97/3) yielded 281 mg (40%) of CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one (SC_2147). 1H NMR (600 MHz, DMSO) δ 7.90-7.84 (m, 2H), 7.47-7.40 (m, 2H), 7.42-7.27 (m, 4H), 7.27-7.22 (m, 1H), 7.15-7.06 (m, 2H), 6.92-6.83 (m, 2H), 4.16 (s, 2H), 3.72 (s, 3H), 3.24 (s, 2H), 2.99 (ddd, 2H), 2.70-2.62 (m, 2H), 2.42 (s, 3H), 2.01 (s, 6H), 1.56-1.49 (m, 2H), 1.31 (td, 2H). Mass: m/z 548.3 (M+H)+.
    • Synthesis of SC_2170: CIS-8-(dimethylamino)-8-phenyl-3-(2-phenylpropan-2-yl)-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00129
    • Step 1: Synthesis of Tert-Butyl CIS-4-(dimethylamino)-4-phenyl-1-(2-phenylpropan-2-ylcarbamoyl)cyclohexylcarbamate
  • To a stirred solution of CIS-1-(tert-butoxycarbonylamino)-4-(dimethylamino)-4-phenylcyclohexanecarboxylic acid (INT-1023) (1 g, 2.76 mmol) in DMF (15 mL) were added diisopropylethyl amine (1.78 g, 13.81 mmol) and HATU (2.09 g, 5.52 mmol) at 0° C. The reaction mixture was stirred at 0° C. for 45 min and then 2-phenylpropan-2-amine (0.74 g, 5.52 mmol) was added. The reaction mixture was warmed to RT and stirred for 16 h. The reaction mixture was quenched with sat. aq. NaHCO3 and the organic product was extracted with EtOAc (3×25 mL). The combined organic extracts were dried over anhydr. Na2SO4 and concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel 230-400 mesh) using 5-8% methanol in DCM as eluent gave 0.7 g (52%) of tert-butyl CIS-4-(dimethylamino)-4-phenyl-1-(2-phenylpropan-2-ylcarbamoyl)cyclohexylcarbamate as a liquid. (TLC system: 10% MeOH in DCM a Rf: 0.30).
    • Step 2: Synthesis of CIS-1-amino-4-(dimethylamino)-4-phenyl-N-(2-phenylpropan-2-yl)cyclohexanecarboxamide Hydrochloride
  • 4N HCl in dioxane (15 mL) was added to a stirred solution of tert-butyl CIS-4-(dimethylamino)-4-phenyl-1-(2-phenylpropan-2-ylcarbamoyl)cyclohexylcarbamate (0.7 g, 1.46 mmol) in DCM (15 mL) at 0° C. The reaction mixture was stirred at RT for 2 h and then concentrated under reduced pressure to afford 0.7 g of CIS-1-amino-4-(dimethylamino)-4-phenyl-N-(2-phenylpropan-2-yl)cyclohexanecarboxamide hydrochloride as an off-white solid. The product was used in the next step without additional purification. (TLC system: 10% MeOH in DCM a Rf: 0.20).
    • Step 3: Synthesis of CIS-N,N-dimethyl-1-phenyl-4-((2-phenylpropan-2-ylamino)methyl)cyclohexane-1,4-diamine
  • A solution of CIS-1-amino-4-(dimethylamino)-4-phenyl-N-(2-phenylpropan-2-yl)cyclohexanecarboxamide (0.7 g, 1.84 mmol) in THF (10 mL) was added to BH3×THF solution (1M in THF, 18 mL, 18.46 mmol) at RT. The resulting mixture was refluxed for 2 h. The reaction mixture was cooled to 0° C. and slowly quenched with 6N HCl (20 mL). The aqueous layer was extracted with EtOAc and then basified (pH˜10) with 20% aq. NaOH. The organic product was extracted with 10% MeOH/DCM (20 mL×4). The combined organic layer was washed with brine, dried over anhydr. Na2SO4 and concentrated in vacuo to give 0.3 g of CIS-N,N-dimethyl-1-phenyl-4-((2-phenylpropan-2-ylamino)methyl)cyclohexane-1,4-diamine as a liquid. The product was used in the next step without additional purification. (TLC system: 10 vol % methanol in DCM, Rf: 0.10).
    • Step 3: Synthesis of CIS-8-(dimethylamino)-8-phenyl-3-(2-phenylpropan-2-yl)-1,3-diazaspiro[4.5]decan-2-one SC_2170
  • 1,1′-Carbonyldiimidazole (0.90 g, 5.58 mmol) was added to a solution of CIS-N,N-dimethyl-1-phenyl-4-((2-phenylpropan-2-ylamino)methyl)cyclohexane-1,4-diamine (1.7 g, 4.65 mmol) in DMF (20 mL) at RT. The reaction mixture was stirred at RT for 16 h. The reaction mixture was quenched with cold water, the precipitated solid was filtered off and dried under reduced pressure to give the product which was further purified by preparative HPLC (column: Column: Kinetex-C18 (150*21.2 mm) 5 μm, mobile phase: 0.1% formic acid in water (A): Acetonitrile (B), gradient: T/% B: 0/20, 7/50, 7.1/98, 9/98, 9.1/20, 12/20, flow rate: 18 ml/min, diluent: mobile phase+THF) to yield 0.83 g (55%) of CIS-8-(dimethylamino)-8-phenyl-3-(2-phenylpropan-2-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_2170) as a white solid. (TLC system: 10% MeOH in DCM Rf: 0.30). 1H NMR (DMSO-d6): δ 7.36-7.22 (m, 9H), 7.16-7.13 (m, 1H), 6.64 (s, 1H), 3.10 (s, 2H), 2.28 (m, 2H), 1.93-1.79 (m, 10H), 1.52 (s, 6H), 1.37 (m, 2H). Mass: m/z 392.2 [M+H]+.
    • Synthesis of SC_2180: CIS-8-(dimethylamino)-8-phenyl-3-(pyridin-4-ylmethyl)-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00130
    • Step 1: synthesis of CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one
  • CIS-8-(dimethylamino)-8-phenyl-1-(p-tolylsulfonyl)-1,3-diazaspiro[4.5]decan-2-one (INT-1028) (200 mg, 0.47 mmol, 1 equiv.) was dissolved in DMF (3.6 mL) under argon atmosphere and the solution was cooled down to 0° C. Sodium hydride (60 wt % in mineral oil, 2.1 equiv., 0.98 mmol, 39 mg) was added and the reaction mixture was stirred at RT for 15 min. 4-(Bromomethyl)pyridine hydrobromide (1.05 equiv., 0.49 mmol, 124 mg) was added at 0° C. The reaction mixture was stirred overnight at RT, then quenched with sat. aq. NaHCO3 (2 mL) and water (2 mL) and extracted with EtOAc (2×15 mL). The combined organic extract was washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (100% acetonitrile) to yield CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one (112 mg, 46%). Mass: m/z 519.2 [M+H]+.
    • Step 2: synthesis of CIS-8-(dimethylamino)-8-phenyl-3-(pyridin-4-ylmethyl)-1,3-diazaspiro[4.5]decan-2-one (SC 2180)
  • CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one (110 mg, 0.212 mmol, 1 equiv.) was dissolved in THF (2 mL) and MeOH (4.4 mL) under argon atmosphere. Magnesium turnings (103 mg, 4.24 mmol, 20 equiv.) were added and the resulting mixture was stirred at RT for 18 h. The reaction mixture was diluted with DCM (30 mL) and water (10 mL), stirred at RT for 1.5 h, filtered through celite and the solid residue was washed with DCM (3×). The organic phase of the filtrate was separated and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (EtOH 100% to EtOH/MeOH 70/30) to yield 33 mg (43%) of CIS-8-(dimethylamino)-8-phenyl-3-(pyridin-4-ylmethyl)-1,3-diazaspiro[4.5]decan-2-one (SC_2180). 1H NMR (600 MHz, DMSO-d6) δ 8.52-8.47 (m, 2H), 7.36-7.28 (m, 4H), 7.25-7.21 (m, 1H), 7.21-7.17 (m, 2H), 7.01 (s, 1H), 4.23 (s, 2H), 2.98 (s, 2H), 2.37-2.22 (m, 2H), 1.93 (s, 6H), 1.87-1.61 (m, 4H), 1.42-1.29 (m, 2H). Mass: m/z 365.2 [M+H]+.
    • Synthesis of SC_2183: CIS-8-(dimethylamino)-3-((2-(4-methylpiperazin-1-yl)pyridin-4-yl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00131
  • A mixture of 3-[(2-chloro-4-pyridyl)methyl]-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1065) (100 mg, 0.251 mmol), 1-methylpiperazine (50 equiv., 12.54 mmol, 1.39 mL) and DIPEA (5 equiv., 1.25 mmol, 0.22 mL) was stirred at 140° C. under microwave irradiation until complete conversion of INT-1065 (LCMS control). The reaction mixture was diluted with 2 N aq. NaOH and EtOAc, the organic phase was separated, washed with brine, dried over anhydr. Na2SO4 and concentrated under reduced pressure. The resulting crude product was purified by flash chromatography on silica gel (eluent gradient 0.2 N NH3 in MeOH/EtOH/DCM 10/40/50 to 25/25/50 v/v/v) to yield CIS-8-(dimethylamino)-3-((2-(4-methylpiperazin-1-yl)pyridin-4-yl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_2183) (87 mg, 75%). 1H NMR (600 MHz, DMSO) δ 8.02 (d, 1H), 7.36-7.30 (m, 2H), 7.31-7.26 (m, 2H), 7.23 (td, 1H), 6.94 (s, 1H), 6.58 (s, 1H), 6.45 (dd, 1H), 4.12 (s, 2H), 3.45-3.39 (m, 4H), 2.94 (s, 2H), 2.36 (t, 4H), 2.33-2.22 (m, 2H), 2.19 (s, 3H), 1.92 (s, 6H), 1.86-1.62 (m, 4H), 1.34 (t, 2H). Mass: m/z 463.3 (M+H)+.
    • Synthesis of SC_2186: CIS-8-(dimethylamino)-8-phenyl-3-((2-(piperazin-1-yl)pyridin-4-yl)methyl)-1,3-diazaspiro[4.5]decan-2-one
  • Figure US20200399252A1-20201224-C00132
  • A mixture of 3-[(2-chloro-4-pyridyl)methyl]-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1065) (100 mg, 0.251 mmol), piperazine (1.5 equiv., 0.38 mmol, 32 mg), DIPEA (5 equiv., 1.25 mmol, 0.22 mL) and n-butanol (1 mL) was stirred 4 h at 140° C. under microwave irradiation. A new portion of piperazine (4.5 equiv, 1.13 mmol, 97 mg) was added and the reaction mixture was stirred further 16 h at 140° C. under microwave irradiation. The resulting mixture was concentrated under reduced pressure, taken in water/EtOAc, organic phase separated, aqueous phase extracted with EtOAc. The combined organic phase was washed with brine, dried over anhydr. Na2SO4 and concentrated under reduced pressure. The resulting crude product was purified by flash chromatography on silica gel (eluent gradient 0.2 N NH3 in MeOH/EtOH/DCM 0/20/80 to 30/0/70 v/v/v) to yield CIS-8-(dimethylamino)-8-phenyl-3-((2-(piperazin-1-yl)pyridin-4-yl)methyl)-1,3-diazaspiro[4.5]decan-2-one (SC_2186) (48 mg, 43%). 1H NMR (600 MHz, CDCl3) δ 8.13-8.09 (m, 1H), 7.37 (t, 2H), 7.31-7.24 (m, 3H), 6.49 (d, 2H), 5.20-5.16 (m, 1H), 4.25 (s, 2H), 3.51-3.46 (m, 4H), 3.01-2.95 (m, 6H), 2.18-2.09 (m, 2H), 2.05 (s, 6H), 2.03-1.92 (m, 2H), 1.92-1.84 (m, 2H), 1.50-1.42 (m, 2H). Mass: m/z 449.3 (M+H)+.
  • For further exemplary compounds the last synthesis step in analogy to previously described methods is given in the following table. The syntheses of the building blocks and intermediates have either been described previously within this application or can be performed in analogy to the herein described methods or by methods known to the person, skilled in the art. Such a person will also know which building blocks and intermediates need to be chosen for synthesis of each exemplary compound.
  •
    in analogy m/z
    Example Chemical Name Reactant I Reactant II to method [M + H]+
    SC_2001 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(4- SC_2136 — SC_2093 510.3
    mthylsulfonyl-phenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2003 CIS-8-Dimethylamino-1-isopropyl-3-[(4-methoxyphenyl)- SC_2097 2-bromopropane SC_2014 436.3
    methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2004 CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[(4- SC_2097 cyclopropyl-methylbromide SC_2125 448.3
    methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]-
    decan-2-one
    SC_2005 CIS-1-(Cyclobutyl-methyl)-3-[(4-methoxyphenyl)-methyl]- SC_2026 Isobutyraldehyde SC_2028 504.4
    8-methyl-(2-methyl-propyl)-amino]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2006 CIS-2-[[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8- SC_2092 — SC_2019 475.3
    phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-benzamide
    SC_2007 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3- INT-987 2-(bromomethyl)pyrazine SC_2002 434.3
    (pyrazin-2-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one
    SC_2009 CIS-4-[[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8- SC_2085 — SC_2109 475.3
    phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-benzamide
    SC_2011 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(4- SC_2016 (bromomethyl)cyclobutan SC_2010 480.3
    fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2012 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3- SC_2139 (bromomethyl)cyclobutan SC_2010 492.3
    methoxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2013 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(4- SC_2140 (bromomethyl)cyclobutan SC_2010 492.3
    methoxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2015 CIS-1-Butyl-8-dimethylamino-3-[(4-methoxyphenyl)- SC_2097 1-bromobutane SC_2010 450.3
    methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2016 CIS-8-Dimethylamino-8-(4-fluorophenyl)-3-[(4- INT-966 dimethylamine/KCN 4-fluoro- SC_2017 412.2
    methoxyphenyl)-methyl]1,3-diazaspiro[4.5]decan-2-one phenylmagnesium bromide
    SC_2020 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[[3-[2-[2-[2- SC_2089 2,5,8,11,14,17-hexaoxanona- SC_2089 726.5
    [2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethoxy]- decan-19-ol
    ethoxy]-phenyl]-methyl]-8-phenyl-1,3-diazaspiro[4.5]-
    decan-2-one
    SC_2021 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(4- INT-967 — SC_2018 478.3
    hydroxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3
    diazaspiro[4.5]decan-2-one hydrochloride
    SC_2022 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]- INT-799 1-(bromomethyl)-3-methoxy- SC_2019 478.3
    3-[(3-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro- benzene
    [4.5]decan-2-one
    SC_2023 CIS-1-(Cyclopentyl-methyl)-8-dimethylamino-3-[(4- SC_2097 (bromomethyl)cyclopentane SC_2010 476.3
    methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]-
    decan-2-one
    SC_2024 CIS-8-Dimethylamino-1-(2-hydroxy-2-methyl-propyl)-3- SC_2097 2,2-dimethyl-oxirane SC_2010 466.3
    [(4-methosyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]-
    decan-2-one
    SC_2027 CIS-3-[[1-((Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-2- INT-798 (bromomethyl)cyclobutan SC_2010 471.3
    oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-
    benzonitrile
    SC_2029 CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-3-[(3- SC_2026 acetaldehyde SC_2028 476.3
    methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]-
    decan-2-one
    SC_2030 CIS-3-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2- SC_2097 3-bomopropanenitrile SC_2010 447.3
    oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-propionitrile
    SC_2031 CIS-1-(Cyclobutyl-methyl)-8-methylamino-8-phenyl-3- SC_2019 — SC_2026 419.3
    (pyridin-3-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one
    SC_2032 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1- SC_2097 3-(bromomethyl)oxetane SC_2014 464.3
    (oxetan-3-yl-methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-
    2-one
    SC_2033 CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8- INT-986 bromomethylpyridine hydro- SC_2002 447.3
    phenyl-3-(pyridin-3-yl-methyl)-1,3-diazaspiro[4.5]decan- bromide
    2-one
    SC_2035 CIS-8-Dimethylamino-1-(2,2-dimethyl-propyl)-3-[(4- SC_2097 1-bromo-2,2-dimethylpropane SC_2014 464.3
    methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]-
    decan-2-one
    SC_2036 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1- SC_2097 1-bromo-3-methylbutane SC_2010 464.3
    (3-methyl-butyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2037 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8- SC_2097 1-bromo-3-(trifluoromethoxy)- SC_2010 520.3
    phenyl-1-[3-(trifluoromethoxy)-propyl]-1,3-diazaspiro- propane
    [4.5]decan-2-one
    SC_2038 CIS-1-(2-Cyclobutyl-ethyl)-8-dimethylamino-3-[(4- SC_2097 2-cyclobutylethyl-4-methyl- SC_2010 476.3
    methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]- benzenesulfonate
    decan-2-one
    SC_2039 CIS-1-[(3,3-Difluoro-cyclobutyl)-methyl]-8-dimethylamino- SC_2097 3-(bromomethyl)-1,1-difluoro- SC_2010 498.3
    3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro- cyclobutane
    [4.5]decan-2-one
    SC_2041 CIS-1-(Cyclobutyl-methyl)-8-[(2-methoxy-ethyl)-methyl- SC_2044 1-bromo-2-methoxyethane SC_2008 506.3
    amino]-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]deacan-2-one
    SC_2044 CIS-1-(Cyclobutyl-methyl)-3-[(4-methoxyphenyl)-methyl]- SC_2125 — SC_2026 448.3
    8-methylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2045 CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2- SC_2097 methyl 2-bromoacetate SC_2010 466.3
    oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-acetic acid
    methyl ester
    SC_2046 CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2- SC_2043 NH4Cl SC_2049 451.3
    oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-acetamide
    SC_2047 CIS-1-Benzyl-8-dimethylamino-3-[(4-methoxyphenyl)- SC_2097 (bromomethyl)benzene SC_2010 484.3
    methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2048 CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]- SC-2043 methylamine SC_2049 465.3
    2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N-methyl-
    acetamide
    SC_2050 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1- SC_2097 1-bromo-3-methoxypropane SC_2010 466.3
    (3-methoxy-propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-
    2-one
    SC_2051 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]- SC_799 1-(bromomethyl)-4-methoxy- SC_2019 478.3
    3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro- benzene
    [4.5]decan-2-one
    SC_2052 CIS-8-Dimethylamino-1-(2-methoxy-ethyl)-3-[(4-methoxy- SC_2097 1-bromo-2-methoxyethane SC_2014 452.3
    phenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2054 CIS-8-Dimethylamino-1-hexyl-3-[(4-methoxyphenyl)- SC_2097 1-bromohexane SC_2014 478.3
    methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2055 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8- SC_2097 4-(bromomethyl)tetrahydro- SC_2014 492.3
    phenyl-1-(tetrahydro-pyran-4-yl-methyl-1,3-diazaspiro- 2H-pyran
    [4.5]decan-2-one
    SC_2056 CIS-1-(Cyclohexyl-methyl)-8-dimethylamino-3-[(4- SC_2097 (bromomethyl)cyclohexane SC_2014 490.3
    methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]-
    decan-2-one
    SC_2057 CIS-N-(Cyano-methyl)-2-[8-dimethylamino-3-[(4- SC_2043 2-aminoacetonitrile SC_2049 490.3
    methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro-
    [4.5]decan-1-yl]-acetamide
    SC_2058 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]- SC_2097 3-(bromomethyl)pyridine SC_2014 485.3
    8-phenyl-1-(pyridin-3-yl-methyl)-1,3-diazaspiro[4.5]-
    decan-2-one
    SC_2059 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8- INT-966 dimethylamine/KCN 3- SC_2017 390.3
    (3-methoxy-propyl)-1,3-diazaspiro[4.5]decan-2-one methoxypropyl magnesium
    bromide
    SC_2060 CIS-2-[8-Dimethylamino-3[(4-methoxyphenyl)-methyl]- SC_2043 2-methoxyethanamine SC_2049 509.3
    2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N-(2-
    methoxy-ethyl)-acetamide
    SC_2062 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1- SC_2043 pyrrolidine SC_2049 505.3
    (2-oxo-2-pyrrolidin-1-yl-ethyl)-8-phenyl-1,3-diazaspiro-
    [4.5]decan-2-one
    SC_2063 CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]- SC_2043 dimethylamine SC_2049 479.3
    2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N,N-
    dimethyl-acetamide
    SC_2064 CIS-N-(1-Cyano-cyclopropyl)-2-[8-dimethylamino-3-[(4- SC_2043 1-aminocyclopropane- SC_2049 516.3
    methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro- carbonitrile
    [4.5]decan-1-yl]-acetamide
    SC_2065 CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]- SC_2043 N-methylpropan-1-amine SC_2049 507.3
    2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N-methyl-
    N-propyl-acetamide
    SC_2066 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(4- SC_2059 (bromomethyl)cyclobutane SC_2125 458.3
    methoxyphenyl)-methyl]-8-(3-methoxy-propyl)-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2067 CIS-8-Dimethylamino-1-(3-hydroxy-propyl)-3-[(4- SC_2097 (3-bromopropoxy)(tert-butyl)- SC_2034 452.3
    methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]- dimethylsilane
    decan-2-one
    SC_2068 CIS-8-Dimethylamino-1-(4-methoxy-butyl)-3-[(4- SC_2097 1-bromo-4-methoxybutane SC_2014 480.3
    methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]-
    decan-2-one
    SC_2069 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]- SC_2097 1-(bromo-methyl)-1-methyl- INT-982 476.3
    1-[(1-methyl-cyclobutyl)-methyl]-8-phenyl-1,3- cyclobutane step 1
    diazaspiro[4.5]decan-2-one
    SC_2070 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclohexyl)-methyl]- SC_2097 O-tert-butyldimethylsilyl-1- SC_2124 506.3
    3-[4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro- (4-methylbenzenesulfonoxy-
    [4.5]decan-2-one methyl)cyclohexanol
    SC_2071 CIS-5-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]- SC_2097 5-aminopentanenitrile SC_2014 475.3
    2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-pentane-
    nitrile
    SC_2072 CIS-3-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2- SC_2132 NH4Cl SC_2049 465.3
    oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-propionamide
    SC_2074 CIS-1-[[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl- SC_2097 1-(aminomethyl)cyclobutane- SC_2014 487.3
    2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-methyl]- carbonitrile
    cyclobutane-1-carbonitrile
    SC_2075 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclopentyl)-methyl]- SC_2097 O-tert-butyldimethylsilyl-1- SC_2124 492.3
    3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro- (4-methylbenzenesulfonoxy-
    [4.5]decan-2-one methyl)cyclopentanol
    SC_2076 CIS-3-[(2-Bromophenyl)-methyl]-1-(cyclobutyl-methyl)- INT-987 1-bromo-2-(bromomethyl)- SC_2002 510.2
    8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one benzene
    SC_2077 CIS-3-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]- SC_2132 methylamine SC_2049 479.3
    2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N-methyl-
    propionamide
    SC_2078 CIS-3-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]- SC_2131 propan-1-amine SC_2049 507.3
    2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N-propyl-
    propionamide
    SC_2079 CIS-8-Dimethylamino-1-[(1-fluoro-cyclobutyl)-methyl]- SC_2097 1-(bromomethyl)-1-fluoro- SC_2014 480.3
    3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro- cyclobutane
    [4.5]decan-2-one
    SC_2080 CIS-1-(2-Cyclohexyl-ethyl)-8-dimethylamino-3-[(4- SC_2097 2-cyclohexylethanamine SC_2014 504.4
    methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspriro[4.5]-
    decan-2-one
    SC_2081 CIS-3-[[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8- 3-(aminomethyl)benzonitrile SC_2002 457.3
    phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-benzonitrile
    SC_2082 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1- SC_2097 Iodo-methane SC_2010 408.3
    methyl-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2083 CIS-8-Dimethylamino-1-[2-[2-[2-[2-[2-[2-[2-(2-methoxy- SC_2097 25-bromo-2,5,8,11,14,17,20,23- SC_2014 760.5
    ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]- octaoxapentacosane
    ethyl]-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2084 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8- SC_2097 4-(2-bromoethyl)tetrahydro-2H- SC_2014 506.3
    pheny-1-(2-tetrahydro-pyran-4-yl-ethyl)-1,3-diazaspiro- pyran
    [4.5]decan-2-one
    SC_2085 CIS-4-[[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8- INT-987 4-(bromomethyl)benzonitrile SC_2002 457.3
    phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-benzonitrile
    SC_2086 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl- INT-987 5-(bromomethyl)-2-(trifluoro- SC_2002 501.3
    3-[[6-(trifluoromethyl)-pyridin-3-yl]-methyl]-1,3- methyl)pyridine
    diazaspiro[4.5]decan-2-one
    SC_2088 CIS-3-[[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8- SC_2081 — SC_2109 475.3
    phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-benzamide
    SC_2090 CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-3- SC_2044 acetaldehyde SC_2028 476.3
    [(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro-
    [4.5]decan-2-one
    SC_2091 CIS-8-Dimethylamino-1-[(1-methoxy-cyclobutyl)-methyl]- SC_2075 methyliodide SC_2025 492.3
    3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro-
    [4.5]decan-2-one
    SC_2092 CIS-2-[[1-(Cyclobutyl-methyl)-8-diamethylamino-2-oxo- INT-987 2-(aminomethyl)benzonitrile SC_2002 457.3
    8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-
    benzonitrile
    SC_2094 CIS-8-Dimethylamino-1-ethyl-3-[(4-methoxyphenyl)- SC_2097 1-iodo-ethane SC_2010 422.3
    methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2095 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8- SC-2097 1-iodopropane SC_2010 436.3
    phenyl-1-propyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2096 CIS-3-Benzyl-1-(cyclobutyl-methyl)-8-dimethylamino- INT-963 cyclobutyl-methylbromide SC_2014 432.3
    8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2099 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8- SC_2097 4-(bromomethyl)pyrimidine SC_2010 486.3
    phenyl-1-(pyrimidin-4-yl-methyl)-1,3-diazaspiro[4.5]-
    decan-2-one
    SC_2100 CIS-3-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]- SC_2097 3-amino-2,2-dimethylpropane- SC_2014 475.3
    2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-2,2- nitrile
    dimethyl-propionitrile
    SC_2101 CIS-2[[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]- SC_2097 methyl 2-(bromomethyl)- SC_2125 542.3
    2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-methyl]- benzoate
    benzoic acid methyl ester
    SC_2102 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl- INT-987 2-(bromomethyl)pyridine SC_2002 433.3
    3-(pyridin-2-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one
    SC_2103 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3- INT-987 4-(bromomethyl)pyridine SC_2002 433.3
    (pyridin-4-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one
    SC_2104 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8- SC_2097 3-(bromomethyl)tetrahydro- SC_2014 478.3
    phenyl-1-(tetrahydro-furan-3-yl-methyl)-1,3- furan
    diazaspiro[4.5]decan-2-one
    SC_2105 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3- INT-987 2-(bromomethyl)pyrimidine SC_2002 434.3
    (pyrimidin-2-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one
    SC_2016 CIS-3-[[1-[(5-Cyano-2-methoxy-phenyl)-methyl]-8- SC_2142 3-(bromomethyl)-4-methoxy- SC_2125 564.3
    dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]- benzonitrile
    decan-3-yl]-methyl]-4-methoxy-benzonitrile
    SC_2108 CIS-8-Dimethylamino-1-(3-methoxy-3-methyl-butyl)-3- SC_2107 Methyliodide SC_2025 494.3
    [(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro-
    [4.5]decan-2-one
    SC_2110 CIS-3-[[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)- SC_2141 — SC_2109 491.3
    methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-
    yl]-methyl]-benzamide
    SC_2111 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1- SC_2097 1-bromo-2-(methylsulfonyl)- SC_2010 500.3
    (2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]- ethane
    decan-2-one
    SC_2112 CIS-1-[(1-Hydroxy-cyclobutyl)-methyl]-3-[(4-methoxy- SC_2051 — SC_2026 464.3
    phenyl)-methyl]-8-methylamino-8-phenyl-1,3-diazaspiro-
    [4.5]decan-2-one
    SC_2113 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8- SC_2097 (tetrahydrofuran-2-yl)methan- SC_2014 478.3
    phenyl-1-(tetrahydro-furan-2-yl-methyl)-1,3-diazaspiro- amine
    [4.5]decan-2-one
    SC_2114 CIS-3-Benzyl-8-dimethylamino-8-phenyl-1,3- INT-976 (bromomethyl)benzene SC_2097 364.2
    diazaspiro[4.5]decan-2-one
    SC_2115 CIS-3-Benzyl-8-dimethylamino-1-ethyl-8-phenyl-1,3- SC_2114 1-bromoethane SC_2010 392.3
    diazaspiro[4.5]decan-2-one
    SC_2117 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]- SC_2097 1-chloro-2-(methylsulfinyl) SC_2010 484.3
    1-[2-(methylsulfinyl)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]- ethane
    decan-2-one
    SC_2118 CIS-8-Dimethylamino-1-[(2R)-2-hydroxy-propyl]-3-[(4- SC_2087 (R)-propylene oxide SC_2010 452.3
    methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]-
    decan-2-one
    SC_2119 CIS-8-Dimethylamino-1-[(2S)-2-hydroxy-propyl]-3- (S)-propylene oxide SC_2010 452.3
    [(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro-
    [4.5]decan-2-one
    SC_2120 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8- SC_2097 3-(bromomethyl)tetrahydro- SC_2010 478.3
    phenyl-1-(tetrahydro-furan-3-yl-methyl)-1,3-diazaspiro- furan
    [4.5]decan-2-one
    SC_2122 CIS-8-Dimethylamino-1-ethyl-3-[(4-methoxyphenyl)- SC_2097 1-bromoethane SC_2010 422.3
    methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
    SC_2126 CIS-3-[[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)- SC_2142 (1-(tert-butyldimethylsilyloxy)- SC_2124 503.3
    methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]- cyclobutyl)methyl-4-methyl-
    methyl]-4-methoxy-benzonitrile benzenesulfonate
    SC_2127 CIS-8-Dimethyamino-1-ethyl-8-phenyl-3-(pyridin-3-yl- INT-949 3-(bromomethyl)pyridine SC_2019 393.3
    methyl)-1,3-diazaspiro[4.5]decan-2-one
    SC_2129 CIS-8-Dimethylamino-1-[2-(1-methoxy-cyclobutyl)- SC_2097 3-(bromomethyl)pyridine SC_2014 506.3
    ethyl]-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-
    diazaspiro[4.5]decan-2-one
    SC_2130 CIS-8-Dimethylamino-8-[3-(methoxymethyloxy)- INT-966 dimethylamine/KCN 3- SC_2017 454.3
    phenyl]-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro- methoxy-methoxy-phenyl-
    [4.5]decan-2-one magnesium bromide
    SC_2131 CIS-8-Dimethylamino-8-[4(methoxymethyloxy)-phenyl]- INT-966 dimethylamine/KCN 4- SC_2017 454.3
    3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan- methoxymethoxy-phenyl-
    2-one magnesium bromide
    SC_2132 CIS-3-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]- SC_2133 — SC_2043 466.3
    2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-propionic
    acid
    SC_2133 CIS-3-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]- SC_2097 tert-butyl acrylate SC_2042 522.3
    2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-propionic
    acid tert-butyl ester
    SC_2134 CIS-2-[[1-(Cyclobutyl-methyl)-3-[(4-methoxyphenyl)- SC_2044 methyl 2-bromoacetate SC_2040 520.3
    methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-8-yl]-
    methyl-amino]-acetic acid methyl ester
    SC_2135 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]- SC_2097 1-bromo-3-methylbut-2-ene SC_2010 462.3
    1-(3-methyl-but-2-enyl)-8-phenyl-1,3-diazaspiro[4.5]-
    decan-2-one
    SC_2137 CIS-3-[(3-Bromophenyl)-methyl]-1-(cyclobutyl-methyl)- INT-987 1-bromo-3-(bromomethyl)- SC_2002 510.2
    8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one benzene
    SC_2138 CIS-2-((8-dimethylamino)-1-((1-hydroxycyclobutyl)- INT-987 2-(bromomethyl)benzonitrile SC_2019 473.3
    methyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-
    methyl)benzonitrile
    SC_2139 CIS-8-Dimethylamino-8-(3-methoxyphenyl)-3-[(4- INT-966 dimethylamine/KCN 3- SC_2017 424.3
    methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one methoxy-phenylmagnesium
    bromide
    SC_2140 CIS-8-Dimethylamino-8-(4-methoxyphenyl)-3-[(4- INT-966 dimethylamine/KCN 4- SC_2017 424.3
    methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one methoxy-phenylmagnesium
    bromide
    SC_2141 CIS-3-((8-(dimethylamino-1-((1-hydroxycyclobutyl)- INT-987 3-(bomomethyl)benzonitrile SC_2019 473.3
    methyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-
    methyl)benzonitrile
    SC_2142 CIS-3-((8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro- INT-976 3-(bromomethyl)-4-methoxy- SC_2097 419.2
    [4.5]decan-3-yl)methyl)-4-methoxybenzonitrile benzonitrile
    in analogy m/z
    Example Chemical Name Reactant I Reactant II to method 1H NMR Data (M + H)+
    SC_2146 CIS-8-Methylamino-8-phenyl- SC_2143 SC_2026 1HNMR (DMSO-d6, 400 341.4
    3-(1H-[1,2,3]triazol-4-yl- MHz), δ (ppm) = 14.33 (bs,
    methyl)-1,3-diazaspiro[4.5]- 1H), 7.67 (s, 1H), 7.38 (d,
    decan-2-one 2H, J = 7.4 Hz), 7.29 (t,
    2H, J = 7.56 Hz), 7.17 (t,
    1H, J = 7.12 Hz), 6.65 (s,
    1H), 4.30 (s, 2H), 3.10 (s,
    2H), 1.92 (t, 2H, J = 11.86
    Hz), 1.83-1.78 (m, 5H, 1.63
    (t, 2H, J = 11.76 Hz), 1.36
    (d, 2H, J = 12.12 Hz).
    SC_2148 CIS-2-[4-[8-Methylamino-2- SC_2145 SC_2026 1HNMR (DMSO-d6, 400 398.2
    oxo-8-phenyl-1,3-diazaspiro- MHz), δ (ppm) = 7.87 (s, 1H),
    [4.5]decan-3-yl)-methyl]-1H- 7.67 (bs, 1H), 7.41-7.27 (m,
    [1,2,3]triazol-1-yl]-acetamide 5H), 7.17 (t, 1H, J = 7.16 Hz),
    6.64 (bs, 1H), 5.02 (s, 2H),
    4.28 (s, 2H), 3.13 (s, 2H),
    1.95-1.79 (m, 8H, J = 11.32
    Hz), 1.66-1.60 (m, 2H), 1.37
    d, 2H, J = 12.16 Hz).
    SC_2149 CIS-8-Dimethylamino-3-[(4- SC_2097 benzyl carbono- SC_2147 1HNMR (600 MHz, DMSO) 528.3
    methoxyphenyl)-methyl]-2- chloridate δ 7.52-7.45 (m, 2H), 7.44-
    oxo-8-phenyl-1,3-diazaspiro- 7.37 (m, 2H), 7.38-7.29 (m,
    [4.5]decane-1-carboxylic acid 3H), 7.30-7.24 (m, 2H), 7.26-
    benzyl ester 7.19 (m, 1H), 7.21-7.15 (m,
    2H), 6.93-6.86 (m, 2H), 5.23
    (s, 2H), 4.28 (s, 2H), 3.73 (s,
    3H), 3.19 (s, 2H), 2.84 (ddd,
    2H), 2.63-2.56 (m, 2H), 1.88
    (s, 6H), 1.37-1.23 (m. 4H).
    SC_2150 CIS-3-[[1-(2-Hydroxy-ethyl)- SC_2144 SC_2026 1HNMR (DMSO-d6, 400
    1H-[1,2,3]triazol-4-yl]-methyl]- MHz), δ (ppm) = 7.88 (s, 1H),
    8-methylamino-8-phenyl-1,3- 7.39 (d, 2H, J = 7.0 Hz), 7.29
    diazaspiro[4.5]decan-2-one (t, 2H, J = 7.38 Hz), 7.19-7.17
    (m, 1H), 6.64 (bs, 1H), 4.99
    (t, 1H, J = 5.24 Hz), 4.35 (t,
    2H, 5.32 Hz), 4.27 (s, 2H),
    3.75-3.73 (m, 2H), 3.12 (s,
    2H), 1.94-1.79 (m, 7H), 1.64
    (m, 2H), 1.36 (d, 2H, J =
    12.22 Hz).
    SC_2151* CIS-8-Dimethylamino-8- INT-795 2-(2-bromoethyl)- step 2 of 1H NMR (DMSO-d6): δ 8.64 393.3
    phenyl-3-(2-pyridin-2-yl- step 1 pyridine INT-795 (br s, 1H), 8.42-8.41 (m, 1H),
    ethyl)-1,3-diazaspiro[4.5]- 7.67-7.63 (m, 1H), 7.40-7.37
    decane-2,4-dione (m, 2H), 7.32-7.26 (m, 3H),
    7.19-7.16 (m, 2H), 3.63-3.61
    (t, 2H)), 2.92-2.90 (t, 2H),
    2.46-2.45 (m, 2H), 1.91 (m,
    8H), 1.51 (m, 2H), 1.45-1.42
    (m, 2H).
    SC_2152 CIS-8-Dimethylamino-8- SC_2151 step 3 of 1H NMR (DMSO-d6): δ 8.45- 379.3
    phenyl-3-(2-pyridin-2-yl)- INT-795 8.44 (d, 1H), 7.69-7.65 (m,
    ethyl)-1,3-diazaspiro[4.5] 1H), 7.37-7.30 (m, 4H), 7.26-
    decan-2-one 7.16 (m, 3H), 6.65 (br s, 1H),
    3.37-3.32 (m, 2H), 2.99 (s,
    2H), 2.86-2.82 (t, 2H), 2.28
    (m, 2H), 1.91 (m, 6H), 1.72-
    1.71 (m, 4H), 1.28-1.26 (m,
    2H).
    SC_2153 CIS-8-Dimethylamino-1-[(1- INT-1012 SC_2144 1HNMR (DMSO-d6, 400 483.2
    hydroxy-cyclobutyl)-methyl]- MHz), δ (ppm) = 7.92 (s, 1H),
    3-[[1-(2-hydroxy-ethyl)-1H- 7.36-7.24 (m, 5H), 6.00 (s,
    [1,2,3]triazol-4-yl]-methyl]-8- 1H), 4.97 (t, 1H, J = 5.32 Hz),
    phenyl-1,3-diazaspiro[4.5]- 4.36-4.34 (m, 4H), 3.73 (q,
    decan-2-one 2H, J = 5.36 Hz), 3.24 (s, 2H),
    3.11 (s, 2H)), 2.62 (d, 2H, J =
    14.0 Hz), 2.08-1.84 (m, 12H),
    1.64-1.61 (m, 1H), 1.38-1.28
    (m, 5H).
    SC_2154* CIS-8-Dimethylamino-3-[2- INT-795 1-(2-bromoethyl)- step 2 of 1H NMR (DMSO-d6): δ 8.71 382.3
    (1H-imidazol-1-yl)-ethyl]-8- step 1 1H-imidazole INT-795 (br s, 1H), 7.42-7.37 (m, 3H),
    phenyl-1,3-diazaspiro[4.5]- hydrobromide 7.32-7.26 (m, 3H), 7.00 (s,
    decane-2,4-dione 1H), 6.79 (s, 1H), 4.15-4.12
    (t, 2H), 3.65-3.62 (t, 2H),
    2.46 (m, 2H), 1.91 (s, 8H),
    1.47-1.37 (m, 4H).
    SC_2155 CIS-2-[4-[[8-Dimethylamino-1- INT-1012 SC_2145 1HNMR (DMSO-d6, 400 496.3
    [(1-hydroxy-cyclobutyl)-methyl]- MHz), δ (ppm) 7.91 (s, 1H),
    2-oxo-8-phenyl-1,3-diazaspiro- 7.67 (s, 1H), 7.34-7.24 (m,
    [4.5]decan-3-yl]-methyl]-1H- 6H), 5.99 (s, 1H), 5.01 (s,
    [1,2,3]triazol-1-yl]-acetamide 2H), 4.36 (s, 2H), 3.25 (s,
    2H), 3.11 (s, 2H), 2.62-2.65
    (m, 2H), 2.08-1.86 (m, 12H),
    1.64-1.61 (m, 1H), 1.38-1.18
    (m, 5H).
    SC_2156 CIS-1-[(1-Hydroxy-cyclobutyl)- SC_2153 SC_2026 1HNMR (DMSO-d6, 400 469.3
    methyl]-3-[[1-(2-hydroxy-ethyl)- MHz), δ (ppm) = 7.93 (s, 1H),
    1H-[1,2,3]triazol-4-yl]-methyl]- 7.44-7.17 (m, 5H), 6.03 (s,
    8-methylamino-8-phenyl-1,3- 1H), 4.98 (t, 1H), 4.36 (s,
    diazaspiro[4.5]decan-2-one 4H), 3.73-3.75 (q, 2H, J =
    5.48 Hz), 3.27 (s, 2H), 3.20
    (s, 2H), 2.11-2.03 (m, 4H),
    1.86 (bs, 7H), 1.62-1.33 (m,
    7H).
    SC_2157* CIS-8-Dimethylamino-8- INT-795 3-(2-bromoethyl)- step 2 of 1H NMR (DMSO-d6): δ 8.65 393.3
    phenyl-3-(2-pyridin-3-yl- step 1 pyridine INT-795 (br s, 1H), 8.38-8.37 (m, 1H),
    ethyl)-1,3-diazaspiro[4.5]- 8.28 (d, 1H), 7.54 (d, 1H),
    decane-2,4-dione 7.40-7.36 (m, 2H), 7.31-7.24
    (m, 4H), 3.56 (t, 2H), 2.83 (t,
    2H), 2.44-2.41 (m, 2H), 1.95-
    1.90 (m, 8H), 1.42-1.35 (m,
    4H).
    SC_2158* CIS-8-Dimethylamino-8- INT-795 4-(2-bromoethyl)- step 2 of 1H NMR (DMSO-d6): δ 8.67 393.3
    phenyl-3-(2-pyridin-4-yl- step 1 pyridine INT-795 br s, 1H), 8.42-8.40 (d, 2H),
    ethyl)-1,3-diazaspiro[4.5]- 7.40-7.36 (m, 2H), 7.31-7.25
    decane-2,4-dione (m, 3H), 7.14-7.12 (d, 2H),
    3.60-3.56 (t, 2H), 2.85-2.82
    (t, 2H), 2.45-2.41 (m, 2H),
    1.95-1.85 (m, 8H), 1.44-1.35
    (m, 4H).
    SC_2159 CIS-2-[4-[[1-(Cyclobutyl- INT-1030 ammonia SC_2145 1HNMR (DMSO-d6, 400 480.1
    methyl)-8-dimethylamino-2- MHz), δ (ppm) = 7.86 (s, 1H),
    oxo-8-phenyl-1,3-diazaspiro- 7.66 (s, 1H), 7.23-7.33 (m,
    [4.5]decan-3-yl]-methyl]-1H- 6H), 5.00 (s, 2H), 4.30 (s,
    [1,2,3]triazol-1-yl]-acetamide 2H), 3.09 (s, 2H), 3.04 (s,
    2H), 2.61-2.64 (m, 2H), 1.95-
    2.02 (m, 11H), 1.69-1.78 (m,
    4H), 1.28-1.33 (m, 4H).
    SC_2160 CIS-1-(Cyclobutyl-methyl)- INT-1030 SC_2144 1HNMR (DMSO-d6, 400 467.0
    8-dimethylamino-3-[[1-(2- MHz), δ (ppm) = 7.87 (s, 1H),
    hydroxy-ethyl)-1H-[1,2,3]- 7.23-7.35 (m, 5H), 4.97 (t,
    triazol-4-yl]-methyl]-8-phenyl- 1H), J = 5.28 Hz), 4.34 (t,
    1,3-diazaspiro[4.5]decan-2-one 2H), J = 5.34 Hz), 4.29 (s,
    2H), 3.71-3.75 (q, 2H), 3.09
    (s, 2H), 3.04-3.05 (d, 2H, J =
    7.2 Hz), 1.95-2.05 (m, 11H),
    1.67-1.85 (m, 4H), 1.25-1.33
    (bs, 4H).
    SC_2161 CIS-2-[4-[[1-[(1-Hydroxy- SC_2155 SC_2026 1HNMR (DMSO-d6, 400 482.3
    cyclobutyl)-methyl]-8-methyl- MHz), δ (ppm) = 7.91 (s, 1H),
    amino-2-oxo-8-phenyl-1,3- 7.68 (s, 1H), 7.44-7.42 (m,
    diazaspiro[4.5]decan-3-yl]- 2H), 7.35-7.28 (m, 3H), 7.19-
    methyl]-1H-[1,2,3]triazol-1- 7.16 (m, 1H), 6.03 (s, 1H),
    yl]-acetamide 5.02 (s, 2H), 4.37 (s, 2H),
    3.28 (s, 2H), 3.20 (s, 2H),
    2.14-2.01 (m, 4H), 1.90-1.84
    (m, 7H), 1.62-1.56 (m, 3H),
    1.46.133 (m, 3H).
    SC_2162 CIS-1-(Cyclobutyl-methyl)-3- SC_2160 SC_2026 1HNMR (DMSO-d6, 400 453.1
    [[1-(2-hydroxy-ethyl)-1H- MHz), δ (ppm) = 7.87 (s, 1H),
    [1,2,3]triazol-4-yl]-methyl-8- 7.40-7.42 (d, 2H, J = 7.64 Hz),
    methylamino-8-phenyl-1,3- 7.29 (t, 2H, J = 7.48 Hz), 7.17
    diazaspiro[4.5]decan-2-one (t, 1H, J = 7.18 Hz), 4.98 (t,
    1H, J = 5.32 Hz), 4.35 (t, 2H,
    J = 5.44 Hz), 4.31 (s, 2H),
    3.71-3.75 (q, 2H), 3.13 (s,
    2H), 3.07-3.09 (d, 2H, J =
    7.36 Hz), 2.53-2.57 (m, 1H),
    2.05-2.32 (m, 3H), 1.93-1.97
    (m, 2H), 1.67-1.86 (m, 8H),
    1.53-1.60 (m, 2H), 1.22-1.25
    (m, 2H).
    SC_2163 CIS-2-[4-[[1-(Cyclobutyl- SC_2159 SC_2026 1HNMR (DMSO-d6, 400 466.3
    methyl)-8-methylamino-2-oxo- MHz), δ (ppm) = 7.86 (s, 1H),
    8-phenyl-1,3-diazaspiro[4.5] 7.68 (s, 1H), 7.27-7.37 (m,
    decan-3-yl]-methyl]-1H- 5H), 7.17 (t, 1H, J = 7.10 Hz),
    [1,2,3]triazol-1-yl]-acetamide 5.02 (s, 2H), 4.32 (s, 2H),
    3.07-3.13 (m, 4H), 2.26 (bs,
    1H), 2.05-2.11 (m, 2H), 1.95
    (bs, 2H), 1.67-1.86 (m, 8H),
    1.57-1.60 (m, 2H), 1.22-1.25
    (m, 2H).
    SC_2164 CIS-8-Dimethylamino-8- SC_2157 step 3 of 1H NMR (DMSO-d6): δ (8.39- 379.3
    phenyl-3-(2-pyridin-3-yl- INT-795 8.37 (m, 2H), 7.61-7.60 (m,
    ethyl)-1,3-diazaspiro[4.5]- 1H), 7.38-7.23 (m, 6H), 6.67
    decan-2-one (br s, 1H), 3.26 (t, 2H), 3.01
    (s, 2H), 2.72 (t, 2H), 2.27 (m,
    2H), 1.91 (s, 6H), 1.73-1.71
    (m, 4H), 1.28-1.24 (m, 2H).
    SC_2165 CIS-8-Dimethylamino-3-[2- SC_2154 step 3 of 1H MHR (CDCl3): δ 7.45 (s, 368.2
    (1H-imidazol-1-yl)-ethyl]-8- INT-795 1H), 7.38-7.34 (m, 2H), 7.31-
    phenyl-1,3-diazaspiro[4.5]- 7.21 (m, 3H), 7.04 (s, 1H),
    decan-2-one 6.92 (s, 1H), 4.95 (br s, 1H),
    4.12-4.09 (t, 2H), 3.45-3.43
    (t, 2H), 2.67 (s, 2H), 2.03-
    1.96 (s, 8H), 1.84-1.68 (m,
    4H), 1.38-1.29 (m, 2H).
    SC_2166 CIS-8-Dimethylamino-8- SC_2158 step 3 of 1H NMR (DMSO-d6): δ 379.2
    phenyl-3-(2-pyridin-4-yl- INT-795 8.50-8.48 (m, 2H), 7.39-7.35
    ethyl)-1,3-diazaspiro[4.5]- (m, 2H), 7.30-7.27 (m, 3H),
    decan-2-one 7.14-7.12 (d, 2H), 4.62 (br s,
    1H), 3.46-3.43 (t, 2H), 2.95
    (s, 2H), 2.82-2.78 (t, 2H),
    2.17-2.02 (m, 10H), 1.85-
    1.75 (m, 2H), 1.41-1.29 (m,
    2H).
    SC_2167 CIS-8-Dimethylamino-8- INT-976 2-(2-bromoethyl)- SC_2097 1H NMR (DMSO-d6): δ 8.70 380.3
    phenyl-3-(2-pyrimidin-2-yl- pyrimidine (d, 2H), 7.38-7.23 (m, 6H),
    ethyl)-1,3-diazaspiro[4.5]- 6.65 (br s, 1H), 3.45 (t, 2H),
    decan-2-one 3.00-2.49 (m, 4H), 2.28 (br
    m, 2H), 1.91 (s, 6H), 1.73-
    1.71 (m, 4H), 1.29-1.27 (m,
    2H).
    SC_2168 CIS-8-Dimethylamino-8- INT-976 5-(2-chloroethyl)- SC_2097 1H NMR (DMSO-d6): δ 9.00 380.2
    phenyl-3-(2-pyrimidin-5-yl- pyrimidine (s, 1H), 8.64 (s, 2H), 7.38-
    ethyl)-1,3-diazaspiro[4.5]- 7.31 (m, 4H), 7.26-7.23 (m,
    decan-2-one 1H), 6.69 (br s, 1H), 3.26 (m,
    2H), 3.05 (s, 2H), 2.74 (t, 2H),
    2.27 (br m, 2H), 1.92-1.69 (m,
    10H), 1.28-1.24 (m, 2H).
    SC_2169 CIS-8-Dimethylamino-1-ethyl- INT-976 1-(chloromethyl)- SC_2097 1H NMR (600 MHz, DMSO) 470.3
    3-[(4-methylsulfonyl-phenyl)- 4-methylsulfonyl- (for δ 7.92-7.86 (m, 2H), 7.50-
    methyl]-8-phenyl-1,3-diazaspiro- benzene (step 1), step 1), 7.46 (m, 2H), 7.38-7.28 (m,
    [4.5]decan-2-one bromoethane SC_2010 4H), 7.27-7.19 (m, 1H), 4.37
    (step 2) (for step 2) (s, 2H), 3.19 (s, 3H), 3.15-
    3.03 (m, 4H), 2.69-2.60 (m,
    2H), 2.15-2.06 (m, 2H), 1.97
    (s, 6H), 1.38-1.27 (m, 4H),
    1.14 (t, 3H).
    SC_2171 CIS-8-Dimethylamino-8- INT-1023 1-phenylcyclo- SC_2170 1H NMR (DMSO-d6): δ 390.2
    phenyl-3-(1-phenyl-cyclo- propanamine 7.36-7.14 (m, 8H), 7.08 (d,
    propyl)-1,3-diazaspiro[4.5]- (step 1) 2H), 6.77 (br s, 1H), 3.08 (s,
    decan-2-one 2H), 2.29 (m, 2H), 1.92 (s,
    6H), 1.79-1.77 (m, 4H), 1.35-
    1.33 (m, 2H), 1.23-1.21 (m,
    2H), 1.09-1.06 (m, 2H).
    SC_2172 CIS-8-Dimethylamino-1,3- INT-976 1-(bromomethyl)- SC_2097 1H NMR (DMSO-d6): δ 7.32- 514.2
    bis[(2-methoxyphenyl)-methyl]- 2-methoxybenzene 7.14 (m, 9H), 6.99-6.90 (m,
    8-phenyl-1,3-diazaspiro[4.5]- 4H), 4.32-4.27 (m, 4H), 3.84-
    decan-2-one 3.77 (m, 6H), 3.14 (s, 2H),
    2.58-2.54 (m, 2H), 2.03-1.97
    (m, 2H), 1.89 (s, 6H), 1.29-
    1.22 (m, 4H).
    SC_2173 CIS-8-Dimethylamino-3-[(3- INT-976 1-(bromomethyl)- SC_2097 1H NMR (600 MHz, DMSO) 442.2
    methylsulfonyl-phenyl)-methyl]- 3-methylsulfonyl- δ 7.84-7.79 (m, 1H), 7.74 (d,
    8-phenyl-1,3-diazaspiro[4.5]- benzene 1H), 7.62 (t, 1H), 7.55 (d, 1H),
    decan-2-one 7.36-7.27 (m, 4H), 7.23 (t,
    1H), 6.99 (br s, 1H), 4.33 (s,
    2H), 3.19 (s, 2H), 2.97 (s,
    2H), 2.35-2.24 (m, 2H), 1.93
    (d, 6H), 1.85-1.66 (m, 4H),
    1.38-1.31 (m, 2H).
    SC_2174 CIS-8-Dimethylamino-1-[(1- SC_2170 (1-tertbutyl- INT-799 1H NMR (DMSO-d6): δ 7.36- 476.3
    hydroxy-cyclobutyl)-methyl]- dimethylsilyloxy)- (step 1) 7.14 (m, 10H), 5.88 (m, 1H),
    3-(1-methyl-1-phenyl-ethyl)- cyclobutyl)methyl- 3.33 (s, 2H), 3.03 (s, 2H),
    8-phenyl-1,3-diazaspiro[4.5]- 4-methylbenzene- 2.68-2.64 (m, 2H), 2.09-1.95
    decan-2-one sulfonate (m, 10H), 1.89-1.81 (m, 2H),
    1.61-1.56 (m, 7H), 1.48-1.28
    (m, 5H).
    SC_2175 CIS-3-[(3-Cyclopropyl-phenyl)- INT-976 1-(bromomethyl)- SC_2097 1H NMR (600 MHz, DMSO) 403.3
    methyl]-8-dimethylamino-8- 3-cyclopropyl- δ 8.17 (s, 1H), 7.41-7.29 (m,
    phenyl-1,3-diazaspiro[4.5]- benzene 4H), 7.30-7.20 (m, 1H), 7.18
    decan-2-one (t, 1H), 6.98-6.89 (m, 3H),
    6.87 (t, 1H), 4.15 (s, 2H),
    2.89 (s, 2H), 2.28 (s, 2H),
    1.97 (s, 6H), 1.91-1.83 (m,
    1H)), 1.80-1.75 (m, 3H), 1.34-
    1.27 (m, 2H), 0.96-0.88 (m,
    2H), 0.65-0.57 (m, 2H).
    SC_2176 CIS-3-(1,3-Benzodioxol-4-yl- INT-976 4-(bromomethyl)- SC_2097 1H NMR (600 MHz, DMSO) 408.2
    methyl)-8-dimethylamino-8- 1,3-benzodioxole δ 7.37-7.27 (m, 4H), 7.27-
    phenyl-1,3-diazaspiro[4.5]- 7.20 (m, 1H), 6.88 (s, 1H),
    decan-2-one 6.83-6.76 (m, 2H), 6.67 (dd,
    1H), 5.96 (s, 2H), 4.18 (s, 2H),
    2.95 (s, 2H), 2.30-2.26 (m,
    2H), 1.93 (s, 6H), 1.84-1.63
    (m, 4H), 1.33 (t, 2H).
    SC_2177 CIS-8-Dimethylamino-1-[(1- SC_2171 (1-tertbutyl- INT-799 1H NMR (DMSO-d6): δ 474.2
    hydroxy-cyclobutyl)-methyl]- dimethylsilyl- (step 1) 7.34-7.17 (m, 8H), 7.15-7.13
    8-phenyl-3-(1-phenyl-cyclo- oxy)cyclobutyl)- (m, 2H), 5.89 (s, 1H), 3.29
    propyl)-1,3-diazaspiro[4.5]- methylbenzene- (s, 2H), 3.09 (s, 2H), 2.64-
    decan-2-one sulfonate 2.61 (m, 2H), 2.08-2.03 (m,
    4H), 1.96 (s, 6H), 1.91-1.84
    (m, 2H), 1.64-1.61 (m, 1H),
    1.42-1.29 (m, 5H), 1.26-1.26
    (m, 2H), 1.13-1.01 (m, 2H)
    SC_2178 CIS-4-[[8-Dimethylamino-3- SC_2179 4-(bromomethyl)- SC_2097 1H NMR (DMSO-d6): δ 7.81 509.2
    [(2-methoxyphenyl)-methyl]- benzonitrile (d, 2H), 7.53 (d, 2H), 7.32-
    2-oxo-8-phenyl-1,3-diazaspiro- 7.21 (m, 6H), 7.15-7.13 (m,
    [4.5]decan-1-yl]-methyl]- 1H), 6.99-6.92 (m, 2H),
    benzonitrile 4.38-4.31 (m, 4H), 3.77 (s,
    3H), 3.16 (s, 2H), 2.58-2.55
    (m, 2H), 2.00-1.89 (m, 8H),
    1.29-1.23 (m, 4H).
    SC_2179 CIS-8-Dimethylamino-3-[(2- INT-976 1-(bromomethyl)- SC_2097 1H NMR (600 MHz, DMSO) 394.3
    methoxyphenyl)-methyl]-8- 2-methoxybenzene δ 7.37-7.27 (m, 4H), 7.27-7.19
    phenyl-1,3-diazaspiro[4.5]- (m, 2H), 7.08 (dd, 1H), 6.96
    decan-2-one (dd, 1H), 6.91 (td, 1H), 6.85
    (s, 1H), 4.19 (s, 2H), 3.75
    (s, 3H), 2.96 (s, 2H), 2.30 (d,
    2H), 1.93 (s, 6H), 1.86-1.69
    (m, 4H), 1.38-1.32 (m, 2H).
    SC_2181 CIS-8-Dimethylamino-8- INT-1028 2-(bromomethyl)- SC_2180 1H NMR (600 MHz, DMSO) 365.2
    phenyl-3-(pyridin-2-yl- pyridine hydro- δ 8.48 (ddd, 1H), 7.76 (td, 1H),
    methyl)-1,3-diazaspiro[4.5]- bromide (step 1) 7.37-7.27 (m, 4H), 7.29-7.17
    decan-2-one (m, 3H), 6.93 (s, 1H), 4.30 (s,
    2H), 3.05 (s, 2H), 2.36-2.21
    (m, 2H), 1.93 (s, 6H), 1.88-
    1.58 (m, 4H), 1.41-1.31 (m,
    2H).
    SC_2182 CIS-8-Dimethylamino-8- INT-1028 3-(bromomethyl)- SC_2180 1H NMR (600 MHz, DMSO) 365.2
    phenyl-3-(pyridin-3-yl-methyl)- pyridine hydro- δ 8.46 (dd, 1H), 8.42 (dd, 1H),
    1,3-diazaspiro[4.5]decan-2-one bromide (step 1) 7.60 (dt, 1H), 7.38-7.30 (m,
    3H), 7.31-7.26 (m, 2H), 7.26-
    7.20 (m, 1H), 6.97-6.93 (m,
    1H), 4.24 (s, 2H), 2.95 (s, 2H),
    2.33-2.20 (m, 2H), 1.92 (s,
    6H), 1.84-1.60 (m, 4H), 1.35-
    1.29 (m, 2H).
    SC_2184 CIS-8-Dimethylamino-8- INT-1065 piperidine SC_2183 1H NMR (600 MHz, CDCl3) 448.3
    phenyl-3-[(2-piperidin-1-yl- δ 8.09 (d, 1H), 7.38 (dd, 2H),
    pyridin-4-yl-methyl]-1,3- 7.30 (d, 3H), 6.48 (s, 1H), 6.42
    diazaspiro[4.5]decan-2-one (dd, 1H), 5.47 (s, 1H), 4.23 (s,
    2H), 3.54-3.46 (m, 4H), 2.96
    (s, 2H), 2.20-2.15 (m, 4H),
    2.07 (s, 6H), 1.92-1.84 (m,
    2H), 1.66-1.60 (m, 6H), 1.47-
    1.39 (m, 2H).
    SC_2185 CIS-8-Dimethylamino-3-[(2- INT-1065 morpholine SC_2183 1H NMR (600 MHz, DMSO) 450.3
    morpholin-4-yl-pyridin-4-yl)- δ 8.05 (d, 1H), 7.37-7.27 (m,
    methyl]-8-phenyl-1,3- 4H), 7.26-7.20 (m, 1H), 6.94
    diazaspiro[4.5]decan-2-one (s, 1H), 6.59 (s, 1H), 6.50 (dd,
    1H), 4.13 (s, 2H), 3.68 (t, 4H),
    3.41-3.36 (m, 4H), 2.96 (s,
    2H), 2.37-2.22 (m, 2H), 1.93
    (s, 6H), 1.86-1.62 (m, 4H),
    1.42-1.29 (m, 2H).
    (*Comparative Example)
    Chemical Structure of all examples
    Figure US20200399252A1-20201224-C00133
         		SC_2001
    Figure US20200399252A1-20201224-C00134
         		SC_2002
    Figure US20200399252A1-20201224-C00135
         		SC_2003
    Figure US20200399252A1-20201224-C00136
         		SC_2004
    Figure US20200399252A1-20201224-C00137
         		SC_2005
    Figure US20200399252A1-20201224-C00138
         		SC_2006
    Figure US20200399252A1-20201224-C00139
         		SC_2007
    Figure US20200399252A1-20201224-C00140
         		SC_2008
    Figure US20200399252A1-20201224-C00141
         		SC_2009
    Figure US20200399252A1-20201224-C00142
         		SC_2010
    Figure US20200399252A1-20201224-C00143
         		SC_2011
    Figure US20200399252A1-20201224-C00144
         		SC_2012
    Figure US20200399252A1-20201224-C00145
         		SC_2013
    Figure US20200399252A1-20201224-C00146
         		SC_2014
    Figure US20200399252A1-20201224-C00147
         		SC_2015
    Figure US20200399252A1-20201224-C00148
         		SC_2016
    Figure US20200399252A1-20201224-C00149
         		SC_2017
    Figure US20200399252A1-20201224-C00150
         		SC_2018
    Figure US20200399252A1-20201224-C00151
         		SC_2019
    Figure US20200399252A1-20201224-C00152
         		SC_2020
    Figure US20200399252A1-20201224-C00153
         		SC_2021
    Figure US20200399252A1-20201224-C00154
         		SC_2022
    Figure US20200399252A1-20201224-C00155
         		SC_2023
    Figure US20200399252A1-20201224-C00156
         		SC_2024
    Figure US20200399252A1-20201224-C00157
         		SC_2025
    Figure US20200399252A1-20201224-C00158
         		SC_2026
    Figure US20200399252A1-20201224-C00159
         		SC_2027
    Figure US20200399252A1-20201224-C00160
         		SC_2028
    Figure US20200399252A1-20201224-C00161
         		SC_2029
    Figure US20200399252A1-20201224-C00162
         		SC_2030
    Figure US20200399252A1-20201224-C00163
         		SC_2031
    Figure US20200399252A1-20201224-C00164
         		SC_2032
    Figure US20200399252A1-20201224-C00165
         		SC_2033
    Figure US20200399252A1-20201224-C00166
         		SC_2034
    Figure US20200399252A1-20201224-C00167
         		SC_2035
    Figure US20200399252A1-20201224-C00168
         		SC_2036
    Figure US20200399252A1-20201224-C00169
         		SC_2037
    Figure US20200399252A1-20201224-C00170
         		SC_2038
    Figure US20200399252A1-20201224-C00171
         		SC_2039
    Figure US20200399252A1-20201224-C00172
         		SC_2040
    Figure US20200399252A1-20201224-C00173
         		SC_2041
    Figure US20200399252A1-20201224-C00174
         		SC_2042
    Figure US20200399252A1-20201224-C00175
         		SC_2043
    Figure US20200399252A1-20201224-C00176
         		SC_2044
    Figure US20200399252A1-20201224-C00177
         		SC_2045
    Figure US20200399252A1-20201224-C00178
         		SC_2046
    Figure US20200399252A1-20201224-C00179
         		SC_2047
    Figure US20200399252A1-20201224-C00180
         		SC_2048
    Figure US20200399252A1-20201224-C00181
         		SC_2049
    Figure US20200399252A1-20201224-C00182
         		SC_2050
    Figure US20200399252A1-20201224-C00183
         		SC_2051
    Figure US20200399252A1-20201224-C00184
         		SC_2052
    Figure US20200399252A1-20201224-C00185
         		SC_2053
    Figure US20200399252A1-20201224-C00186
         		SC_2054
    Figure US20200399252A1-20201224-C00187
         		SC_2055
    Figure US20200399252A1-20201224-C00188
         		SC_2056
    Figure US20200399252A1-20201224-C00189
         		SC_2057
    Figure US20200399252A1-20201224-C00190
         		SC_2058
    Figure US20200399252A1-20201224-C00191
         		SC_2059
    Figure US20200399252A1-20201224-C00192
         		SC_2060
    Figure US20200399252A1-20201224-C00193
         		SC_2061
    Figure US20200399252A1-20201224-C00194
         		SC_2062
    Figure US20200399252A1-20201224-C00195
         		SC_2063
    Figure US20200399252A1-20201224-C00196
         		SC_2064
    Figure US20200399252A1-20201224-C00197
         		SC_2065
    Figure US20200399252A1-20201224-C00198
         		SC_2066
    Figure US20200399252A1-20201224-C00199
         		SC_2067
    Figure US20200399252A1-20201224-C00200
         		SC_2068
    Figure US20200399252A1-20201224-C00201
         		SC_2069
    Figure US20200399252A1-20201224-C00202
         		SC_2070
    Figure US20200399252A1-20201224-C00203
         		SC_2071
    Figure US20200399252A1-20201224-C00204
         		SC_2072
    Figure US20200399252A1-20201224-C00205
         		SC_2073
    Figure US20200399252A1-20201224-C00206
         		SC_2074
    Figure US20200399252A1-20201224-C00207
         		SC_2075
    Figure US20200399252A1-20201224-C00208
         		SC_2076
    Figure US20200399252A1-20201224-C00209
         		SC_2077
    Figure US20200399252A1-20201224-C00210
         		SC_2078
    Figure US20200399252A1-20201224-C00211
         		SC_2079
    Figure US20200399252A1-20201224-C00212
         		SC_2080
    Figure US20200399252A1-20201224-C00213
         		SC_2081
    Figure US20200399252A1-20201224-C00214
         		SC_2082
    Figure US20200399252A1-20201224-C00215
         		SC_2083
    Figure US20200399252A1-20201224-C00216
         		SC_2084
    Figure US20200399252A1-20201224-C00217
         		SC_2085
    Figure US20200399252A1-20201224-C00218
         		SC_2086
    Figure US20200399252A1-20201224-C00219
         		SC_2087
    Figure US20200399252A1-20201224-C00220
         		SC_2088
    Figure US20200399252A1-20201224-C00221
         		SC_2089
    Figure US20200399252A1-20201224-C00222
         		SC_2090
    Figure US20200399252A1-20201224-C00223
         		SC_2091
    Figure US20200399252A1-20201224-C00224
         		SC_2092
    Figure US20200399252A1-20201224-C00225
         		SC_2093
    Figure US20200399252A1-20201224-C00226
         		SC_2094
    Figure US20200399252A1-20201224-C00227
         		SC_2095
    Figure US20200399252A1-20201224-C00228
         		SC_2096
    Figure US20200399252A1-20201224-C00229
         		SC_2097
    Figure US20200399252A1-20201224-C00230
         		SC_2099
    Figure US20200399252A1-20201224-C00231
         		SC_2100
    Figure US20200399252A1-20201224-C00232
         		SC_2101
    Figure US20200399252A1-20201224-C00233
         		SC_2102
    Figure US20200399252A1-20201224-C00234
         		SC_2103
    Figure US20200399252A1-20201224-C00235
         		SC_2104
    Figure US20200399252A1-20201224-C00236
         		SC_2105
    Figure US20200399252A1-20201224-C00237
         		SC_2106
    Figure US20200399252A1-20201224-C00238
         		SC_2107
    Figure US20200399252A1-20201224-C00239
         		SC_2108
    Figure US20200399252A1-20201224-C00240
         		SC_2109
    Figure US20200399252A1-20201224-C00241
         		SC_2110
    Figure US20200399252A1-20201224-C00242
         		SC_2111
    Figure US20200399252A1-20201224-C00243
         		SC_2112
    Figure US20200399252A1-20201224-C00244
         		SC_2113
    Figure US20200399252A1-20201224-C00245
         		SC_2114
    Figure US20200399252A1-20201224-C00246
         		SC_2115
    Figure US20200399252A1-20201224-C00247
         		SC_2117
    Figure US20200399252A1-20201224-C00248
         		SC_2118
    Figure US20200399252A1-20201224-C00249
         		SC_2119
    Figure US20200399252A1-20201224-C00250
         		SC_2120
    Figure US20200399252A1-20201224-C00251
         		SC_2122
    Figure US20200399252A1-20201224-C00252
         		SC_2123
    Figure US20200399252A1-20201224-C00253
         		SC_2124
    Figure US20200399252A1-20201224-C00254
         		SC_2125
    Figure US20200399252A1-20201224-C00255
         		SC_2126
    Figure US20200399252A1-20201224-C00256
         		SC_2127
    Figure US20200399252A1-20201224-C00257
         		SC_2129
    Figure US20200399252A1-20201224-C00258
         		SC_2130
    Figure US20200399252A1-20201224-C00259
         		SC_2131
    Figure US20200399252A1-20201224-C00260
         		SC_2132
    Figure US20200399252A1-20201224-C00261
         		SC_2133
    Figure US20200399252A1-20201224-C00262
         		SC_2134
    Figure US20200399252A1-20201224-C00263
         		SC_2135
    Figure US20200399252A1-20201224-C00264
         		SC_2136
    Figure US20200399252A1-20201224-C00265
         		SC_2137
    Figure US20200399252A1-20201224-C00266
         		SC_2138
    Figure US20200399252A1-20201224-C00267
         		SC_2139
    Figure US20200399252A1-20201224-C00268
         		SC_2140
    Figure US20200399252A1-20201224-C00269
         		SC_2141
    Figure US20200399252A1-20201224-C00270
         		SC_2142
    Figure US20200399252A1-20201224-C00271
         		SC_2143
    Figure US20200399252A1-20201224-C00272
         		SC_2144
    Figure US20200399252A1-20201224-C00273
         		SC_2145
    Figure US20200399252A1-20201224-C00274
         		SC_2146
    Figure US20200399252A1-20201224-C00275
         		SC_2147
    Figure US20200399252A1-20201224-C00276
         		SC_2148
    Figure US20200399252A1-20201224-C00277
         		SC_2149
    Figure US20200399252A1-20201224-C00278
         		SC_2150
    Figure US20200399252A1-20201224-C00279
         		SC_2151*
    Figure US20200399252A1-20201224-C00280
         		SC_2152
    Figure US20200399252A1-20201224-C00281
         		SC_2153
    Figure US20200399252A1-20201224-C00282
         		SC_2154*
    Figure US20200399252A1-20201224-C00283
         		SC_2155
    Figure US20200399252A1-20201224-C00284
         		SC_2156
    Figure US20200399252A1-20201224-C00285
         		SC_2157*
    Figure US20200399252A1-20201224-C00286
         		SC_2158*
    Figure US20200399252A1-20201224-C00287
         		SC_2159
    Figure US20200399252A1-20201224-C00288
         		SC_2160
    Figure US20200399252A1-20201224-C00289
         		SC_2161
    Figure US20200399252A1-20201224-C00290
         		SC_2162
    Figure US20200399252A1-20201224-C00291
         		SC_2163
    Figure US20200399252A1-20201224-C00292
         		SC_2164
    Figure US20200399252A1-20201224-C00293
         		SC_2165
    Figure US20200399252A1-20201224-C00294
         		SC_2166
    Figure US20200399252A1-20201224-C00295
         		SC_2167
    Figure US20200399252A1-20201224-C00296
         		SC_2168
    Figure US20200399252A1-20201224-C00297
         		SC_2169
    Figure US20200399252A1-20201224-C00298
         		SC_2170
    Figure US20200399252A1-20201224-C00299
         		SC_2171
    Figure US20200399252A1-20201224-C00300
         		SC_2172
    Figure US20200399252A1-20201224-C00301
         		SC_2173
    Figure US20200399252A1-20201224-C00302
         		SC_2174
    Figure US20200399252A1-20201224-C00303
         		SC_2175
    Figure US20200399252A1-20201224-C00304
         		SC_2176
    Figure US20200399252A1-20201224-C00305
         		SC_2177
    Figure US20200399252A1-20201224-C00306
         		SC_2178
    Figure US20200399252A1-20201224-C00307
         		SC_2179
    Figure US20200399252A1-20201224-C00308
         		SC_2180
    Figure US20200399252A1-20201224-C00309
         		SC_2181
    Figure US20200399252A1-20201224-C00310
         		SC_2182
    Figure US20200399252A1-20201224-C00311
         		SC_2183
    Figure US20200399252A1-20201224-C00312
         		SC_2184
    Figure US20200399252A1-20201224-C00313
         		SC_2185
    Figure US20200399252A1-20201224-C00314
         		SC_2186
    *Comparative Example
  • Pharmacological Investigations
  • Functional investigation on the human mu-opioid receptor (hMOP), human kappa-opioid receptor (kKOP), human delta-opioid receptor (hDOP), and human nociceptin/orphanin FQ peptide receptor (hNOP).
  • Human Mu-Opioid Peptide (hMOP)Receptor Binding Assay
  • The hMOP receptor binding assay was performed as homogeneous SPA-assay (scintillation proximity assay) using the assay buffer 50 mM TRIS-HCl (pH 7.4) supplemented with 0.052 mg/ml bovine serum albumin (Sigma-Aldrich Co. St. Louis. Mo.). The final assay volume (250 μl/well) included 1 nM of [N-allyl-2.33H]naloxone as ligand (PerkinElmer Life Sciences. Inc. Boston. Mass. USA). and either test compound in dilution series or 25 μM unlabelled naloxone for determination of unspecific binding. The test compound was diluted with 25% DMSO in H2O to yield a final 0.5% DMSO concentration. which also served as a respective vehicle control. The assay was started by adding wheat germ agglutinin coated SPA beads (GE Healthcare UK Ltd. Buckinghamshire. UK) which had been preloaded with hMOP receptor membranes (PerkinElmer Life Sciences. Inc. Boston. Mass. USA). After incubation for 90 minutes at RT and centrifugation for 20 minutes at 500 rpm the signal rate was measured by means of a 1450 Microbeta Trilux β-counter (PerkinElmer Life Sciences/Wallac. Turku. Finland). Half-maximal inhibitory concentration (IC50) values reflecting 50% displacement of [3H]naloxone-specific receptor binding were calculated by nonlinear regression analysis and Ki values were calculated by using the Cheng-Prusoffequation. (Cheng and Prusoff. 1973).
  • Human Kappa-Opioid Peptide (hKOP) Receptor Binding Assay
  • The hKOP receptor binding assay is run as homogeneous SPA-assay (scintillation proximity assay) using the assay buffer 50 mM TRIS-HCl (pH 7.4) supplemented with 0.076 mg BSA/ml. The final assay volume of 250 μl per well includes 2 nM of [3H]U69,593 as ligand, and either test compound in dilution series or 100 μM unlabelled naloxone for determination of unspecific binding. The test compound is diluted with 25% DMSO in H2O to yield a final 0.5% DMSO concentration which serves as respective vehicle control, as well. The assays are started by the addition of wheat germ agglutinin coated SPA beads (1 mg SPA beads/250 μl final assay volume per well) which has been preloaded for 15 minutes at room temperature with hKOP receptor membranes (14.8 μg/250 μl final assay volume per well). After short mixing on a mini-shaker, the microtiter plates are covered with a lid and the assay plates are incubated for 90 minutes at room temperature. After this incubation, the microtiter plates are sealed with a topseal and centrifuged for 20 minutes at 500 rpm. The signal rate is measured after a short delay of 5 minutes by means of a 1450 Microbeta Trilux β-counter (PerkinElmer Life Sciences/Wallac, Turku, Finland). Half-maximal inhibitory concentration (IC50) values reflecting 50% displacement of [3H]U69.593-specific receptor binding are calculated by nonlinear regression analysis and Ki values are calculated by using the Cheng-Prusoff equation, (Cheng and Prusoff, 1973).
  • Human Delta-Opioid Peptide (hDOP) Receptor Binding Assay
  • The hDOP receptor binding assay is performed as homogeneous SPA-assay using the assay buffer 50 mM TRIS-HCl, 5 mM MgCl2 (pH 7.4). The final assay volume (250 μl/well) includes 1 nM of [Tyrosyl-3,5-3H]2-D-Ala-deltorphin II as ligand, and either test compound in dilution series or 10 μM unlabelled naloxone for determination of unspecific binding. The test compound is diluted with 25% DMSO in H2O to yield a final 0.5% DMSO concentration which serves as respective vehicle control, as well. The assays are started by the addition of wheat germ agglutinin coated SPA beads (1 mg SPA beads/250 μl final assay volume per well) which has been preloaded for 15 minutes at room temperature with hDOP receptor membranes (15.2 μg/250 μl final assay volume per well). After short mixing on a mini-shaker, the microtiter plates are covered with a lid and the assay plates are incubated for 120 minutes at room temperature and centrifuged for 20 minutes at 500 rpm. The signal rate is measured by means of a 1450 Microbeta Trilux β-counter (PerkinElmer Life Sciences/Wallac, Turku, Finland). Half-maximal inhibitory concentration (IC50) values reflecting 50% displacement of [Tyrosyl-3,5-3H]2-D-Ala-deltorphin II-specific receptor binding are calculated by nonlinear regression analysis and Ki values are calculated by using the Cheng-Prusoffequation, (Cheng and Prusoff, 1973).
  • Human Nociceptin/Orphanin FQ Peptide (hNOP) Receptor Binding Assay
  • The hNOP receptor binding assay was performed as homogeneous SPA-assay (scintillation proximity assay) using the assay buffer 50 mM TRIS-HCl. 10 mM MgCl2. 1 mM EDTA (pH 7.4). The final assay volume (250 μl/well) included 0.5 nM of [leucyl-3H]nociceptin as ligand (PerkinElmer Life Sciences. Inc. Boston. Mass. USA). and either test compound in dilution series or 1 μM unlabelled nociceptin for determination of unspecific binding. The test compound was diluted with 25% DMSO in H2O to yield a final 0.5% DMSO concentration. which also served as a respective vehicle control. The assay was started by adding wheat germ agglutinin coated SPA beads (GE Healthcare UK Ltd. Buckinghamshire. UK) which had been preloaded with hMOP receptor membranes (PerkinElmer Life Sciences. Inc. Boston. Mass. USA). After incubation for 60 minutes at RT and centrifugation for 20 minutes at 500 rpm the signal rate was measured by means of a 1450 Microbeta Trilux β-counter (PerkinElmer Life Sciences/Wallac. Turku. Finland). Half-maximal inhibitory concentration (IC50) values reflecting 50% displacement of [3H]nociceptin-specific receptor binding were calculated by nonlinear regression analysis and Ki values were calculated by using the Cheng-Prusoff equation. (Cheng and Prusoff. 1973).
  • hNOP Ki [nM] or % hMOP Ki [nM] or %
    Example inhibition @ 1 μM inhibition @ 1 μM
    SC_2001 2.7 245
    SC_2002 4.3 965
    SC_2003 585 5875
    SC_2004 21.5 1310
    SC_2005 12% @ 1 μM —
    SC_2006 0.8 43
    SC_2007 1.1 43.5
    SC_2008 690 not determined
    SC_2009 17.6 385
    SC_2010 88.5 not determined
    SC_2011 50.5 880
    SC_2012 50 1350
    SC_2013 125 18.4
    SC_2014 23.5 470
    SC_2015 6.4 162.5
    SC_2017 80 5460
    SC_2018 70.8 66.8
    SC_2019 0.8 50.8
    SC_2020 15.5 305
    SC_2021 1200 4615
    SC_2022 5.4 420
    SC_2023 3.8 180
    SC_2024 48 1450
    SC_2025 49.5 920
    SC_2026 11 255
    SC_2027 12 1415
    SC_2028 135 3260
    SC_2029 50 2150
    SC_2030 96.5 1260
    SC_2031 4.6 139.5
    SC_2032 36 1035
    SC_2033 27 855
    SC_2034 490 4025
    SC_2035 39 1240
    SC_2036 3.1 215
    SC_2037 19.5 160
    SC_2038 13.5 380
    SC_2039 2.8 54.5
    SC_2040 34 705
    SC_2041 195 1925
    SC_2042 16.5 1275
    SC_2043 530 20% @ 1 μM
    SC_2044 10.8 275
    SC_2045 21 1035
    SC_2046 38% @ 1 μM 23% @ 1 μM
    SC_2047 85.5 600
    SC_2048 390 3430
    SC_2049 24 1570
    SC_2050 11.5 310
    SC_2051 9 515
    SC_2052 26.2 996.7
    SC_2053 220 1385
    SC_2054 43.5 340
    SC_2055 96.5 2780
    SC_2056 31 545
    SC_2057 330 5475
    SC_2058 49.5 195
    SC_2059  4% @ 1 μM 26% @ 1 μM
    SC_2060 45 1035
    SC_2061 0.5 86.5
    SC_2062 20.5 1750
    SC_2063 18 3430
    SC_2064 41 2000
    SC_2065 27 650
    SC_2066 455 90
    SC_2067 217.5 4700
    SC_2068 34.5 230
    SC_2069 14 675
    SC_2070 18.5 5875
    SC_2071 40 860
    SC_2072 620 19% @ 1 μM
    SC_2073 200 3440
    SC_2074 3.4 310
    SC_2075 9.1 480
    SC_2076 51.5 925
    SC_2077 325 3460
    SC_2078 170 563.3
    SC_2079 19.3 710
    SC_2080 87.5 625
    SC_2081 1.2 147
    SC_2082 180 2390
    SC_2083 405 5250
    SC_2084 34 880
    SC_2085 3.8 230
    SC_2086 3.5 150
    SC_2087 47 1365
    SC_2088 1.9 110
    SC_2089 1.8 73
    SC_2090 106 3185
    SC_2091 26 1620
    SC_2092 5.6 380
    SC_2093 0.8 53.7
    SC_2094 19 50.5
    SC_2095 11.2 575
    SC_2096 1.3 81
    SC_2097 91 2645
    SC_2099 215 5135
    SC_2100 11.8 1320
    SC_2101 135 1170
    SC_2102 3.3 84.5
    SC_2103 1.5 54
    SC_2104 22.5 1000
    SC_2105 2.4 45
    SC_2106 16.5 1540
    SC_2107 57 1700
    SC_2108 10.1 195
    SC_2109 17 260
    SC_2110 16.5 134
    SC_2111 159 1675
    SC_2112 135 925
    SC_2113 4 310
    SC_2114 300 3045
    SC_2115 720 2480
    SC_2117 630 not determined
    SC_2118 195 995
    SC_2119 85 90
    SC_2120 19 1000
    SC_2122 310 830
    SC_2123 not determined 3840
    SC_2124 4 43
    SC_2125 3.4 120
    SC_2143 405 5290
    SC_2144 715 5180
    SC_2145 340 4940
    SC_2146 2% 9%
    SC_2147 14%  10% 
    SC_2148 8% 0%
    SC_2149 160 250
    SC_2150 6% 4%
    SC_2152 175 2475
    SC_2153 22 130
    SC_2155 12.5 98
    SC_2156 130 330
    SC_2159 2.35 40.5
    SC_2160 4 39
    SC_2161 100.5 295
    SC_2162 31 82.5
    SC_2163 13 93.5
    SC_2164 130 2765
    SC_2165 255 2000
    SC_2166 106.5 3690
    SC_2168 240 13% 
    SC_2169 785 790
    SC_2170 325 not determined
    SC_2171 49.25 362.5
    SC_2172 50 630
    SC_2173 145 5245
    SC_2174 8.15 235
    SC_2175 90.5 1830
    SC_2176 110 3090
    SC_2177 18 99.5
    SC_2178 390 1050
    SC_2179 108.5 2660
    SC_2180 240 4085
    SC_2181 190 19%
    SC_2182 250 13%
    SC_2183 63 3580
    SC_2184 25 845
    SC_2185 115 6980
    SC_2186 40 2775
  • Protocol for [35S]GTPγS Functional NOP/MOP/KOP/DOP Assays
  • Cell membrane preparations of CHO-K1 cells transfected with the human MOP receptor (Art.-No. RBHOMM) or the human DOP receptor (Art.-No. RBHODM), and HEK293 cells transfected with the human NOP receptor (Art.-No. RBHORLM) or the human KOP receptor (Art.-No. 6110558) are available from PerkinElmer (Waltham, Mass.). Membranes from CHO-K1 cells transfected with the human nociceptin/orphanin FQ peptide (hNOP) receptor (Art.-No. 93-0264C2, DiscoveRx Corporation, Freemont, Calif.) are also used. [35S]GTPγS (Art.-No. NEG030H; Lot-No. #0112, #0913, #1113 calibrated to 46.25 TBq/mmol) is available from PerkinElmer (Waltham, Mass.).
  • The [35S]GTPγS assays are carried out essentially as described by Gillen et al (2000). They are run as homogeneous scintillation proximity (SPA) assays in microtiter luminescence plates, where each well contains 1.5 mg of WGA-coated SPA-beads. To test the agonistic activity of test compounds on recombinant hNOP, hMOP, hDOP, and hKOP receptor expressing cell membranes from CHO-K1 or HEK293 cells, 10 or 5 μg membrane protein per assay are incubated with 0.4 nM [35S]GTPγS and serial concentrations of receptor-specific agonists in buffer containing 20 mM HEPES pH 7.4, 100 mM NaCl, 10 mM MgCl2, 1 mM EDTA, 1 mM dithiothreitol, 1.28 mM NaN3, and 10 μM GDP for 45 min at room temperature. The microtiter plates are then centrifuged for 10 min at 830 to sediment the SPA beads. The microtiter plates are sealed and the bound radioactivity [cpm] is determined after a delay of 15 min by means of a 1450 Microbeta Trilux (PerkinElmer, Waltham, Mass.).
  • The unstimulated basal binding activity (UBSobs [cpm]) is determined from 12 unstimulated incubates and is set as 100% basal binding. For determination of the potency and the efficacy, the arithmetic mean of the observed total [3S]GTPγS binding (TBobs [cpm]) of all incubates (duplicates) stimulated by the receptor-specific agonists (i.e. N/OFQ, SNC80, DAMGO, or U69,593) are transformed in percent total binding (TBobs [%]) relative to the basal binding activity (i.e. 100% binding). The potency (EC50) of the respective agonist and its maximal achievable total [35S]GTPγS binding (TBcalc [%]) above its calculated basal binding (UBScalc [%]) are determined from its transformed data (TBobs [%]) by means of nonlinear regression analysis with XLfit for each individual concentration series. Then the difference between the calculated unstimulated [35S]GTPγS binding (UBScalc [%]) and the maximal achievable total [35S]GTPγS binding (TBcalc [%]) by each tested agonist is determined (i.e. B1calc [%]). This difference (B1calc [%]) as a measure of the maximal achievable enhancement of [35S]GTPγS binding by a given agonist is used to calculate the relative efficacy of test compounds versus the maximal achievable enhancement by a receptor-specific full agonist, e.g. N/OFQ (B1calc-N/OFQ [%]) which is set as 100% relative efficacy for the hNOP receptor. Likewise, the percentage efficacies of test compounds at the hDOP, hMOP, or hKOP receptor are determined versus the calculated maximal enhancement of [35S]GTPγS binding by the full agonists SNC80 (B1calc-SNC80 [%]), DAMGO (B1calc-DAMGO [%]) and U69,593 (B1calc-U69,593 [%]) which are set as 100% relative efficacy at each receptor, respectively.
  • The foregoing description and examples have been set forth merely to illustrate the invention and are not intended to be limiting. Since modifications of the described embodiments incorporating the spirit and substance of the invention may occur to persons skilled in the art, the invention should be construed broadly to include all variations within the scope of the appended claims and equivalents thereof.

Claims (28)

1. A compound according to general formula (I)
Figure US20200399252A1-20201224-C00315
wherein
n means 1, 2 or 3;
R1 and R2 independently of one another mean
—H;
—C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —OH, —OCH3, —CN and —CO2CH3;
a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —OH, —OCH3, —CN and —CO2CH3; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted; or
a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —OH, —OCH3, —CN and —CO2CH3; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted;
or
R1 and R2 together with the nitrogen atom to which they are attached form a ring and mean —(CH2)3-6—; —(CH2)2—O—(CH2)2—; or —(CH2)2—NRA—(CH2)2—, wherein RA means —H or —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br and —I;
R3 means
—C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or
a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
R4 means
—H;
—C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said —C1-C6-alkyl is optionally connected through —C(═O)—, —C(═O)O—, or —S(═O)2—;
a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C(═O)—, —C(═O)O—, —C(═O)O—CH2—, or —S(═O)2—;
a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C(═O)—, —C(═O)O—, —C(═O)O—CH2—, or —S(═O)2—;
a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 6-14-membered aryl moiety is optionally connected through —C(═O)—, —C(═O)O—, —C(═O)O—CH2—, or —S(═O)2—; or
a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 5-14-membered heteroaryl moiety is optionally connected through —C(═O)—, —C(═O)O—, —C(═O)O—CH2—, or —S(═O)2—;
R5 means
a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; or
a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted;
R7, R8, R11, R12, R13, R14, R15, R16, R17, R18, R19, and R20 independently of one another mean —H, —F, —Cl, —Br, —I, —OH, or —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;
or wherein R7 and R8 together with the carbon atom to which they are attached form a ring and mean —(CH2)2— or —(CH2)3—;
wherein “mono- or polysubstituted” means that one or more hydrogen atoms are replaced by a substituent independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —R21, —C(═O)R21, —C(═O)OR21, —C(═O)NR21R22, —O—(CH2CH2—O)1-30—H, —O—(CH2CH2—O)1-30—CH3, ═O, —OR21, —OC(═O)R21, —OC(═O)OR21, —OC(═O)NR21R22, —NO2, —NR21R22, —NR21—(CH2)1-6—C(═O)R22, —NR21—(CH2)1-6—C(═O)OR22, —NR23—(CH2)1-6—C(═O)NR21R22, —NR21C(═O)R22, —NR21C(═O)—OR22, —NR32C(═O)NR21R22, —NR21S(═O)2R22, —SR21, —S(═O)R21, —S(═O)2R21, —S(═O)2OR21, and —S(═O)2NR21R22;
wherein
R21, R22 and R23 independently of one another mean
—H;
—C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH2, and —O—C1-C6-alkyl;
a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH2, —C1-C6-alkyl and —O—C1-C6-alkyl;
a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH2, —C1-C6-alkyl and —O—C1-C6-alkyl;
a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH2, —C1-C6-alkyl and —O—C1-C6-alkyl;
a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is optionally connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH2, —C1-C6-alkyl and —O—C1-C6-alkyl;
or R21 and R22 within —C(═O)NR21R22, —OC(═O)NR21R22, —NR21R22, —NR23—(CH2)1-6—C(═O)NR21R22, —NR23C(═O)NR21R22, or —S(═O)2NR21R22 together with the nitrogen atom to which they are attached form a ring and mean —(CH2)3-6—; —(CH2)2—O—(CH2)2—; or —(CH2)2—NRB—(CH2)2—, wherein RB means —H or —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br and —I;
or a physiologically acceptable salt thereof.
2. The compound according to claim 1, wherein R7, R8, R11, R12, R13, R14, R15, R16, R17, R18, R19, and R20 independently of one another mean —H, —F, —OH, or —C1-C6-alkyl; or R7 and R8 together with the carbon atom to which they are attached form a ring and mean —(CH2)2—.
3. The compound according to claim 1, wherein R1 means —H; and R2 means —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
4. The compound according to claim 1, wherein R means —CH3; and R2 means —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
5. The compound according to claim 1, wherein R1 means —H or —CH3; and wherein R2 means —CH2-cycloalkyl, —CH2-cyclobutyl, —CH2-cyclopentyl, —CH2-oxetanyl or —CH2-tetrahydrofuranyl.
6. The compound according to claim 1, wherein R1 and R2 together with the nitrogen atom to which they are attached form a ring and mean —(CH2)3-6—.
7. The compound according to claim 1, wherein R3 means —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
8. The compound according to claim 1, wherein R3 means a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted.
9. The compound according to claim 1, wherein R3 means a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted.
10. The compound according to claim 1, wherein R4 means —H.
11. The compound according to claim 1, wherein R4 means —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
12. The compound according to claim 1, wherein R4 means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein the 3-12-membered cycloalkyl moiety is connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
13. The compound according to claim 1, wherein R4 means a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
14. The compound according to claim 1, wherein R4 means a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
15. The compound according to claim 1, wherein R4 means a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is connected through —C1-C6-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
16. The compound according to claim 1, wherein n means 1 or 2.
17. The compound according to claim 1, wherein R5 means -phenyl, unsubstituted, mono- or polysubstituted.
18. The compound according to claim 1, wherein R5 means -pyrazinyl, -pyridazinyl, -pyridinyl, -pyrimidinyl, -thienyl, -imidazolyl, triazolyl, or -1,3-benzodioxolyl in each case unsubstituted, mono- or polysubstituted.
19. The compound according to claim 1, which has a structure according to any of general formulas (II-A) to (VIII-C):
Figure US20200399252A1-20201224-C00316
Figure US20200399252A1-20201224-C00317
Figure US20200399252A1-20201224-C00318
Figure US20200399252A1-20201224-C00319
wherein in each case
R1, R2, R3, R4, and R5 are defined as in claim 1,
RC means —H, —OH, —F, —CN or —C1-C4-alkyl;
RD means —H or —F;
or a physiologically acceptable salt thereof.
20. The compound according to claim 1, wherein R5 is selected from the group consisting of:
Figure US20200399252A1-20201224-C00320
Figure US20200399252A1-20201224-C00321
21. The compound according to claim 1, wherein
n means 1 or 2;
R1 means —H or —CH3;
R2 means —H or —C1-C6-alkyl, linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with —OH, —OCH3, —C(═O)OCH3, or —CN;
R3 means
—C1-C4-alkyl, optionally monosubstituted with —OCH3;
-phenyl, -thienyl or -pyridinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —CN, —CH3, —CH2CH3, —CH2F, —CHF2, —CF3, —OCF3, —OH, —OCH3, —O—CH2—O—CH3, —C(═O)NH2, C(═O)NHCH3, —C(═O)N(CH3)2, —NH2, —NHCH3, —N(CH3)2, —NHC(═O)CH3, —CH2OH, SOCH3 and SO2CH3; or
R4 means
—H;
—C1-C6-alkyl, linear or branched, saturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, ═O, —OH, —O—C1-C4-alkyl, —CO2H, —C(═O)O—C1-C4-alkyl, —C(═O)NH2, —C(═O)NH—C1-C4-alkyl, —C(═O)N(C1-C4-alkyl)2, —C(═O)NH—C1-C4-alkyl-CN, —C(═O)NCH3—C1-C4-alkyl-CN, —C(═O)NH-cyclopropyl-CN, —C(═O)NCH3-cyclopropyl-CN, —C(═O)NH—C1-C4-alkyl-OH, —C(═O)NCH3—C1-C4-alkyl-OH, —C(═O)NH—C1-C4-alkyl-OCH3, —C(═O)NCH3—C1-C4-alkyl-OCH3, —C(═O)NRR′ wherein R and R′ together with the nitrogen atom to which they are attached form a ring and mean —(CH2)2-4—;
3-6-membered cycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, and —O—C1-C4-alkyl, wherein said 3-6-membered cycloalkyl is connected through —C1-C6-alkylene;
3-6-membered heterocycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —CO2H, —C(═O)O—C1-C4-alkyl, —OH, and —O—C1-C4-alkyl, wherein said 3-6-membered heterocycloalkyl is connected through —C1-C6-alkylene;
6-14-membered aryl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —CO2H, —C(═O)O—C1-C4-alkyl, —OH, and —O—C1-C4-alkyl; wherein said 6-14-membered aryl is connected through —C1-C6-alkylene- or —S(═O)2—;
5-14-membered heteroaryl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —CO2H, —C(═O)O—C1-C4-alkyl, —OH, and —O—C1-C4-alkyl; wherein said 5-14-membered heteroaryl is connected through —C1-C6-alkylene- or —S(═O)2—;
R5 means -phenyl, -pyrazinyl, -pyridazinyl, -pyridinyl, -pyrimidinyl, -thienyl, -imidazolyl, triazolyl, or -1,3-benzodioxolyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F; —Cl; —Br; —I; —CN; —OH; —C1-C4-alkyl; —CF3; —C1-C4-alkyl-OH; —C1-C4-alkyl-C(═O)NH2; -3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; preferably -cyclopropyl, saturated, unsubstituted; -3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; —O—CH2—O—; —O—C1-C4-alkyl; —O—(CH2CH2—O)1-30—H; —O—(CH2CH2—O)1-30—CH3; —C(═O)OH; —C(═O)OC1-C4-alkyl; —C(═O)NH2; —C(═O)NHC1-C4-alkyl; —C(═O)N(C1-C4-alkyl)2; —SC1-C4-alkyl; —S(═O)C1-C4-alkyl and —S(═O)2C1-C4-alkyl; and
R7, R8, R11, R12, R13, R14, R15, R16, R17, R18, R19, and R20 mean —H.
22. The compound according to claim 1, which has a structure according to general formula (I′)
Figure US20200399252A1-20201224-C00322
wherein R1 to R5, R7, R8, R10 to R20 and n are defined as in claim 1,
or a physiologically acceptable salt thereof.
23. The compound according to claim 1, which has a structure according to general formula (IX)
Figure US20200399252A1-20201224-C00323
wherein
RC means —H or —OH;
R3 means -phenyl or -3-fluorophenyl; and
R5 means
6-14-membered aryl, unsubstituted, mono- or polysubstituted; or
5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted;
or a physiologically acceptable salt thereof.
24. The compound according to claim 23, wherein R5 is selected from -phenyl, -pyridyl, pyrimidinyl, or -triazolyl, in each case unsubstituted, mono- or polysubstituted.
25. The compound according to claim 1, which is selected from the group consisting of
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(4-methylsulfonyl-phenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(3-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1-isopropyl-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-(Cyclobutyl-methyl)-3-[(4-methoxyphenyl)-methyl]-8-[methyl-(2-methyl-propyl)-amino]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-2-[[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-benzamide;
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-(pyrazin-2-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-(Allyl-methyl-amino)-1-(cyclobutyl-methyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-4-[[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-benzamide;
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(4-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-methoxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(4-methoxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1-(2-methyl-propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-Butyl-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-8-(4-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-hydroxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-(pyridin-3-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[[3-[2-[2-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-phenyl]-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(4-hydroxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one hydrochloride;
CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[(3-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-(Cyclopentyl-methyl)-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1-(2-hydroxy-2-methyl-propyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1-(2-methoxy-2-methyl-propyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-(Cyclobutyl-methyl)-3-[(3-methoxyphenyl)-methyl]-8-methylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-3-[[1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-benzonitrile;
CIS-1-(Cyclobutyl-methyl)-3-[(3-methoxyphenyl)-methyl]-8-(methyl-propyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-3-[(3-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-3-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-propionitrile;
CIS-1-(Cyclobutyl-methyl)-8-methylamino-8-phenyl-3-(pyridin-3-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1-(oxetan-3-yl-methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-3-(pyridin-3-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1-(2-hydroxy-ethyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1-(2,2-dimethyl-propyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1-(3-methyl-butyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1-[3-(trifluoromethyloxy)-propyl]-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-(2-Cyclobutyl-ethyl)-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-[(3,3-Difluoro-cyclobutyl)-methyl]-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-2-[[1-(Cyclobutyl-methyl)-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-8-yl]-methyl-amino]-acetonitrile;
CIS-1-(Cyclobutyl-methyl)-8-[(2-methoxy-ethyl)-methyl-amino]-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-acetic acid tert-butyl ester;
CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-acetic acid; 2,2,2-trifluoro-acetic acid salt;
CIS-1-(Cyclobutyl-methyl)-3-[(4-methoxyphenyl)-methyl]-8-methylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-acetic acid methyl ester;
CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-acetamide;
CIS-1-Benzyl-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N-methyl-acetamide;
CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N-propyl-acetamide;
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1-(3-methoxy-propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1-(2-methoxy-ethyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-acetonitrile;
CIS-8-Dimethylamino-1-hexyl-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1-(tetrahydro-pyran-4-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-(Cyclohexyl-methyl)-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-N-(Cyano-methyl)-2-[8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-acetamide;
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1-(pyridin-3-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-(3-methoxy-propyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N-(2-methoxy-ethyl)-acetamide;
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N,N-dimethyl-acetamide;
CIS-N-(1-Cyano-cyclopropyl)-2-[8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-acetamide;
CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N-methyl-N-propyl-acetamide;
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-(3-methoxy-propyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1-(3-hydroxy-propyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1-(4-methoxy-butyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1-[(1-methyl-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1-[(1-hydroxy-cyclohexyl)-methyl]-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-5-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-pentanenitrile;
CIS-3-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-propionamide;
CIS-1-(Cyclobutyl-methyl)-8-[(2-hydroxy-ethyl)-methyl-amino]-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-[[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-methyl]-cyclobutane-1-carbonitrile;
CIS-8-Dimethylamino-1-[(1-hydroxy-cyclopentyl)-methyl]-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-3-[(2-Bromophenyl)-methyl]-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-3-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N-methyl-propionamide;
CIS-3-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N-propyl-propionamide;
CIS-8-Dimethylamino-1-[(1-fluoro-cyclobutyl)-methyl]-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-(2-Cyclohexyl-ethyl)-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-3-[[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-benzonitrile;
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1-methyl-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1-[2-[2-[2-[2-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethyl]-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1-(2-tetrahydro-pyran-4-yl-ethyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-4-[[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-benzonitrile;
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[[6-(trifluoromethyl)-pyridin-3-yl]-methyl]-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[[4-[2-[2-[2-[2-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-phenyl]-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-3-[[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-benzamide;
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(4-hydroxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1-[(1-methoxy-cyclobutyl)-methyl]-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-2-[[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-benzonitrile;
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(3-methylsulfonyl-phenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1-ethyl-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1-propyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-3-Benzyl-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1-(pyrimidin-4-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-3-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-2,2-dimethyl-propionitrile;
CIS-2-[[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-methyl]-benzoic acid methyl ester;
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-(pyridin-2-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-(pyridin-4-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1-(tetrahydro-furan-3-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-(pyrimidin-2-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-3-[[1-[(5-Cyano-2-methoxy-phenyl)-methyl]-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-4-methoxy-benzonitrile;
CIS-8-Dimethylamino-1-(3-hydroxy-3-methyl-butyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1-(3-methoxy-3-methyl-butyl)-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-2-[[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-benzamide;
CIS-3-[[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-benzamide;
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-[(1-Hydroxy-cyclobutyl)-methyl]-3-[(4-methoxyphenyl)-methyl]-8-methylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1-(tetrahydro-furan-2-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-3-Benzyl-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-3-Benzyl-8-dimethylamino-1-ethyl-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1-[2-(methylsulfamyl)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1-[(2R)-2-hydroxy-propyl]-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1-[(2S)-2-hydroxy-propyl]-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1-(tetrahydro-furan-3-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1-ethyl-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Amino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-(2-phenyl-ethyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one;
CIS-3-[[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-4-methoxy-benzonitrile;
CIS-8-Dimethylamino-1-ethyl-8-phenyl-3-(pyridin-3-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1-[2-(1-methoxy-cyclobutyl)-ethyl]-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-8-[3-(methoxymethyloxy)-phenyl]-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-8-[4-(methoxymethyloxy)-phenyl]-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one;
CIS-3-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-propionic acid;
CIS-3-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-propionic acid tert-butyl ester;
CIS-2-[[1-(Cyclobutyl-methyl)-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-8-yl]-methyl-amino]-acetic acid methyl ester;
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-1-(3-methyl-but-2-enyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(3-methylsulfanyl-phenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-3-[(3-Bromophenyl)-methyl]-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-2-((8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)methyl)benzonitrile;
CIS-8-Dimethylamino-8-(3-methoxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-8-(4-methoxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one;
CIS-3-((8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)methyl)benzonitrile;
CIS-3-((8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)methyl)-4-methoxybenzonitrile;
CIS-8-Dimethylamino-8-phenyl-3-(1H-[1,2,3]triazol-4-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-3-[[1-(2-hydroxy-ethyl)-1H-[1,2,3]triazol-4-yl]-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-2-[4-[(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-methyl]-1H-[1,2,3]triazol-1-yl]-acetamide;
CIS-8-Methylamino-8-phenyl-3-(1H-[1,2,3]triazol-4-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1-(p-tolylsulfonyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-2-[4-[(8-Methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-methyl]-1H-[1,2,3]triazol-1-yl]-acetamide;
CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decane-1-carboxylic acid benzyl ester;
CIS-3-[[1-(2-Hydroxy-ethyl)-1H-[1,2,3]triazol-4-yl]-methyl]-8-methylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-8-phenyl-3-(2-pyridin-2-yl-ethyl)-1,3-diazaspiro[4.5]decane-2,4-dione;
CIS-8-Dimethylamino-8-phenyl-3-(2-pyridin-2-yl-ethyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[[1-(2-hydroxy-ethyl)-1H-[1,2,3]triazol-4-yl]-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-3-[2-(1H-imidazol-1-yl)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione;
CIS-2-[4-[[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-1H-[1,2,3]triazol-1-yl]-acetamide;
CIS-1-[(1-Hydroxy-cyclobutyl)-methyl]-3-[[1-(2-hydroxy-ethyl)-1H-[1,2,3]triazol-4-yl]-methyl]-8-methylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-8-phenyl-3-(2-pyridin-3-yl-ethyl)-1,3-diazaspiro[4.5]decane-2,4-dione;
CIS-8-Dimethylamino-8-phenyl-3-(2-pyridin-4-yl-ethyl)-1,3-diazaspiro[4.5]decane-2,4-dione;
CIS-2-[4-[[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-1H-[1,2,3]triazol-1-yl]-acetamide;
CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[[1-(2-hydroxy-ethyl)-1H-[1,2,3]triazol-4-yl]-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-2-[4-[[1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-1H-[1,2,3]triazol-1-yl]-acetamide;
CIS-1-(Cyclobutyl-methyl)-3-[[1-(2-hydroxy-ethyl)-1H-[1,2,3]triazol-4-yl]-methyl]-8-methylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-2-[4-[[1-(Cyclobutyl-methyl)-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-1H-[1,2,3]triazol-1-yl]-acetamide;
CIS-8-Dimethylamino-8-phenyl-3-(2-pyridin-3-yl-ethyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-3-[2-(1H-imidazol-1-yl)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-8-phenyl-3-(2-pyridin-4-yl-ethyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-8-phenyl-3-(2-pyrimidin-2-yl-ethyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-8-phenyl-3-(2-pyrimidin-5-yl-ethyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1-ethyl-3-[(4-methylsulfonyl-phenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-3-(1-methyl-1-phenyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-8-phenyl-3-(1-phenyl-cyclopropyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1,3-bis[(2-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-3-[(3-methylsulfonyl-phenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(1-methyl-1-phenyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-3-[(3-Cyclopropyl-phenyl)-methyl]-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-3-(1,3-Benzodioxol-4-yl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-(1-phenyl-cyclopropyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-4-[[8-Dimethylamino-3-[(2-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-methyl]-benzonitrile;
CIS-8-Dimethylamino-3-[(2-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-8-phenyl-3-(pyridin-4-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-8-phenyl-3-(pyridin-2-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-8-phenyl-3-(pyridin-3-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-3-[[2-(4-methyl-piperazin-1-yl)-pyridin-4-yl]-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-8-phenyl-3-[(2-piperidin-1-yl-pyridin-4-yl)-methyl]-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-3-[(2-morpholin-4-yl-pyridin-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
CIS-8-Dimethylamino-8-phenyl-3-[(2-piperazin-1-yl-pyridin-4-yl)-methyl]-1,3-diazaspiro[4.5]decan-2-one;
and the physiologically acceptable salts thereof.
26. The compound according to claim 1 for use in the treatment of pain.
27. A medicament comprising a compound according to claim 1.
28. A method of treating pain in a patient in need thereof, said method comprising administering to said patient an effective amount therefor of at least one compound according to claim 1.
US17/007,258 2016-01-13 2020-08-31 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives Abandoned US20200399252A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US17/007,258 US20200399252A1 (en) 2016-01-13 2020-08-31 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US17/188,743 US20210179592A1 (en) 2016-01-13 2021-03-01 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US18/103,180 US20230174520A1 (en) 2016-01-13 2023-01-30 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP16151013.6 2016-01-13
EP16151013 2016-01-13
US15/405,896 US20170197947A1 (en) 2016-01-13 2017-01-13 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives
US15/984,919 US20180327392A1 (en) 2016-01-13 2018-05-21 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US16/265,080 US10829480B2 (en) 2016-01-13 2019-02-01 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives
US17/007,258 US20200399252A1 (en) 2016-01-13 2020-08-31 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US16/265,080 Continuation US10829480B2 (en) 2016-01-13 2019-02-01 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/188,743 Continuation US20210179592A1 (en) 2016-01-13 2021-03-01 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

Publications (1)

Publication Number Publication Date
US20200399252A1 true US20200399252A1 (en) 2020-12-24

Family

ID=55129634

Family Applications (6)

Application Number Title Priority Date Filing Date
US15/405,896 Abandoned US20170197947A1 (en) 2016-01-13 2017-01-13 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives
US15/984,919 Abandoned US20180327392A1 (en) 2016-01-13 2018-05-21 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US16/265,080 Active US10829480B2 (en) 2016-01-13 2019-02-01 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives
US17/007,258 Abandoned US20200399252A1 (en) 2016-01-13 2020-08-31 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US17/188,743 Abandoned US20210179592A1 (en) 2016-01-13 2021-03-01 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US18/103,180 Pending US20230174520A1 (en) 2016-01-13 2023-01-30 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US15/405,896 Abandoned US20170197947A1 (en) 2016-01-13 2017-01-13 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives
US15/984,919 Abandoned US20180327392A1 (en) 2016-01-13 2018-05-21 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US16/265,080 Active US10829480B2 (en) 2016-01-13 2019-02-01 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives

Family Applications After (2)

Application Number Title Priority Date Filing Date
US17/188,743 Abandoned US20210179592A1 (en) 2016-01-13 2021-03-01 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US18/103,180 Pending US20230174520A1 (en) 2016-01-13 2023-01-30 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives

Country Status (28)

Country Link
US (6) US20170197947A1 (en)
EP (1) EP3402784B1 (en)
JP (1) JP6893517B2 (en)
KR (1) KR20180098369A (en)
CN (1) CN108602777B (en)
AR (1) AR107360A1 (en)
AU (1) AU2017206909B2 (en)
BR (1) BR112018014303B1 (en)
CA (1) CA3011177A1 (en)
CL (1) CL2018001912A1 (en)
CO (1) CO2018008444A2 (en)
CY (1) CY1122818T1 (en)
DK (1) DK3402784T3 (en)
EA (1) EA037481B1 (en)
EC (1) ECSP18060848A (en)
ES (1) ES2797904T3 (en)
HR (1) HRP20200837T1 (en)
HU (1) HUE049813T2 (en)
IL (1) IL260491B (en)
LT (1) LT3402784T (en)
MX (1) MX2018008644A (en)
PE (1) PE20181375A1 (en)
PL (1) PL3402784T3 (en)
PT (1) PT3402784T (en)
RS (1) RS60315B1 (en)
SI (1) SI3402784T1 (en)
TW (1) TWI636048B (en)
WO (1) WO2017121648A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR107358A1 (en) 2016-01-13 2018-04-25 Gruenenthal Gmbh DERIVATIVES OF 3- (CARBOXIMETHYL) -8-AMINO-2-OXO-1,3-DIAZA-ESPIRO- [4.5] -DECANO
BR112018014305B1 (en) 2016-01-13 2023-10-17 Grünenthal GmbH 3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECAN DERIVATIVES
CO2018008450A2 (en) 2016-01-13 2018-09-20 Gruenenthal Gmbh Derivatives of 8-amino-2-oxo-1,3-diaza-spiro- [4.5] -decane
PE20181375A1 (en) 2016-01-13 2018-08-28 Gruenenthal Chemie DERIVATIVES OF 3 - ((HETERO) ARYL) -ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO- [4.5] -DECANE
TWI635081B (en) 2016-01-13 2018-09-11 歌林達有限公司 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
AU2019255310B2 (en) 2018-04-18 2022-11-24 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US11919912B2 (en) 2018-05-21 2024-03-05 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2734265B1 (en) 1995-05-17 1997-06-13 Adir NOVEL HETEROCYCLIC SPIRO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP1997818A3 (en) 2001-04-18 2009-04-08 Euro-Celtique S.A. Quinolinone derivatives and their use to treat pain
DE10130020A1 (en) 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituted 1-oxa-2,8-diaza-spiro [4.5] dec-2-ene derivatives
DE10210195B4 (en) 2002-03-07 2005-12-15 Schwarz Pharma Ag Use of 1,3-diazaspiro [4,5] decane-2,4-dithione for the treatment of pain
WO2004005293A2 (en) 2002-07-05 2004-01-15 Targacept, Inc. N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
DE10252667A1 (en) * 2002-11-11 2004-05-27 Grünenthal GmbH New spiro-((cyclohexane)-tetrahydropyrano-(3,4-b)-indole) derivatives, are ORL1 receptor ligands useful e.g. for treating anxiety, depression, epilepsy, senile dementia, withdrawal symptoms or especially pain
EP1628978A2 (en) 2003-05-23 2006-03-01 Zealand Pharma A/S Triaza-spiro compounds as nociceptin analogues and uses thereof
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Substituted diaza-spiro-(4,5)-Decane derivatives and their use as neurokinin antagonists
CA2666489C (en) 2006-10-19 2012-10-02 F. Hoffmann-La Roche Ag Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes
EP2150552B1 (en) 2007-04-09 2013-01-02 Janssen Pharmaceutica NV 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
BRPI0909527A2 (en) * 2008-03-27 2019-09-24 Gruenenthal Gmbh substituted 4-aminocyclohexane derivatives
WO2010151815A2 (en) 2009-06-25 2010-12-29 Abbott Laboratories 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
TWI582092B (en) 2010-07-28 2017-05-11 歌林達股份有限公司 Cis-tetrahydro-spiro(cyclohexane-1,1'-pyrido[3,4-b]indole)-4-amine derivatives
WO2014106238A1 (en) * 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof
EP3154971A4 (en) 2014-06-13 2017-11-01 Purdue Pharma L.P. Heterocyclic morphinan derivatives and use thereof
CO2018008450A2 (en) 2016-01-13 2018-09-20 Gruenenthal Gmbh Derivatives of 8-amino-2-oxo-1,3-diaza-spiro- [4.5] -decane
AR107358A1 (en) 2016-01-13 2018-04-25 Gruenenthal Gmbh DERIVATIVES OF 3- (CARBOXIMETHYL) -8-AMINO-2-OXO-1,3-DIAZA-ESPIRO- [4.5] -DECANO
BR112018014305B1 (en) * 2016-01-13 2023-10-17 Grünenthal GmbH 3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECAN DERIVATIVES
TWI730032B (en) 2016-01-13 2021-06-11 美商必治妥美雅史谷比公司 Spiroheptane salicylamides and related compounds as inhibitors of rock
PE20181375A1 (en) 2016-01-13 2018-08-28 Gruenenthal Chemie DERIVATIVES OF 3 - ((HETERO) ARYL) -ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO- [4.5] -DECANE
TWI635081B (en) 2016-01-13 2018-09-11 歌林達有限公司 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
MX2018008681A (en) 2016-01-13 2018-09-17 Novo Nordisk As Egf(a) analogues with fatty acid substituents.

Also Published As

Publication number Publication date
KR20180098369A (en) 2018-09-03
US20170197947A1 (en) 2017-07-13
ES2797904T3 (en) 2020-12-04
BR112018014303B1 (en) 2023-10-03
CN108602777A (en) 2018-09-28
CO2018008444A2 (en) 2018-08-31
CA3011177A1 (en) 2017-07-20
TWI636048B (en) 2018-09-21
US20230174520A1 (en) 2023-06-08
BR112018014303A2 (en) 2018-12-11
EP3402784B1 (en) 2020-03-11
CL2018001912A1 (en) 2018-10-19
AU2017206909B2 (en) 2020-07-09
PT3402784T (en) 2020-06-18
US10829480B2 (en) 2020-11-10
JP6893517B2 (en) 2021-06-23
HUE049813T2 (en) 2020-10-28
PL3402784T3 (en) 2020-09-21
AR107360A1 (en) 2018-04-25
CY1122818T1 (en) 2021-05-05
TW201731822A (en) 2017-09-16
LT3402784T (en) 2020-06-10
JP2019501939A (en) 2019-01-24
HRP20200837T1 (en) 2020-08-07
RS60315B1 (en) 2020-07-31
US20210179592A1 (en) 2021-06-17
AU2017206909A1 (en) 2018-08-30
US20200002319A1 (en) 2020-01-02
EA037481B1 (en) 2021-04-01
PE20181375A1 (en) 2018-08-28
IL260491B (en) 2021-07-29
CN108602777B (en) 2022-05-03
US20180327392A1 (en) 2018-11-15
EA201891609A1 (en) 2019-01-31
EP3402784A1 (en) 2018-11-21
MX2018008644A (en) 2018-11-19
ECSP18060848A (en) 2018-08-31
WO2017121648A1 (en) 2017-07-20
DK3402784T3 (en) 2020-05-25
SI3402784T1 (en) 2020-07-31

Similar Documents

Publication Publication Date Title
US10829480B2 (en) 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives
US10793556B2 (en) 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US10793528B2 (en) 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US10807989B2 (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

Legal Events

Date Code Title Description
AS Assignment

Owner name: GRUENENTHAL GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KUEHNERT, SVEN;KOENIGS, RENE MICHAEL;KLESS, ACHIM;AND OTHERS;SIGNING DATES FROM 20170309 TO 20170502;REEL/FRAME:053654/0631

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION